

CURRICULUM VITAE

Personal Data:

Name: Mario C. Raviglione, M.D., F.R.C.P¹. (UK), F.E.R.S², Hon.R.S.P. (Russia)³

Title: Professor – Professore Ordinario
Global Health Centre
Milan Institute for Innovative Health Research (MIC)
University of Milan
Dipartimento di Scienze Biomediche della Salute
Via Festa del Perdono, 7 - 20122 Milano, Italy

Place of Birth: Biella (BI), Italy

Private Address: 415F, Route des Alpes, F-01280 Preveessin-Möens, France

Office Address: Università degli Studi di Milano
Via Festa del Perdono, 7
20122 Milano, Italy

e-Mail 1: raviglionemc@gmail.com

e-Mail 2; mario.raviglione@unimi.it

Skype: mario.raviglione

On Facebook, Twitter, LinkedIn

Publications: Over 350 articles and chapters. Among the top 10 most cited authors in the TB field, with over 42,000 citations and an h-index of 99.
Among the top 20 Italian Scientists for Clinical Sciences -
http://www.topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Clinical_Sciences.htm

Education:

1969-1974 Liceo Scientifico "A. Avogadro", Biella (BI), Italy

1974-1980 MD University of Turin Medical School, Italy

Postdoctoral Training:

1981-1982 Internship in Internal Medicine, Biella General Hospital, Italy

1984-1986 Intern and Junior Resident in Internal Medicine at Cabrini Medical Center, New York City

1986-1988 Chief Medical Resident at Cabrini Medical Center, New York City

¹ Fellow of the Royal Academy of Physicians (London, UK)

² Founding Fellow of the European Respiratory Society

³ Honorary Member of the Russian Society of Phthisiologists (Rossiiskoe Odshestva Phytisiatrov) (Russia)

Research Fellowships:

1987-1988	Research Fellow in Infectious Diseases at Cabrini Medical Center, New York City
1988-1989	Clinical Fellow in Infectious Diseases at Cabrini Medical Center, New York City
1989-1990	Research Fellow in Infectious Diseases at Cabrini Medical Center, New York City
1990-1991	AIDS Clinical Research Fellow, Division of Infectious Diseases, Beth Israel Hospital, Harvard Medical School, Boston, MA

Licensure and Certification:

1980	State License, University of Turin Medical School, Italy
1982	ECFMG Examination
1982	Visa Qualifying Examination
1987	Diplomate in Internal Medicine, American Board of Internal Medicine
1988	FLEX Examination
1988	New York License Registration No. 177621
1990	Massachusetts License Registration No. 72541
1990	Diplomate in the Subspecialty of Infectious Diseases, American Board of Internal Medicine
2005-2007	Global Leadership Programme, WHO

Hospital and Other Clinical Appointments:

1981-1982	Physician in Emergency Service, Biella District, Italy
1983-1984	Assistant M.D. in Emergency Medicine Department, Biella General Hospital, Italy
1987	Physician, St. Mary's and St. Philip's Mission Clinics, Missionary Sisters of the Sacred Heart, Lobamba, Swaziland

Academic Appointments:

1990-1991	Clinical Fellow in Medicine, Harvard Medical School, Boston, MA
1995-	Visiting Professor on Tuberculosis, Faculty of Medicine, Division of Infectious Diseases, University of Brescia, Italy
2002	Visiting Professor of Medicine and International Health, Center for Tuberculosis Research, Johns Hopkins Medical Institutions, Baltimore, Md, USA
2003-2011	Visiting Professor of Tuberculosis and Infectious Respiratory Diseases, Faculty of Medicine, Specialty School of Respiratory Diseases, University of Modena and Reggio Emilia, Italy.
2012	Visiting Professor, Faculty of Science MMFFNN, Master Programme in Molecular Biology and Genetics, University of Pavia, Italy.
2018	Professor of Global Health, University of Milan, Italy

WHO Appointments:

1991-1993	Medical Officer (JPO), Tuberculosis Programme/CDS, World Health Organization, Geneva, Switzerland
1993	Medical Officer (Short-Term Professional), Tuberculosis Programme/CDS, World Health Organization, Geneva, Switzerland
1993-1997	Medical Officer, Tuberculosis Research and Surveillance Unit (TRS), Global Tuberculosis Programme (GTB), World Health Organization, Geneva, Switzerland
1998	Chief, Surveillance, Epidemiology and Respiratory Health (SEP) Unit, Global Tuberculosis Programme (GTB), World Health Organization (WHO), Geneva, Switzerland
1999	a.i. Team Coordinator, Operational and Epidemiological Research Team (OER), Communicable Disease Prevention and Control Department (CPC), Communicable Diseases Cluster (CDS), World Health Organization (WHO), Geneva, Switzerland
1999-2000	Coordinator, Strategy Development and Monitoring of Endemic Bacterial and Viral Diseases (EBV), Control, Prevention and Eradication Department (CPE), Communicable Diseases Cluster (CDS), World Health Organization (WHO), Geneva, Switzerland
2000	WHO's TB Coordinator, Communicable Diseases (CDS), World Health Organization (WHO), Geneva, Switzerland
2001-2003	Coordinator, TB Strategy and Operations Team (TBS), StopTB (STB), Communicable Diseases Cluster (CDS), World Health Organization (WHO), Geneva, Switzerland
2003	Acting Director, StopTB Department, Communicable Diseases Cluster (CDS), World Health Organization (WHO), Geneva, Switzerland
2003-2017	Director, Global TB Programme; HIV/AIDS, Tuberculosis, Malaria & Neglected Tropical Diseases (HTM) Cluster (CDS); World Health Organization (WHO), Geneva, Switzerland

Most recent positions and summary of past years

2018: Professor of Global Health, Department of Biomedical Health Sciences, University of Milan, Italy

In March 2018 I received an official call for “Chiara Fama” (“Of the Highest Repute”) from the University of Milan, Italy, to direct a **new Centre of Global Health**. Located administratively in the department of Biomedical Health Sciences, the new Centre has four functions and work areas: (1) **didactic**, through teaching and educational activities on global health in collaboration with Italian and foreign academic institutions and with NGOs that add the field perspective; (2) **research** with focus on innovations, determinants of health and impact of poverty and social protection on major burden diseases; (3) **policy analysis** to facilitate innovative, multi-sectoral policies in global health; and (4) **communication / health promotion** focused on global health main topics and related prevention and care. A fifth function across the others is that of partnering with collaborating institutions through establishment of close links. The Centre collaborates closely with experts from other sectors, and pursues activities in the field of major infectious and non-communicable diseases, migrants' health, etc. without ignoring, as relevant, maternal & child health and mental health. Collaborations with important institutions in Italy and abroad is pursued to develop innovative ideas and promote fair and universal access to health anywhere in the world. Solidarity, social justice, and equity are the principles of the new academic centre so that a cadre of future professionals in various sectors able to innovate towards universal access to health can be created.

2003- November 2017: Director, Global Tuberculosis Programme, HTM, WHO, Geneva, Switzerland

In January 2003, following the nomination by the WHO Executive Board of Dr J.W. Lee to Director General of WHO, I was nominated Acting Director of the then StopTB Department. Subsequently, on 21 July 2003, I was appointed Director of the then StopTB Department of the HTM Cluster by the new WHO's Director General, Dr J.W. Lee. This appointment was confirmed in January 2007 by the new Director General, Dr Margaret Chan. The Department, renamed Global TB Programme in June 2013, was composed by five units: Policy, Strategy and Innovations (PSI), Technical Support Coordination (TSC), TB Monitoring and Evaluation (TME), TB/HIV and Community Engagement (THC), Laboratories, Diagnostics and Drug Resistance (LDR), besides the Research for TB Elimination Team (RTE) and the Programme Management Unit (PMU). In addition, between 2003 and 2014, the Programme hosted and administered the Stop TB Partnership Secretariat (TBP). The Programme had two major areas of work. First, PSI, TSC, TME, all led by a coordinator, and RTE led by a team leader, represented the core WHO functions of policy and norm development, technical support coordination, global monitoring of the TB epidemic, and formulation and promotion of the research strategy. Secondly, THC and LDR, all led by coordinators, addressed, through operational research and implementation support, three key challenges faced by all countries: HIV-associated TB, drug-resistant TB, and laboratory strengthening. The latest HQ 2016-2017 biennium budget ceiling for tuberculosis (TB) activities was about 36 million US\$, of which over 90% were from grants and voluntary donations from both governmental sources (USAID, PepFar, US CDC, DfID, as well as international cooperation agencies of Australia, Canada, Japan, Republic of Korea, Italy, Norway, The Netherlands, Sweden, Luxembourg, Russian Federation, Region Lombardia etc) and other sources, including UN Agencies (UNAIDS), Foundations (Bill & Melinda Gates Foundation, Rockefeller Foundation), international funding agencies (The Global Fund against AIDS, TB and Malaria, UNITAID), professional societies (ERS), and corporate sector foundations (EliLilly Foundation, BMS Foundation). The number of staff supervised during 2017 was about 45 professionals and 15 general, as well as some 10 consultants, in the various technical teams. In 2006, I directed the formulation and promotion of the new Stop TB Strategy, built on DOTS and enhanced to address all new challenges of the 21st century. In 2012-2014, I directed the formulation of the new EndTB Strategy that was approved by the 67th World Health Assembly in May 2014. In 2016-2017 I directed the planning, organization and conduct of the First WHO Global Ministerial Conference on Ending TB in the Era of Sustainable Development held in Moscow, Russian Federation, on 16-17 November 2017 with the participation of 75 ministers, 120 member state delegations and about 1000 people. This unprecedented ministerial event adopted the Moscow Declaration focused on four elements (universal coverage, sustainable financing, research and accountability). The document was meant to inform the preparation of the United Nations (UN) General Assembly High-level Meeting on TB to be held in 2018. I also directed the preparatory work towards this very first UN event fully dedicated to TB.

2010-2011: WHO Focal Point for World Health Day 2011 devoted to Antimicrobial Resistance

Every year, WHO celebrates World Health Day that is a major advocacy event devoted to a topic of global public health interest. For 2011, the senior management chose the theme of antimicrobial resistance (AMR) *sensu lato*. As focal point I directed a team composed by (i) policy and technical experts from HQ and ROs; and (ii) communication experts. From a technical policy viewpoint, the team developed a policy package reiterating the 6 strategic actions to be undertaken by Member States to contain AMR. This was presented as policy briefs, fact sheets and a summary technical paper. The communication products were posters, website and other materials. The conclusive event on 7 April 2011 convened the key stake-holders at WHO who committed strong support to combating AMR.

2008-2009: WHO Focal Point for the G8 Health Group.

As part of the commitment by WHO to support the Italian Presidency of the G8 Summit 2009 on health-related issues, I was appointed by the DG as "G8 Focal Point". In this capacity, while continuing my work as Director STB Department, I linked closely with the Italian G8 Health Expert Group and, together with colleagues, provided advice and support in the identification and description of the main global health themes that Italy and the G8 promoted at the Summit.

2007 February: Assistant Director-General ad interim, HTM Cluster, WHO, Geneva, Switzerland

During the month of February 2007 I served as *ad interim* ADG for the HTM cluster upon nomination by DG Dr Margaret Chan and Deputy DG Dr A. Asamoah-Baah.

2001-2003: Coordinator, TB Strategy and Operations Team (TBS), StopTB (STB), CDS, WHO, Geneva, Switzerland

In January 2001, following a restructuring of the TB activities in WHO, the TB team was transferred to the newly formed StopTB Department (STB) directed by Dr J.W. Lee. I was nominated Coordinator of the new team in charge of all strategic, technical and policy-related activities on TB (TB Strategy and Operations– TBS). The objectives of the team were: (i) to develop, manage and monitor a strategic global work-plan with Regional and Country offices in their efforts to assist national TB control programmes and to develop, update and monitor a coordinated plan for expansion of TB control with governments of endemic countries, partners and the entire WHO network (Global DOTS Expansion Plan); (ii) to develop, test and assess new policies and strategies for control of TB, based on proper epidemiological and economic assessment, with the ultimate aim of deriving international policies. Activities were included in the following workplan components: 1. Team management; 2. Global DOTS Expansion Plan; 3-8. Regional and Country Office support for TB control; 9. New strategy and policy development for TB/HIV; 10. New strategy and policy development for management of MDR-TB (DOTS-Plus); 11. Involvement of private sector in TB control; 12. Practical Approach to Lung Health (PAL)/Adult Lung Health Initiative; 13. Monitoring and Surveillance (since January 2002 responsibility of a new team). Fundings for these activities were secured through various grants and donations from the governments of Australia (AusAID), Germany, Ireland, Italy, Japan, Luxembourg, the Netherlands, Norway, Sweden, Switzerland, UK (DFID), and USA (USAID), as well as from UNAIDS, World Bank, Rockefeller Foundation, CDC-GAP, and Harvard/BMGF. As a Coordinator, I was responsible for supervision of some 22 P staff and 10 G staff. The total budget for the biennium 2002-2003 was around 32 million US\$. Major achievements included: establishment of a GDEP with planning and interagency coordination in all 22 high-burden countries; establishment of a Green Light Committee to review projects and provide access to 2nd line drugs; re-organization of regional/country support within WHO; normative guidance on TB/HIV, MDR-TB and DOTS expansion; new policies on TB/HIV, DOTS+, PAL, PPM-DOTS, Community care.

1999-2000: Coordinator, Strategy Development and Monitoring of Endemic Bacterial and Viral Diseases (EBV), Control, Prevention and Eradication Department (CPE), Communicable Diseases Cluster (CDS), World Health Organization (WHO), Geneva, Switzerland

2000: WHO's TB Coordinator, CDS, WHO, Geneva, Switzerland

In September 1999, following a restructuring of CDS/WHO, I was nominated Coordinator of the Strategy Development and Monitoring of Endemic Bacterial and Viral Diseases team (EBV) of the Control, Prevention and Eradication Department (CPE), part of the Communicable Diseases Cluster (CDS). In this new team, I supervised 15 professional staff and 8 general staff at the Headquarters in Geneva. The budget of EBV for both activities and staff in 2000-2001 was US\$ 11.5 million a year.

The objectives of the team were: (i) to develop and manage a strategic global work-plan with Regional and Country offices in their efforts to assist national efforts for control and prevention of priority bacterial and viral diseases, and to monitor its implementation; (ii) to develop, test and assess new policies and strategies for control of bacterial and viral diseases, based on proper epidemiological and economic assessment, with the ultimate aim of deriving international policies; (iii) through the link with Ministries of Health and their programmes, to guarantee that programmes are implemented, priorities are carefully selected and findings from research are put in practice.

Activities were structured in 9 Components: **1: Global Planning and Regional and Country Support:** Global planning and support to the work (especially on TB and Buruli ulcer) of regional and country offices by HQ, including monitoring of the process and outcome. Establishment and monitoring of the Global DOTS Expansion Plan. Facilitation of control efforts. Monitoring of the implementation of WHO support activities and of country implementation of WHO-recommended strategies. Normative function. **2-7: Region Specific Support:** Support of regional activities encompassing capacity strengthening (including operational research), conduct of programme reviews and monitoring/advisory visits, and national programme managers meetings, in close collaboration with partners in country activities. **8: Epidemiological Analysis, Modelling and Economics:** Sound assessment of the impact of potential control strategies on the epidemiology of communicable diseases, especially TB and malaria, based on empirical data and modelling approaches including economic analyses. **9: New Strategy and Policy Development for Control and Prevention of Communicable Diseases:** Development of new strategies and policies for the control and prevention of communicable diseases, especially TB, TB/HIV and Buruli ulcer, focusing on a strengthened primary health care (PHC), community engagement, participation of the private sector, and improved prison health.

Funding for these activities were secured through various grants from UNAIDS, World Bank, Global Alliance on Health Policy and System Research, Sasakawa Memorial Health Foundation, Rockefeller Foundation, Open Society Institute, Geneva Foundation, CDC Life Initiative, and the international development agencies of the governments of Australia (AusAID), Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Switzerland, the UK (DFID), and USA (USAID).

In July 2000 (and until December 2000), I was also nominated overall WHO's TB Coordinator, while retaining the functions of EBV Coordinator. In this capacity, I was responsible for ensuring full coordination of TB activities in control, surveillance and research within WHO/CDS. I was also acting as the main focal point at Headquarters for all WHO Regional and Country Office staff working on TB, as well as for StopTB Initiative.

1999: a.i. Team Coordinator, Operational and Epidemiological Research Team (OER), Communicable Disease Prevention and Control Department (CPC), Communicable Diseases Cluster (CDS), World Health Organization (WHO), Geneva, Switzerland

In January 1999 I was nominated coordinator *ad interim* of the Operational and Epidemiological Research team (OER) of the Communicable Disease Prevention and Control Department (CPC), part of the Communicable Diseases Cluster of the renewed WHO. In this new team, in 1999, I supervised 10 professional staff and 6 general staff at the Headquarters in Geneva, and I worked under the direction of Director CPC. The budget of OER for both activities and staff in 1999 was about US\$ 4 million.

The new team was created to provide leadership on communicable disease operational and epidemiological research. The aim was to develop new evidence-based policy and control packages for priority communicable diseases after epidemiological assessment of the need and through proper research methodology. Activities were divided into three main components: (i) **Strengthening health systems and services for control of communicable diseases** (Adult Lung Health Initiative, ProTest, Community Care of TB and malaria, Global Buruli ulcer Initiative, Private Public Mix); (ii) **Improving TB control delivery and adapting DOTS** (DOTS-Plus for MDR-TB, DOTS-Plus for Europe, DOTS in prisons); (iii) **Epidemiological analysis, modelling and economics** (Progress and impact of TB control, Modelling communicable disease control strategies, gender).

1998: Chief, Surveillance, Epidemiology and Respiratory Health (SEP) Unit, Global Tuberculosis Programme (GTB), World Health Organization (WHO), Geneva, Switzerland

In early 1998 I became responsible for the establishment and management of SEP. This new Unit of GTB originated from the previous TRS Unit, where I worked as Medical Officer and, more recently, Deputy Chief with the role of direct supervisor of 5 professional staff between 1995 and 1997. Within SEP, in 1998, I supervised 9 professional staff and 5 general staff at the Headquarters in Geneva, and I worked with direct links to Regional and Country Offices, under the direction of Dr A. Kochi, Director GTB. The budget of SEP for both activities and staff in 1998 was US\$ 2.2 million.

The new Unit was created to provide global leadership on TB surveillance and monitoring and drug resistance surveillance, and to develop and implement two special projects: the Adult Lung Health Initiative (ALHI) and the Global Buruli Ulcer Initiative (GBUI). In the capacity of Chief, I managed all these activities which I had personally established during my previous appointment in TRS. Concrete products of SEP included, among others: (i) the Global Surveillance and Monitoring Project, based on a database enabling publication of the annual Global TB Control Report and various papers, including one in the Lancet; this project received funding from USAID; (ii) a unique set of country-specific estimates of the global TB burden accomplished through a global consensus process; (iii) an assessment of DOTS impact in various countries, based on sound evidence and mathematical modelling exercises; (iv) the Global Antituberculosis Drug Resistance Project, a unique example of a global network project funded with grants from AusAID and USAID enabling, for the first time in the history of TB, publication of standardised information on drug resistance in a widely disseminated book and an article in the New England Journal of Medicine; (v) the development of clinical care algorithms for the management of adult lung diseases at primary health care level, a building block towards the establishment of a new “integrated management of sick adults”; this project was funded with grants from UNAIDS. In addition, using a grant from the Sasakawa Memorial Health Foundation, the SEP team worked to develop a global initiative targeting Buruli ulcer, an emerging infection; through the work of the team and in just 8 months, Buruli ulcer was recognised worldwide as a major health issue and new activities for its control began. SEP ceased to exist in November 1998 as a result of the re-organization of WHO.

1991-97: Medical Officer, Tuberculosis Research and Surveillance Unit (TRS), Global Tuberculosis Programme (GTB), World Health Organization, Geneva, Switzerland

Between 1991, when I joined WHO and 1993, I worked as Junior Professional Officer responsible for a number of research projects, epidemiological studies, and for the establishment of WHO collaboration with former socialist block countries. In 1993-94 I contributed directly to the development and formulation of the DOTS strategy that became, and still remains, the international essential standard for TB control. Starting in 1994, I set up the WHO's Global Drug Resistance Surveillance project, and beginning in 1995 I established the Global TB Monitoring & Evaluation

system of WHO. These two projects allowed global understanding of the TB epidemic over the following decades. Subsequent and additional work conducted while in TRS allowed: (i) the development and implementation in 1996 of a large multi-centre research project, Community-based Care for TB, in 6 countries of Africa and Thailand, for which I was the P.I. receiving a grant of US\$ 650,000 from USAID/CDC; (ii) the establishment of leadership in Europe on TB surveillance and monitoring, an activity conducted together with the International Union against Tuberculosis and Lung Disease (IUATLD) and numerous country representatives; (iii) the production of “TB/HIV: a Clinical Manual”, published in several editions and different languages with nearly 100,000 copies distributed worldwide; (iv) the preparation and implementation of various studies on TB chemoprophylaxis among HIV-infected persons; and (v) cost-effectiveness studies of different control policies in Thailand, Italy and Russia. Work in collaboration with the Unit of National Programme Support (NPS) included (i) preparing and leading a TB National Programme review in Thailand in 1995; (ii) World Bank consultancies for a health project in Kyrgyzstan, resulting in the setting up of a modern TB control programme supported by the World Bank; and (iii) the planning and establishment of a crucial TB control pilot project (operational research) in Ivanovo Oblast, Russia, now regarded as the model programme in Russia, for which GTB received a grant from the Know How Fund of the British ODA.

Awards and Honors:

1981	110/110 Cum Laude and Publication Rights (a special honor) for the Graduation Thesis
1984-1985	Special Award for Excellence in Patient Care , Cabrini Medical Center, New York City
1988	Special Resolution by the Board of Trustees of Cabrini Medical Center for the efforts in combating the malaria epidemic in Swaziland
2005	Princess Chichibu Memorial TB Global Award presented by the Japan Anti-Tuberculosis Association (JATA), Paris, 19 October 2005.
2006	Featured in The Lancet's Lifeline Series (lancet 2006; 367: 895).
2009-	Fellow of the Royal Academy of Physician (F.R.C.P., London, UK)
2010	Profile "Mario Raviglione - Resolute Director of WHO's Stop TB Department. Lancet 2010; 375:1773
2010	Wolfheze Award for "contributing to the Wolfheze Movement that has been instrumental in adoption of modern TB control policies in the WHO European Region", presented by KNCV Tuberculosis Foundation, The Hague, The Netherlands, 1 June 2010
2014	Foundation Fellow of the European Respiratory Society (F.E.R.S.)
2014	Global Public Health Lifetime Achievement Award , presented by the India International Public Health Conference, India Medical Association, Thiruvananthapuram, Kerala, India, 7 November 2014.
2014	BMA Highly Commended Book for Public Health 2014 “Systematic screening for active tuberculosis – Principles and recommendations”, awarded by the British Medical Association to WHO (Global Tuberculosis Programme, director: Mario Raviglione).
2016	Honorary Member of the Russian Society of Phthisiologists (Rossiiskoe Odshestva Phthisiatrov), Moscow, 24-11-2016.
2017	Recognition plaque by the UNESCO Chair on Training and Empowering Human Resources for Health Development in Resource-Limited Countries - University of Brescia, Italy, in the occasion of the Visiting Professorship, 26 April 2017.

- 2017 **Recognition plaque by the UNESCO Chair** on Training and Empowering Human Resources for Health Development in Resource-Limited Countries - University of Brescia, Italy, in the occasion of the conference “SDG n. 3 – Salute e benessere”, 27 October 2017.
- 2017 USAID - From the American People. **Global Leader Award** presented to Dr Mario C. Raviglione “in Recognition of Your Innovative Approach, Scientific Rigor, and Dedicated Service in Partnership to End TB”. Washington, DC, USA, 30 October 2017.
- 2018 **Sigillo Trecentesco della Città di Trieste** / the City of Trieste, Italy, for the “Battle against TB in the world and for having helped the health authorities of Trieste in the occasion of the TB 2016 outbreak”, 16-4-2018.

Membership:

- 1981- Italian Medical Society
- 1983- Italian Entomological Society
- 1994-2011 International Union Against Tuberculosis and Lung Disease (IUATLD)
- 1997-2000 Italian Society of Tropical Medicine
- 1997- Société Entomologique de Genève, Suisse
- 2000-2005 USAID Tuberculosis Coalition for Technical Assistance (TBCTA)
- 2000-2001 Co-Chair, Working Group 1 (Syndromic Management), Rockefeller Foundation Initiative on AIDS Care in Africa
- 2000-2001 Global Plan to Stop Tuberculosis, Planning Committee
- 2001-2003 StopTB Partnership Coordinating Board (as first Chair of the DOTS Expansion Working Group)
- 2003-2017 StopTB Partnership Coordinating Board (as WHO representative)
- 2003-2017 High-Level Working Group on Tuberculosis in the Russian Federation, Moscow, Russian Federation
- 2003-2004 Nomination Committee of the Stakeholders Association, The Global Alliance for TB Drug Development, New York, USA
- 2004-2005 Working Group on Tuberculosis. UN Millennium Project, Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines
- 2004-2005 Global Plan to Stop TB 2006-2015, Steering Committee
- 2006-2010 Member of the Scientific Committee of the Fondazione Maria Bonino, Biella, Italy
- 2008-2014 Member, Osservatorio Italiano di Salute Globale (OISG)
- 2009- Member, Aspen Institute Italy Network "I talenti Italiani nel mondo"
- 2010- Member, Associazione Naturalistica Piemontese, Turin, Italy
- 2012 “Core group”, Task Force “Scienziati e Ricercatori Italiani all’Estero”. Ministero degli Affari Esteri, Roma, Italy.
- 2014 Member, European Respiratory Society.
- 2017 **Commissioner**, Lancet Commission on Tuberculosis chaired by Prof. E. Goosby.

Board of Directors:

- 2005-2010 Member, Board of Directors, World Lung Foundation
- 2010- Member, Board of Directors (Consiglio di Amministrazione) Fondazione "Opera San Francesco Saverio" - C.U.A.M.M., Padova, Italy

2015- Member and Vice-Chair (2018-20), The Global Alliance for TB Drug Development, New York, USA

Advisory Committees:

1994-2000 Executive Committee of the IUATLD, Europe Region
1998-2000 Executive Committee of the Italian Society of Tropical Medicine, Istituto Superiore di Sanità, Rome
1999 TB Advisory Committee of the Open Society Institute (OSI), New York, NY, USA
2000 Advisory Committee Member, CDC LIFE Initiative, Community and Home Based Care cluster, TB Prevention and Care Program Area, Atlanta, USA
2006- Chair, Scientific Advisory Board, TB(e)Ducation. Health (e) Foundation, Amsterdam, The Netherlands
2008 European Academies Science Advisory Council (EASAC), Working Group on Drug-resistant TB
2011- Chairman, Advisory Board, “BE” (a Kempinski Hotels health initiative), Geneva, Switzerland.
2012-2013 Global Fund Committee on Tuberculosis, The Global Fund, Geneva, Switzerland
2015 Advisory Board, WorldMedSchool – Global Education, Berlin, Germany
2015- McGill Global Health Programs International Advisory Board (IAB), Montreal, Canada
2017- External Committee, IDEAL (Infectious Diseases European-African Learning), Erasmus Project, managed by Université Paris Descartes in collaboration with Universiteit Antwerpen, Università Cattolica Roma, NHS Lothian Edinburgh, and two Ugandan institutions.

Scientific Committees:

1996-2002 Advisory Committee of the European Community Project “EuroTB. Surveillance of Tuberculosis in Europe” (CESES/KNCV).
1997-2001 Reviewer of research proposals, National AIDS Programme (Special Projects: Epidemiology, Clinical science, Opportunistic infections), Istituto Superiore di Sanità, Rome, Italy
1997-1998 Secretary, TB Section, International Union against Tuberculosis and Lung Disease, Paris, France.
1998 Reviewer of abstract submissions, XII International Conference on AIDS, Geneva, Switzerland.
1998-2000 General Consultant and Advisor, Scientific Committee, National Tuberculosis Project, Italy.
1998-2000 Programme Secretary, TB Section, International Union against Tuberculosis and Lung Disease, Paris, France.
1998- Member, Wolfheze Programme Committee, The Hague, The Netherlands.
1998-1999 Member, International Scientific Committee, 1st Regional Congress of the Europe Region, IUATLD, Budapest, Hungary.
2000-2008 Member, Editorial Committee, and Editorial Advisor, Bulletin of the World Health Organization, Geneva, Switzerland.

- 2000 Reviewer of abstract submissions, XIII International Conference on AIDS, Durban, South Africa.
- 2002 Reviewer of abstract submissions, XIV International Conference on AIDS, Barcelona, Spain.
- 2001-2002 Editor, Special Theme Issues on HIV/AIDS and on Tuberculosis, Bulletin of the World Health Organization, December 2001 and June 2002.
- 2003-2004 Associate Editor, Emerging Infectious Diseases, Atlanta, Ga, USA.
- 2003 Member, International Advisory Committee, 24th International Congress on Chemotherapy and 5th International Symposium on Antimicrobial Agents and Resistance, Manila, 4-6 June 2005.
- 2005-2008-2009 Editorial Board member, Emerging Infectious Diseases, Atlanta, Ga, USA.
Member, Comitato Tecnico-Scientifico for "Global Health: guiding principles for the Italian Cooperation", Ministero Affari Esteri, Direzione Generale per la Cooperazione allo Sviluppo, Rome, Italy.
- 2009 Member, Steering Committee for the project "Epidemiology and transmission dynamics of MDR- and XDR-tuberculosis", Harvard University School of Public Health, Boston, USA.
- 2009 Member, Honour Committee of the 30th Annual Congress of the European Society of Mycobacteriology (ESM-2009)
- 2010 Guest Editor ("Guru"), Lancet TB Series, The Lancet, starting 22 May 2010
- 2010 External Advisory Committee - Opportunistic Infections. AIDS Clinical Trials Group (ACTG), USA, September 2010
- 2011 Guest Editor, Eur Respir J Series "Update on Tuberculosis"
- 2011- Member, Comitato Scientifico, Fondazione Biblioteca Biomedica Biellese, 3Bi, Biella, Italy.
- 2011- Member, Scientific Committee – Health, Fondazione Ermenegildo Zegna, Trivero (Biella), Italy.
- 2011- Member, International Scientific Advisory Expert Group, All Party Parliamentary Group (APPG) on Global Tuberculosis, London, UK.
- 2011- "External Clinical Research Expert", NIAID HIV/AIDS Clinical Trials Network Strategic Working Group (SWG), National Institutes of Health (NIH), Bethesda, Md, USA.
- 2015- Editorial Board Member, "Tuberculosis and Lung Diseases", monthly Scientific-practical Journal of the Russian Phtisiologists Society, Moscow, Russia
- 2016- Scientific Council, YES Meeting, Centro Universitario de Medicina FMUP/CHSJ, Porto, Portugal
- 2016- Scientific Council of the University Centre for International Solidarity (CeSI) of the Catholic University (CU), Milan, Italy
- 2016- Scientific Committee of Forum della sostenibilità e opportunità nel settore della salute – Forum della Leopolda, Firenze, Italy, 2016

Editorial Reviewer:

- 1993- Transactions of the Royal Society of Tropical Medicine and Hygiene
- 1995- Tubercle and Lung Diseases
- 1995- AIDS
- 1996- Drugs and Aging
- 1996- Acta Haematologica

1997- International Journal of Tuberculosis and Lung Disease
1997- Clinical Infectious Diseases
1997- Lancet
1998- American Journal of Respiratory and Critical Care Medicine
1998- American Journal of Public Health
1999- JAMA
1999- Thorax
1999- The Medical Journal of Australia
1999- Bulletin of the World Health Organization
2000- New England Journal of Medicine
2001- European Respiratory Journal
2002- Acta Tropica
2002- Eastern Mediterranean Health Journal
2002- Emerging Infectious Diseases
2003- Annals of Internal Medicine
2004- Tropical Medicine and International Health
2007- Journal of Clinical Investigation
2018- Pulmonary Pharmacology & Therapeutics

Teaching Experience:

1. Lecturer on “HIV-associated tuberculosis: epidemiology, pathogenesis and clinical aspects” at the Convegno sul tema “Micobatteriosi ed epidemia da HIV”, Manifestazione Conclusiva del IV Corso Residenziale di Medicina Tropicale dell’Università di Brescia, Mantova, Italy, 26 October 1991.
2. Lecturer on “Tuberculosis epidemiology in industrialized countries” at the IUATLD Post Graduate Training Course on Tuberculosis, Mainz, Germany, 14 June 1994.
3. Lecturer on “Framework of effective tuberculosis control” and “Global tuberculosis situation” at the Master Class on tuberculosis of the Netherlands School of Public Health, Utrecht, the Netherlands, 17 February 1995.
4. Lecturer on “Tuberculosis control in industrialized countries: open issues” at the Public Health Course on Tuberculosis of the Istituto Superiore di Sanità (Higher Institute of Health), Rome, Italy, 22 May 1995.
5. Teacher on “Tuberculosis epidemiology” (series of lectures) at the Summer Residential Course on Tropical Medicine of the University of Brescia, Brescia, Italy, 18 September 1995.
6. Teacher on “Tuberculosis epidemiology” (series of lectures) at the Summer Residential Course on Tropical Medicine of the University of Brescia, Brescia, Italy, 24 September 1996.
7. Teacher on “Tuberculosis epidemiology and surveillance” (series of lectures) at the Summer Residential Course on Tropical Medicine of the University of Brescia, Brescia, Italy, 8 September 1997.
8. Teacher on “Tuberculosis epidemiology and surveillance” (series of lectures) at the Summer Residential Course on Tropical Medicine of the University of Brescia, Brescia, Italy, 31 August 1998.

9. Salzburg-Cornell Seminar on Tuberculosis in Eastern Europe. Organized by the American Austrian Foundation, Salzburg, Austria, 16-21 January 1999.
10. Teacher on "Tuberculosis treatment" and "Drug resistance: surveillance and implications for control" (series of lectures) at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 29 March 2000.
11. Teacher on "La situacion global de la tuberculosis. Desafios en el nuevo siglo", at the III Curso Internacional "Nuevos paradigmas en la direccion de los programas de control de la tuberculosis", Lima Chaclacayo, Peru, 6 July 2000.
12. Teacher on "Tuberculosis epidemiology and indicators", "HIV-associated tuberculosis", "Drug-resistant tuberculosis", and "New diagnostic tests for tuberculosis" (series of lectures) at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 26-27 February 2001.
13. Teacher on "Tuberculose" at the "Cours d'enseignement de Médecine Tropicale et Santé Internationale 2001", Université de Genève, Institut de Médecine Sociale et Préventive, Genève, Suisse, 7 December 2001.
14. Lecturer on "The global epidemiology of tuberculosis and current constraints to control" and "The extent of multidrug-resistant tuberculosis", as Visiting Professor, Johns Hopkins University, Baltimore, Md, USA, 5 February 2002.
15. Teacher on "Tuberculosis epidemiology and global situation", "HIV-associated tuberculosis", "Drug-resistant tuberculosis" (series of lectures) at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 4 April 2002.
16. Teacher on "Tuberculose" at the "Cours d'enseignement de Médecine Tropicale et Santé Internationale 2002", Université de Genève, Institut de Médecine Sociale et Préventive, Genève, Suisse, 29 November 2002.
17. Teacher on "Tuberculosis epidemiology: transmission, infection, disease, risk factors", and "DOTS and new strategie promoted by WHO" (series of lectures) at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 31 March 2003.
18. Teacher on "Tuberculosis epidemiology: transmission, infection, disease, risk factors", "Global tuberculosis situation", "The tuberculosis control strategy and new approaches", and "Drug resistant tuberculosis" (series of lectures) as Visiting Professor, for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 24 September 2003.

19. Teacher on "Tuberculose" at the "Cours d'enseignement de Médecine Tropicale et Santé Internationale 2003", Université de Genève, Institut de Médecine Sociale et Préventive, Genève, Suisse, 28 November 2003.
20. Teacher on "Tuberculosis epidemiology: basic aspects and global situation", at the Conference/Seminar, Infectious Disease and Tropical Medicine Specialty Schools, University of Milan - University Pole L. Sacco, Milan, Italy, 8 March 2004.
21. Teacher on "Tuberculosis epidemiology", "Tuberculosis control strategy", and "TB/HIV: burden and interventions", at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 9 March 2004.
22. Teacher on "Tuberculosis epidemiology: basic aspects and global situation" and "The WHO's DOTS strategy", at the Corso di Formazione legge 135/90, University Vita Salute San Raffaele, Milan, Italy, 3 May 2004 (via videoconference).
23. Teacher on "Tuberculose" at the "Cours d'enseignement de Médecine Tropicale et Santé Internationale 2004", Université de Genève, Institut de Médecine Sociale et Préventive, Genève, Suisse, 25 November 2004.
24. Teacher on "Tuberculosis: global epidemiology and control strategies", and "Tuberculosis preventive chemotherapy" (series of lectures) as Visiting Professor, for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 11 April 2005.
25. Teacher on "Tuberculosis epidemiology", and "Tuberculosis control: international initiatives and future directions" at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 12 April 2005.
26. Teacher on "Tuberculose: la situation dans le monde" at the "Cours d'enseignement de Médecine Tropicale et Santé Internationale 2005", Université de Genève, Institut de Médecine Sociale et Préventive, Genève, Suisse, 2 December 2005.
27. Teacher on "Tuberculosis: Essential epidemiology" and "Tuberculosis: global epidemiology and control strategies" (series of lectures) as Visiting Professor, for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 13 March 2006.
28. Teacher on "Tuberculosis: global epidemiology and control strategies" at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 14 March 2006.

29. Teacher on "Tuberculose: un problème de santé internationale", at the "Cours d'enseignement de Médecine Tropicale et Santé Internationale 2006", Université de Genève, Institut de Médecine Sociale et Préventive, Genève, Suisse, 11 December 2006.
30. Teacher on "Tuberculosis: Essential epidemiology", "Tuberculosis: global epidemiology, challenges and strategies", and "MDR-TB and XDR-TB" (series of lectures) as Visiting Professor, for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 26 March 2007.
31. Teacher on "Tuberculosis: global epidemiology" and "Tuberculosis control strategies: DOTS and beyond" at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 27 March 2007.
32. Teacher on "Tuberculosis epidemiology" and "Tuberculosis control strategies: DOTS and beyond" at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 31 March 2008.
33. Teacher on "Tuberculosis 2008: the Global Situation", and "The drug resistance threat" (series of lectures) as Visiting Professor, for the Respiratory Disease Specialty School and the Infectious Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 1 April 2008.
34. Teacher on "Global tuberculosis situation and the Stop TB Strategy: rationale and impact data", and "The future of tuberculosis: challenges and new approaches for control and elimination", at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 20 April 2009.
35. Teacher on "Tuberculosis: global situation, emerging problems, and M/XDR-TB" as Visiting Professor, for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 21 April 2009.
36. Teacher on "La tubercolosi 2010: sfide ed opportunità", as Visiting Professor, for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 3 March 2010.
36. Teacher on "Epidemiologia della tubercolosi e grandi sfide per il controllo globale", at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), and, as Visiting Professor, for the Infectious Disease Specialty School of the Faculty of Medicine of the University of Brescia, Brescia, Italy, 4 March 2010.
37. Teacher on "Role of global institutions: WHO and the Stop TB Partnership", at the Course "Critical challenges in global tuberculosis control and research", Bloomberg School of Public Health - Epidemiology 4th Quarter, Johns Hopkins University, Baltimore, Md, USA, 13 April

- 2010.
38. Teacher on "Global epidemiology of TB and challenges towards elimination" at the On-line Course on Tuberculosis - Update 2011, The European Respiratory Society, 1 March 2011.
 39. Visiting Professor and Teacher on "Tubercolosi globale 2011: epidemiologia di base, grandi sfide e soluzioni" for the Respiratory Disease Specialty School of the Faculty of Medicine of the University of Modena and Reggio Emilia, Modena, Italy, 18 April 2011.
 40. Teacher on "Tubercolosi globale 2011: impatto a livello globale, risultati della strategia Stop TB, maggiori sfide del prossimo futuro", and "WHO policy package to contain antimicrobial resistance", at the Course in International Health of the University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 19 April 2011.
 41. Teacher on "Overview of global tuberculosis burden and progress in control. Update 2011", at the International RIT Course, Research Institute for Tuberculosis, Kiyose, Japan, 1 June 2011.
 42. "The burden of tuberculosis", at the "Journalist to journalist Lung Health Media Training", by the National Press Foundation, Lille, France, 25 October 2011.
 43. Visiting Professor and Teacher on "Epidemiologia e storia naturale della tubercolosi", "Situazione globale e progresso nel controllo della tubercolosi nel mondo", e "Grandi sfide, strategie e soluzioni per l'eliminazione della tubercolosi", at the Seminario del Corso di Perfezionamento in Medicina Tropicale e Salute Internazionale, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 13 April 2012.
 44. Visiting Professor and teacher on (1) TB basic epidemiology and global burden; (2) Today's challenges for TB control; and (3) Interventions and control strategies, at the Faculty of Science MMFFNN of the University of Pavia, Master Course in Molecular Biology & Genetics and PhD Course in Biology and Biotechnology. Pavia, Italy, 26-27 April 2012.
 45. Teacher on "Epidemiology of tuberculosis", at the course for students, Fondazione Centro San Raffaele, Milano, 13 March 2013.
 46. Raviglione, M. (2013), "The international approach to the control of tuberculosis", in: Raviglione, M. and Nunn, P. (eds), Tuberculosis: The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London, 2013. (online at <http://hstalks.com/?t=BL1533174-Raviglione>). Link: <http://hstalks.com/?t=BL1533174-Raviglione>
 47. Visiting Professor and Teacher on "Storia naturale ed epidemiologia della tubercolosi", and on "Strategie globali per il controllo della tubercolosi: successi attuali, sfide future ed innovazioni", at the Corso di Perfezionamento in Medicina Tropicale e Salute Internazionale, Anno Accademico 2012-2013, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 8 April 2013.
 48. "Global dimension of tuberculosis". WorldMedSchool, on-line teaching. Link: <http://www.worldmedschool.com/recent-uploads.html>

49. "Tuberculosis 2013 – An assessment of WHO's role in fighting TB world-wide", for the Interdisciplinary Health Network via Cisco WebEx, organised by Oxford University Training Programme for Students, 23 May 2013.
50. "Tuberculosis: burden; progress in prevention, care and control; challenges towards elimination", for the on-line course "Global Health: an interdisciplinary overview", coordinated by Geissbuhler A, Loutan L, Battams S, Wernli D, Slama S, Ruiz de Castaneda R. Week 2: Emerging Trends in Global Health: Infectious Diseases". Université de Genève, 2013.
51. "21st century perspectives on infectious diseases – The case of tuberculosis and the work of WHO", Yale Model United Nations Conference, Yale University, New Haven, Conn., USA, 24-1-2014 (via videoconference).
52. "Stato attuale della tubercolosi nel mondo", Lectio Magistralis, Dipartimento di Prevenzione e Scuola di Specializzazione di Igiene, Università di Bari, Italy, 18-2-2014 (via videoconference).
53. Visiting Professor and Teacher on "Storia naturale ed epidemiologia della tubercolosi", and on "Strategie globali per il controllo della tubercolosi: successi attuali, sfide future ed innovazioni", at the Corso di Perfezionamento in Medicina Tropicale e Salute Internazionale, Anno Accademico 2013-2014, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 3 April 2014.
54. "The global challenge of TB and WHO response", at the School of Management "SDA Bocconi", Master Course of International Health Care Management, Economics and Policies, Specialization in Global Health & Development, Bocconi University, Milano, Italy, 13 May 2014.
55. "WHO Global Plan for TB beyond 2015 in low-incidence countries", key-note lecture at the Session "TB and TB control in the future", 2nd European Advanced Course in Clinical Tuberculosis, organised by KNCV, TB Net, FILHA and Tartu University; Royal Tropical Institute, Amsterdam, The Netherlands, 24 September 2014.
56. "Ending TB: burden, progress, challenges, way forward", lecture for Nuffield Center for International Health and Development, Geneva Study Tour, Geneva 24 March 2015.
57. Visiting Professor and Teacher on "Storia naturale ed epidemiologia della tubercolosi", and on "Strategie globali per il controllo della tubercolosi: successi attuali, sfide future ed innovazioni", at the Corso di Perfezionamento in Medicina Tropicale e Salute Internazionale, Anno Accademico 2014-2015, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 15 April 2015.
58. "Ending global TB", at Grand Medical Rounds, TB Rounds, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 8 May 2015 (via videoconference).
59. "What will it take to eliminate the global epidemic?", at the 21st Century Medicine - 2015 Lecture Series. Eastern Avenue Auditorium of the University of Sydney, Sydney Medical School, Sydney, Australia, 1 September 2015.
60. "Ending TB: burden, challenges and response in 2015", at the Master Course in Global Health, Global Health Institute, Université de Genève, Genève, Suisse, 2 October 2015.

61. “Tuberculosis and sustainable development goals: from policy to practice”, at the Introduction to International Public Health Course – Communication and Global Health Concentration, Institute for Global Citizenship – Macalester College, St Paul, MN, USA, 23 November 2015 (via video connection).
62. “Tuberculosis and sustainable development goals: from policy to practice”, at the Cours de médecine tropicale, Faculté de Médecin, Université de Genève, Genève, Suisse, 14 January 2016.
63. “Ending TB – Bold policies and innovations in the SDG era”, at the Harvard course “Tuberculosis: the organism, the hose, and the global threat”, Harvard School of Public Health, Boston, Ma, USA, 9 February 2016.
64. Visiting Professor and Teacher on "Storia naturale ed epidemiologia della tubercolosi", and on “Strategie globali per il controllo della tubercolosi: successi attuali, sfide future ed innovazioni”, at the Corso di Perfezionamento in Medicina Tropicale e Salute Internazionale, Anno Accademico 2015-2016, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 4 April 2016.
65. “Tuberculosis: from stopping to ending TB”, lecture for Nuffield Center for International Health and Development, Geneva Study Tour, Geneva, 8 April 2016.
66. “The role of WHO in the fight against TB and infections diseases”, at the AMCLI (Associazione Microbiologi Clinici Italiani) Summer School, Theoretical-practical Course of Clinical Microbiology for Biomedical Laboratory Health Technicians. Aosta, Italy, 7 September 2016 (via recorded video).
67. “Tuberculosis – Burden, challenges, response in 2016”, at the Master Course in Global Health, Global Health Institute, Université de Genève, Genève, Suisse, 10 October 2016.
68. “TB 2016 – Burden, challenges, innovations”, Weekly Seminar Series, Nuffield Lecture Theatre, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 26 October 2016.
69. “Tuberculose: la stratégie d’élimination de l’OMS”, at the Cours de médecine tropicale et santé globale, Faculté de Médecine, Université de Genève, Genève, Suisse, 11 January 2017.
70. “Prospects for Tuberculosis Elimination: Progress and Need for Research and Innovations”, at the Special Seminar, Braun School of Public Health and Community Medicine, Hebrew University of Jerusalem, Hadassah Medical Organization, Jerusalem, Israel, 27 March 2017.
71. Visiting Professor and Teacher on "Natural history of TB, epidemiology and impact, End TB Strategy in the era of the SDG" (4 hr); and on “Universal health coverage, social protection, future perspective: from application of digital health to precision medicine (2 hr), at the TropEd Course in Tropical Medicine and International Health, Academic Year 2016-17, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 26 April 2017.
72. “Managing global health challenges – Tuberculosis Programme at WHO”, at the SDA Bocconi University Master of International Health Care Management, Economics and Policy

- (MIHMEP), Specialization in Global Health & Development, Bocconi University, Milano, Italy, 27 April 2017.
73. “Global health and foreign policy agenda in the United Nations: UNGASS and the Security Council”, at the Executive Course on Global Health Diplomacy, Graduate Institute of International and Development Studies, Geneva, Switzerland, 15 June 2017.
 74. “The End TB Strategy in the light of the of the SDGs”, at the Master of Science in Global Health, Global Health Institute, Université de Genève, Genève, Suisse, 24 October 2017.
 75. “SDGs, infectious disease burden, antimicrobial resistance, tuberculosis, immigration and ethics in TB care and control”, didactic seminar at the “Master in Family and Community Nursing”, Department of Translational Medicine, University of Eastern Piedmont, Vercelli, Italy, 4 December 2017.
 76. “Zoonotic tuberculosis in the WHO End TB Strategy”, at the MOOC on One Health, University of Geneva, Switzerland. <https://www.coursera.org/learn/global-health-human-animal-ecosystem/lecture/yS1TI/zoonotic-tuberculosis-in-the-who-end-tb-strategy-dr-m-raviglione-dr-a-dean-who>
 77. “Tuberculose: la stratégie d’élimination de l’OMS”, at the Cours de médecine tropicale et santé globale, Faculté de Médecine, Université de Genève, Genève, Suisse, 10 January 2018.
 78. Visiting Professor and Teacher on “Why global health is important, evolution of global health, key actors in global health, and international cooperation” (6 hr), at the Corso di Perfezionamento “Global Health – Post-Graduate Course in Global Health”, Academic Year 2017-18, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 16-2-2018.
 79. Visiting Professor and Teacher on “Natural history of TB, epidemiology and impact of interventions”, and “End TB Strategy in the era of the SDG, with special focus on universal health coverage and social protection” (4 hr) at Corso di Perfezionamento “Global Health – Post-Graduate Course in Global Health”, Academic Year 2017-18, Faculty of Medicine, University of Brescia, Core Course for the European Master in International Health (TROPEDEUROP), Brescia, Italy, 27-4-2018.
 80. “Managing a global health programme – The case of tuberculosis”, at the SDA Bocconi University Master of International Health Care Management, Economics and Policy (MIHMEP), Specialization in Global Health & Development, Bocconi University, Milano, Italy, 10 May 2018.
 81. “L’infezione e la malattia tubercolare: quale pattern epidemiologico nel mondo e in Europa?”, at the Corso di Salute Pubblica, Scuola di Medicina 4th Year Medical Students, University of Milan, Polo San Paolo, Milano, Italy, 11-5-2018.

Invited Lectures:

1. "Treatment of HIV infection". In "AIDS: therapeutic management and economic impact"; Annual meeting of the New York State Council of Hospital Pharmacists. Saddle Brook, New Jersey, 9 March 1990.
2. "Global tuberculosis situation". Congresso Annuale della Società Italiana di Medicina Tropicale. Roma, Italy, May 1993.
3. "Guidelines on management of pulmonary tuberculosis in HIV-infected patient". The 17th Eastern Regional Conference on Tuberculosis and Respiratory Diseases of the IUATLD, Eastern Region. Bangkok, Thailand, 1-4 November 1993.
4. "Introduction to the mycobacterioses". Seventh National Conference on AIDS. Bari, Italy, 12-14 November 1993.
5. "Advances in preventive chemotherapy for tuberculosis". Annual Meeting of the Gruppo Italiano Studio Tubercolosi e AIDS (GISTA). Rome, Italy, February 1994.
6. "Surveillance of HIV infection in tuberculosis patients". Second European Meeting on Tuberculosis Control in Low Prevalence Countries. Wolfheze, the Netherlands, 20-25 March 1994.
7. "The tuberculosis situation in Europe". Second European Meeting on Tuberculosis Control in Low Prevalence Countries. Wolfheze, the Netherlands, 20-25 March 1994.
8. "Overview of the tuberculosis problem in Eastern Europe and the former USSR". First Meeting of Tuberculosis Programme Managers of Central and Eastern Europe and former USSR. Warsaw, Poland, 20-22 June 1994.
9. "Framework for national tuberculosis programmes and minimal indicators for disease surveillance and programme monitoring". First Meeting of Tuberculosis Programme Managers of Central and Eastern Europe and former USSR. Warsaw, Poland, 20-22 June 1994.
10. "The WHO project on antituberculosis drug resistance surveillance". Third Consensus Conference on Tuberculosis Eradication of the Associazione Italiana Pneumologi Ospedalieri (AIPO). Palermo, Italy, 27-29 October 1994.
11. "Global Tuberculosis Situation". Invited lecture at the Central Tuberculosis Research Institute of the Academy of Science. Moscow, Russia, 1 November 1994.
12. "The WHO project on antituberculosis drug resistance surveillance". Annual Meeting of the Gruppo Italiano Studio Tubercolosi e AIDS (GISTA). Rome, Italy, 21 March 1995.
13. "Tuberculosis in Eastern Europe". Invited lecture at the Norwegian National Screening Services. Oslo, Norway, 21 September 1995.
14. "The global tuberculosis situation". Epidemiological Grand Round at the Centers for Disease Control, Atlanta, Georgia, USA, 27 February 1996.

15. "Trends in the global rates of tuberculosis". First Mid Year Conference of the IUATLD, North American Region. Chicago, Illinois, USA, 1-2 March 1996.
16. "Global tuberculosis epidemiology". Annual Meeting of the Gruppo Italiano Studio Tubercolosi e AIDS (GISTA). Rome, Italy, 12 April 1996.
17. "The global WHO strategy of tuberculosis surveillance and programme monitoring". Second Meeting of Tuberculosis Programme Managers of Central and Eastern Europe and former USSR. Warsaw, Poland, 28-30 August 1996.
18. "Impact of HIV on tuberculosis in developing countries". The Annual Congress of the European Respiratory Society. Stockholm, Sweden, 7-11 September 1996.
19. "Effects of immigration on tuberculosis rates". The Annual Congress of the European Respiratory Society. Stockholm, Sweden, 7-11 September 1996.
20. "What is the current situation of TB/HIV?". Conference on Global Lung Health and the 1996 Annual Meeting of the International Union Against Tuberculosis and Lung Diseases (IUATLD). Paris, France, 2-5 October 1996.
21. "Tuberculosis as a travel-related disease". Fifth International Conference on Travel Medicine. Geneva, Switzerland, 24-27 March 1997.
22. "Tuberculosis: global situation and the WHO control strategy". Seminar "The epidemics of the 21st century". Barcelona, Spain, 15-17 April 1997.
23. "Treatment outcome and its trend in Europe". Third European Workshop on Tuberculosis Control in Low Prevalence Countries. Noordwijk, The Netherlands, 15-20 June 1997.
24. "State of tuberculosis in the world". Symposium on "Tuberculosis - Present state, future prospects" at the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease, IUATLD/UICTMR. Paris, France, 1-4 October 1997.
25. "Active case detection among high risk groups and chemoprophylaxis". Second Sub-regional Workshop on Tuberculosis Elimination Initiative in the Member States of the Gulf Cooperation Council. Abu Dhabi, U.A.E., 22-24 November 1997.
26. "The epidemiology of global tuberculosis and drug resistance". Invited Panel 15: Global TB Issues and Challenges. International Conference on Emerging Infectious Diseases, organized by CDC, Council of State and Territorial Epidemiologists, American Society of Microbiology, and National Foundation for CDC. Atlanta, GA, USA, 8-11 March 1998.
27. "MDR-TB in the context of the global tuberculosis pandemic" at the meeting "Community-based approaches to the treatment and control of multidrug-resistant tuberculosis", organised by the Harvard Medical School, the World Health Organization, and the Rockefeller Foundation. American Academy of Arts and Sciences, Cambridge, MA, USA, 4-5 April 1998.

28. "The WHO/IUATLD Supranational Reference Laboratory Network". Fourth European Workshop on Tuberculosis Control in Low Prevalence Countries. Wolfheze, The Netherlands, 8-10 June 1998.
29. "The global project on antituberculosis drug resistance surveillance". VIII Annual Meeting of the Gruppo Italiano Studio Tubercolosi e AIDS (GISTA). Rome, Italy, 17 June 1998.
30. "Demographic causes" at the Major Symposium "Causes of tuberculosis increase" jointly organized by ERS, IUATLD (Europe region) and WHO. Annual Congress of the European Respiratory Society. Geneva, Switzerland, 19-23 September 1998.
31. "Progress in the implementation of the WHO DOTS strategy" at the Symposium "DOTS more widely, DOTS more easily and how to contain the reemergence of rifampicin resistance". Global Congress on Lung Health, 29th World Conference of International Union Against Tuberculosis and Lung Disease, IUATLD/UICTMR. Bangkok, Thailand, 23-26 November 1998.
32. "Demographic causes of tuberculosis increase" at the 8th Münchenwiler Symposium "Immigration and Tuberculosis". Annual Conference of the Ligue Pulmonaire Suisse, Münchenwiler, FR, Switzerland, 4 March 1999.
33. "Present status of tuberculosis and future projections" at the session "A global perspective on TB and Canada's challenge". 1999 Tuberculosis Conference, Edmonton, Alberta, Canada, 18-19 March 1999 (via videoconference from Geneva).
34. "How to control emerging multidrug-resistance", guest speaker at the Annual Meeting of the Royal Netherlands Tuberculosis Association (KNCV). Utrecht, the Netherlands, 28 May 1999.
35. "Assessment of current TB epidemic and TB control efforts", at the Global Tuberculosis Research Initiative Second Meeting (GTRI-2). Casablanca, Maroc, 29 June 1999.
36. "Update of the WHO DOTS-PLUS Working Group", at the Meeting on Second-Line Anti-TB Drug Procurement, organized by WHO and the Harvard Medical School/Partners in Health. Academy of Arts and Sciences, Cambridge, Ma, USA, 5 July 1999.
37. "Future directions: the WHO perspective", at the Workshop "Tuberculosis Drug Resistance Surveillance, 30th World Conference of the International Union Against Tuberculosis and Lung Disease, IUATLD, Madrid, Spain, 14 September 1999.
38. "Multidrug resistant tuberculosis", at the Conference "Tuberculosis control in the 21st Century", organised by "Chest, Heart and Stroke Scotland", The Royal College of Physicians, Edinburgh, Scotland, UK, 21-22 September 1999.
39. "The world-wide tuberculosis situation and its impact on the USA", at the "Tuberculosis Symposium", IDSA '99 (Infectious Disease Society of America), Philadelphia, USA, 18-21 November 1999.
40. "Global epidemiology of tuberculosis", keynote address at the International Colloquium "Tuberculosis, the real millennium bug. Addressing the threat in developing and industrialised countries", Institute of Tropical Medicine, Antwerp, Belgium, 14-17 December 1999.

41. "Health policy, health system, and health services research", at the first Scientific Working Group meeting of TDR, Geneva, Switzerland, 9-11 February 2000.
42. "Multidrug-resistant tuberculosis and its management", at the Conference on "Chemotherapy of tuberculosis", Moscow Medical Academy I.M. Sechenov, Moscow, Russian Federation, 6-8 April 2000.
43. "Tuberculosis in Eastern Europe", plenary lecture at the 1st Congress of the IUATLD Europe Region in association with the 51st Congress of the Hungarian Respiratory Society, Budapest, Hungary, 12-15 April 2000.
44. "WHO's DOTS-PLUS Policy", at the 6th Wolfheze Workshop on TB Control in Europe, Wolfheze, The Netherlands, 27-30 May 2000.
45. "Lessons from DOTS and Adult Lung Health Initiative", at the Consultative Meeting on "Good practices in outpatient HIV prevention and treatment", organised by the Rockefeller Foundation, New York City, USA, 12 September 2000.
46. "La situación mundial de la tuberculosis: retos para el nuevo siglo", at III Congreso Nacional de Sanidad Penitenciaria, organised by Sociedad Española de Sanidad Penitenciaria, Granada, Spain, 26-28 October 2000.
47. "DOTS-Plus for MDR-TB – Progress of the WHO Working Group" at the Annual Meeting of the StopTB's Working Group on DOTS-Plus for MDR-TB, Lima, Peru, 25-27 January 2001.
48. "The global TB burden and interventions strategies by partners", at the Strategic Planning Conference on Canada's contribution to the Massive Effort for Global TB Control, Edmonton, Canada, 10 February 2001 (via tele-conference).
49. "The extent of drug resistant tuberculosis", Keynote lecture at the Royal Society of Medicine Symposium "TB Drug Resistance: from molecules to macro-economics", hosted by The Royal Society of Medicine in association with The Liverpool Medical Institutions and TB Focus, London, UK, 29-30 March 2001.
50. "What more need we do? - Europe", at the Royal Society of Medicine Symposium "TB Drug Resistance: from molecules to macro-economics", hosted by The Royal Society of Medicine in association with The Liverpool Medical Institutions and TB Focus, London, UK, 29-30 March 2001.
51. "Syndromic management: introduction", at the Meeting on AIDS Care in Africa, convened by The Rockefeller Foundation, hosted by The Joint Clinical Research Centre and Makerere University, co-sponsored by UNAIDS, US NIH, and GFHR, Kampala, Uganda, 18-20 April 2001.
52. "La situation globale de la tuberculose et les défis actuels", at the Congrès International sur les Maladies Infectieuses, Séance 3: La Tuberculose, organisé par la Société Algérienne de Microbiologie (SAM) et l'Association Solidarité Franco-Maghrebine (France), Alger, Algeria,

12-14 May 2001.

53. "The global tuberculosis situation and the current constraints to DOTS expansion", at the Western Pacific Regional Office (WPRO) - Technical Advisory Group Meeting, Beijing, China, 4 June 2001.
54. "L'attualità della tubercolosi nel panorama mondiale. Il contributo dell'OMS nel controllo globale", at the Convegno "La tubercolosi come problema globale e attuale", organised by the University of Pavia, Faculty of Medicine, Pavia, Italy, 14 September 2001.
55. "Global trends in tuberculosis and constraints for DOTS", at the Congress "Pulmonologija in Alergologija v Sloveniji 21. Stoletju", organised by Bolnisnica Golnik, Cankarijev Dom, Ljubljana, Slovenia, 5 October 2001.
56. "The global epidemiology of TB", at the 32nd IUATLD World Conference on Lung Health, Symposium "The year in review: the studies that changed my practices". Paris, France, 2 November 2001.
57. "New challenges to global TB control and possible solutions", at the the 32nd IUATLD World Conference on Lung Health, "Meet the Professor" session. Paris, France, 3 November 2001.
58. "Global initiatives to control TB and HIV/AIDS", at the 12th Meeting of the Interagency Coordinating Committee (ICC) focused on Tuberculosis. EURO, Copenhagen, 23 January 2002.
59. "TB information system in low and middle incidence countries", at the Western Pacific Regional Office (WPRO) - Technical Advisory Group Meeting, Osaka, Japan, 18 February 2002.
60. "TB control in urban settings: global perspective", at the Conference "Cities and Health: Summit on TB Control, Osaka, Japan", organised by the WHO Centre for Health and Development, Kobe. Osaka, Japan, 20 February 2002.
61. "DOTS expansion: how far have we come?", at "Stop Tuberculosis, Fight Poverty – World TB Day 2002 Conference", organised by StopTB Canada, Ottawa, Canada, 22 March 2002 (via videoconference from Geneva).
62. "TB – The epidemic from 1992-2002", plenary session, at the 4th World Congress on Tuberculosis, Washington, DC, USA, 3-5 June 2002.
63. "Introduction to the Practical Approach to Lung Health (PAL) vision", at the 1st International Consultation on PAL, Rabat, Maroc, 4-6 September 2002.
64. "Situacion global de la TB y la expansion de DOTS", at the NTP Managers Meeting of the Latin American Region, la Habana, Cuba, 11-13 September 2002.
65. "Global DOTS expansion: how are we doing?", at the 3rd StopTB DOTS Expansion Working Group Meeting, Montreal, Canada, 6 October 2002.

66. "Global DOTS expansion: will we reach the targets?", at the 33rd IUATLD World Conference on Lung Health, Symposium "Global Partnership to Stop TB – Progress and Challenges", Montreal, Canada, 6-10 October 2002.
67. "Tubercolosi: un problema globale", at the Conference "La tubercolosi polmonare tra migrazioni e multiresistenza", organised by the University of Modena and Reggio Emilia, Modena, Italy, 16 November 2002.
68. "La tubercolosi nel mondo ed in Africa", at "Saturday Cuamm – Le Nuove Frontiere del Prendersi Cura: Un male che toglie il respiro – Tbc in Africa", organised by Cuamm – Medici con l’Africa, Padova, Italy, 25 January 2003.
69. "Tuberculosis: highlights from the Global Report 2003". Faculty Seminar, organised by University of Brescia, Brescia, Italy, 31 March 2003.
70. "The Global Plan to Stop TB and new tools", at the Annual Meeting of the Stakeholders Association of the Global Alliance for TB Drug Development. Paris, France, 30 October 2003.
71. "DOTS expansion in the 22 high-burden countries: progress, challenges and the way ahead", at the Meeting of Russian and International Partners on Financial Mobilization for Tuberculosis and HIV/AIDS Control in the Russian Federation. Ministry of Health, Moscow, Russian Federation, 21 November 2003.
72. "Controllo globale della tubercolosi", at Convegno Tubercolosi, Modena, Italy, 11 December 2003 (via video from Geneva).
73. "Tuberculosis: current situation and modern challenges in modern times", at a plenary session of the International Conference on Emerging Infectious Diseases 2004, Atlanta, Georgia, USA, 3 March 2004.
74. "Why is tuberculosis such an important issue? Human and economic impact" and "What can be done to control tuberculosis on a global level?", at the Building Media Awareness on Tuberculosis - A Seminar for Journalists, Moscow, Russia, 23 June 2004.
75. "Global situation and future perspectives", at the plenary session "Past, present and future of tuberculosis control" of the 3rd Congress of the Europe Region of IUATLD, Moscow, Russia, 24 June 2004.
76. "Esperti associati e giovani funzionari: quali aspettative per le generazioni future alla luce di esperienze vissute". Session I of "Associate Expert Programme and Young Officers - 30 Years of Cooperation with International Organizations", as part of the "Giornate della Cooperazione Italiana", Rome, Italy, 3 December 2004.
77. "TB control worldwide: situation and problems", at the session "Multidrug-resistant tuberculosis: global challenge" of the 5th International Symposium on Antimicrobial Agents and Resistance (ISAAR - 2005), Seoul, Korea, 28 April 2005.
78. "Strategies for planning: setting appropriate targets - The case of tuberculosis", at the 785th Wilton Park Conference "Improving the effectiveness of health interventions in developing countries: how is performance-based funding working?", Wilton Park, Steyning, West Sussex,

UK, 18 June 2005.

79. "Stopping TB: progress, challenges and the new DOTS framework", Lunch-time Seminars, USAID, Washington, DC, USA, 30 September 2005.
80. "WHO-recommended StopTB Strategy - Achieving the MDGs", at the "Joint Meeting of the StopTB Partnership Working Groups on DOTS Expansion, TB/HIV and DOTS-Plus for MDR-TB, in memory of Lisa Véron", Versailles, France, 15 October 2005.
81. "WHO-recommended StopTB Strategy - The role of communities and PLWHA", at the "4th TB/HIV Community Mobilisation Workshop", Paris, France, 19 October 2005.
82. "WHO/StopTB, the GDF and the GLC", at the "Open Forum on key issues in TB drug development", organized by the Global Alliance for TB Drug Development and the Bill & Melinda Gates Foundation. Arlington, Va, USA, 6-7 December 2005.
83. "La tuberculose, maladie oubliée?", Colloque International "Faim et pandémies en Afrique: comment en finir avec ces tragédies?", organisé par l'Institut Euro-Méditerranéen et l'Assemblée Nationale, Commission des Affaires Etrangères, Paris, France, 14 Décembre 2005.
84. "The perfect storm - TB & TB/HIV, MDR-TB", at the conference "Reversing the tide. The end of tuberculosis", organized by the Earth Institute at Columbia University and the Global Alliance for TB Drug Development, Low Memorial Library, Columbia University, New York, NY, USA, 7 March 2006.
85. "La tubercolosi nel mondo - Il grande ritorno", al Convegno "Tubercolosi - Un problema globale. L'impegno italiano nella lotta alla tubercolosi nel mondo" organised by Stop TB Italia. Istituto Scientifico Universitario San Raffaele, Milan, Italy, 23 March 2006.
86. "Tuberculosis - global status", at the Conference "What is new in an old disease", 5th Spring Conference 2006, organised by Stop TB Canada. University of Alberta, Edmonton, Canada, 24 March 2006 (via videoconference).
87. "Promise of the new Stop TB Strategy", at the "MDR-TB Summit - Partners Meeting for MDR-TB Control", hosted by The Task Force for Child Survival, Atlanta, USA, 10-11 May 2006.
88. "Global tuberculosis control: burden, targets, strategy and plan", at the Annual Meeting of the KNCV Tuberculosis Foundation, The Hague, The Netherlands, 17 May 2006.
89. "Global tuberculosis: burden, targets, strategy and plan", at the Cabrini Medical Center Alumni Grand Round, New York, USA, 25 May 2006 (via videoconference).
90. "TB in the world - Emergency in Europe", at the Public Health Seminar "TB is an emergency in Europe", organized by the Italian Red Cross and WHO/EURO, with the co-sponsorship of Italian Cooperation Agency, Ministry of Health, Istituto Superiore di Sanità, Stop TB Italia, Roma, Italy, 8 June 2006.
91. "The new Stop TB Strategy", at the Symposium "Challenges in long-term drug delivery (HIV & TB)", Geneva Forum - Towards Global Access to Health, Geneva, Switzerland, 1 September

2006.

92. "Global issues in TB control and the new Stop TB Strategy of WHO", at the 11th Meeting of the NTP Managers of the Eastern Mediterranean Region, Cairo, Egypt, 4 September 2006.
93. "The new Stop Tb Strategy of WHO", at the Meeting of the NTP Managers of the European Region, Vilnius, Lithuania, 25 September 2006.
94. "Standard internazionali diagnostico-terapeutici per la tubercolosi", at the 5th National Congress of the Italian Society of Infectious and Tropical Diseases (SIMIT), Taormina, Italy, 13 October 2006.
95. "Moving ahead with the Stop Tb Strategy: where are we today?", at the Joint Meeting of the Core Teams of the Implementation Working Groups of the Stop Tb Partnership and High-Burden Countries, Paris, France, 30 October 2006.
96. "Infectious diseases and globalization", at the XXI International Conference "The Pastoral Aspects of the Treatment of Infectious Diseases", The Pontifical Council for Health Pastoral Care of the Holy See, Vatican City, 23-25 November 2006.
97. "Global TB control: achievements, challenges, and the need for better tools", at the MSF Symposium "No Time to Wait - Overcoming Gaps in TB Drug Research and Development", The Cornell Club, New York, USA 11-12 January 2007.
98. "Progress in meeting the 2005 targets and challenges to meet the 2015 goals", at the Stop TB Canada Meeting, 11th Annual Conference, North American Region of IUATLD, Vancouver, BC, Canada, 22-2-2007 (via videoconference).
99. "Briefing on global tuberculosis" at the meeting on "Global threat of drug-resistant tuberculosis: a call to action for World TB Day" of the Subcommittee on Africa and Global Health, Committee on Foreign Affairs of the U.S. House of Representatives, Washington, DC, USA, 21-3-2007.
100. "State of the TB epidemic and global control efforts", at the StopTB Partnership - Private Sector Constituency Meeting, organized by the World Economic Forum, Genève 20 April 2007.
101. "Drivers and determinants of the tuberculosis epidemic", at the "Workshop on Infectious Diseases and Social Determinants", organized by the European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden, 26-27 April 2007.
102. "Global tuberculosis: burden, challenges, and the new Stop TB Strategy", at the Plenary session 1 "125 years after the discovery of Robert Koch, what is new in TB control?"; 4th European Region Congress of the International Union against Tuberculosis and Lung Disease (the Union), Riga, Latvia, 27-30 June 2007.
103. "Multidrug-resistant TB and XDR-TB: burden and response", at the "Tuberculosis Parallel Session" of the Meeting "Health Strategies in Europe", organized by the Portugal 2007 Presidency of the Council of the European Union, Lisboa, Portugal, 12-13-July 2007.

104. "From dream to reality check on MDR-TB management scale-up", at the "6th Meeting of the Working Group on MDR-TB of the StopTB Partnership", Tbilisi, Georgia, 20-22 September 2007.
105. Moderator. Session 2 "Disease prevention: the challenge of communicable and chronic conditions", at the Ministerial Conference "Health and Migration in the European Union - Better Health for All in an inclusive Society". Organized by the Portuguese EU Presidency, Lisboa, Portugal, 27-28 September 2007.
106. "La salute dei poveri - Come affrontare il problema della tubercolosi", part of "BergamoScienza", Conferenza n. 3, Bergamo - Città Alta, Italy, 6 October 2007.
107. "Global TB: burden, challenges and response", at the Global Health Council (GHC) Policy Series "Next steps in the fight against TB", organized by the GHC, Washington, DC, USA, 16 October 2007.
108. "Emerging threats: XDR/MDR-TB", at the Policy Luncheon "The TB frontier: new strategies, HIV linkages, threats and tools", organized by the CSIS Task Force on HIV/AIDS and the Henry J. Kaiser Family Foundation, Dirksen Senate Office Building, Washington, DC, USA, 17 October 2007.
109. "Europe and the White Plague: close to tragedy in the East, far from elimination in the west", at the "WHO European Ministerial Forum - All against tuberculosis", Berlin, Germany, 22 October 2007.
110. "MDR-TB and TB/HIV: global policy highlights", at "StopTB Symposium - MDR-TB and TB/HIV: a threat or opportunity for TB control", Satellite Symposium, 38th Union Conference on Lung Health, Cape Town, South Africa, 8 November 2007.
111. Panelist at "Challenging TB orthodoxy: confronting policy barriers", at the "Time to change", Satellite Symposium organized by OSI, MSF, TAC, ARASA, PIH, 38th Union Conference on Lung Health, Cape Town, South Africa, 9 November 2007.
112. "XDR-TB: a mass media scare or a serious threat to TB control? Policy implications of MDR/XDR-TB", at the "Meet the Expert" session, 38th Union Conference on Lung Health, Cape Town, South Africa, 12 November 2007.
113. Panelist at "African Generation: Struggling for Life - From the fight against AIDS to multidrug-resistant tuberculosis", at "The Next Generation", 8th World Summit of the Nobel Peace Laureates, Campidoglio, Roma, Italy, 14 December 2007.
114. "The global TB situation", at "Tuberculosis - A global and local threat", Symposium organized by Irish Aid, Royal Irish Academy, Dublin, Ireland, 13 February 2008.
115. "MDR- and XDR-TB", at "Tuberculosis - A global and local threat", Symposium organized by Irish Aid, Royal Irish Academy, Dublin, Ireland, 13 February 2008.
116. "Global epidemiology and Stop TB Strategy", at the "Joint Ministry of Health & WHO Mission for TB Control", Ezulwini-Mbabane, Swaziland, 20 February 2008.

117. Statement on "The MDR-TB situation based on the 4th Anti-tuberculosis Drug Resistance Surveillance Project", at the Subcommittee on Africa and Global Health, Committee on Foreign Affairs of the U.S. House of Representatives, Washington, DC, USA, 27 February 2008.
118. "Global epidemiology of tuberculosis: from MDR to XDR", at the AMMI Canada / CACMID Annual Conference 2008, Vancouver, Canada, 29-2-2008 (via videoconference).
119. "TBC, emergenza globale", at "TB Day 2008 - Giornata Mondiale per la Lotta alla Tuberculosis", organized by Stop TB Italia, Istituto Scientifico Universitario San Raffaele, Milan, Italy, 6 March 2008.
120. "La tubercolosi nel terzo millennio", at the "Forum Internazionale di Terapia Antinfettiva - Infection 2008", organized by the University of Verona in collaboration with FADOI, SIC, SITA, SIMIT. Verona, Italy, 14 March 2008.
121. "How to move forward on the TB Research Movement", at the meeting "How to boost R&D for low-cost and better tools to fight TB", organized by MSF Suisse, Genève, Suisse, 11 April 2008.
122. Panelist at "The integrated response to the dual epidemic", at the "UNAIDS-PCB - Thematic Session on TB", Chiang Mai, Thailand, 23 April 2008.
123. "Global TB epidemiology" at the meeting "Moving forward in diagnosis of infectious diseases in developing countries - A focus on tuberculosis", organized by WHO and Fondation Mérieux, Veyrier-du-Lac, France, 8 May 2008 (via videoconference).
124. "The need for new tools to control TB", at the meeting "Harnessing alternative mechanisms to boost R&D for tuberculosis: putting IGWG into action", organized by MSF, Palais des Nations, Room XI, Genève, Suisse, 21 May 2008.
125. "TB situation in the world - WHO priorities to accelerate impact", at the Regional Meeting of the National Tuberculosis Programme Managers, PAHO. Bogotá, Colombia 8 September 2008.
126. "La tubercolosi resistente ai farmaci: tubercolosi MDR e XDR sono un pericolo reale? Definizione ed epidemiologia globale", in "9° Congresso Nazionale della Pneumologia - Simposio del Gruppo di Studio "Infezioni e tubercolosi", organized by Unione Italiana per la Pneumologia - SIMeR - AIPO - FIMPST, Genova, Italy, 12 September 2008.
127. "Key challenges to global tuberculosis control", in "Session 38: Tuberculosis - Issues from the molecules to the globe: national and international perspective on TB". Health Protection 2008, University of Warwick, UK, 17 September 2008.
128. "Tuberculosis is a global health issue: research needs and new tools". Keynote lecture at "Immunodiagnosis of tuberculosis. New questions, new tools", organized by PHRI, NJ, USA and SSI, Denmark. Virginia Beach, Va, USA, 21-23 September 2008.
129. "Global tuberculosis control: facts and challenges", at the Symposium "New insights into tuberculosis control". 18th Annual Congress of the European Respiratory Society, Berlin, Germany, 7 October 2008.

130. Panelist at "Promoting public health and human rights in MDR-TB care". Organized by Open Society Institute and WHO. Paris, 17 October 2008.
131. "Global coordination in TB research", Session V - Tuberculosis: looking beyond" in the "International Conference: Challenges for the Future - Research on HIV/AIDS, Malaria, and Tuberculosis". European Commission. Bruxelles, 13-14 November 2008.
132. Luncheon on TB. Center for Strategic and International Studies (CSIS). Washington, DC, USA, 10 December 2008.
133. "What future for tuberculosis?" - The George Comstock Lecture, at the 13th Annual Conference, International Union against Tuberculosis and Lung Diseases, North American Region "Reaching the Un-reached", Vancouver, Canada, 26 February 2009.
134. "Implementation of current tools and financing. Progress and challenges globally", Plenary session at the 3rd Stop TB Partners' Forum, Rio de Janeiro, Brazil, 23 March 2009.
135. "The challenge of M/XDR-TB: the way forward", at the Ministerial Meeting of High M/XDR-TB Burden Countries, organized by the Government of the People's Republic of China, WHO, and the Bill & Melinda Gates Foundation, Beijing, China, 1st April 2009.
136. "The role of in-vitro diagnostics in global TB control" at the "First IVD-Public Health Conference", organized by the European Diagnostic Manufacturers Association (EDMA), Fondation Mérieux, Veyrier-du-Lac, France, 4 June 2009.
137. "Strategie di Stop TB", at the Seminar on Tuberculosis, Dept. of Biology, Univesrità degli Studi di Roma "Tor Vergata", Roma, Italy, 5 June 2009 (via video).
138. "MDR/XDR-TB: burden and control", at the Third Annual New England TB Symposium, organized by Harvard University, Broad Institute, Cambridge, Ma, USA, 12 June 2009.
139. Panelist at Plenary Panel Session IV "Effective global health delivery - how does it work? How should it work?", at the Pacific Health Summit 2009 - MDR-TB: overcoming global resistance. Seattle, Wa., USA, 17 June 2009.
140. Chair of the Working Breakfast "Universal access through universal health coverage: a case for health system strengthening". Pacific Health Summit 2009. Seattle, Wa., USA, 17 June 2009.
141. "MDR-TB as a global threat", Keynote speech at the Meeting on Tuberculosis un der the High Patronage of H.R.H. The Grand Duchess of Luxembourg. Organized by EC-DG SANCO, ECDC, WHO-EURO. Luxembourg, 1 July 2009.
142. "Facing MDR/XDR-TB control: policies and strategies", Plenary Session at the 6th European Congress on Tropical Medicine and International Health, Verona, Italy, 8 September 2009.
143. "Facing tuberculosis: burden and strategies", at the "Networking Day - BioAlps - Infectious Diseases", Merck-Serono, Geneva, Suisse, 23 September 2009.
144. "Stop TB - The state of treatment for XDR-, MDR- and drug-sensitive TB: thinking out of the box to treat TB and interrupt new infections on a global scale", at the 2010 Keystone Symposia

- "Overcoming the crisis of TB and AIDS. Part of the Keystone Symposia "Global Health Series". Arusha, Tanzania, 20-25 October 2009.
145. "The global challenge of tuberculosis", at the "Jacques Grosset Birthday Symposium", Johns Hopkins University, Center for TB Research, Baltimore, Md, USA, 13 November 2009 (via videoconnection).
 146. "Combating tuberculosis: from social determinants to policy bottlenecks", at The All-Party Parliamentary Group on Global Tuberculosis, House of Commons, London, UK, 24 November 2009.
 147. "TB and tobacco control joining forces", at the "Tuberculosis and tobacco - WHO/Union Joint Panel Discussion on the challenges in implementing joint activities of TB and tobacco control", satellite event of 40th the Union World Conference on Lung Health, Cancun, Mexico, 4 December 2009.
 148. "The First Sir John Crofton Lecture: MDR-/XDR-TB and poverty", Plenary at the 40th Union World Conference on Lung Health, Cancun, Mexico, 5 December 2009.
 149. "Tuberculosis: global burden, challenges, and a strategy", at the 16th Meeting of the International Task Force for Disease Eradication, The Carter Center, Atlanta, Ga, USA, 12 January 2010.
 150. "Global tuberculosis control today: expectations from the PPM Subgroup", at the 6th Meeting of the Sub-Group on Public-Private Mix for TB Care and Control. Sponsored by the Turkish Thoracic Society, Istanbul, Turkey, 16 February 2010.
 151. "Global achievements and challenges in tuberculosis control and research" - The 3rd Annual Dr George W. Comstock Lecture. Johns Hopkins Bloomberg School of Public Health, Sheldon Hall, Baltimore, Md, USA, 14 April 2010.
 152. "The first three articles of the Lancet TB Series", at the World Health Assembly satellite session "Towards the MDGs: progress, opportunities and challenges of TB control. Launch of the Lancet TB Series and The Lancet TB Observatory". World Health Assembly, Room XXIII, Geneva, 18 May 2010.
 153. Chair - Symposium "Multidrug-resistant tuberculosis and novel influenza: back to the future. Lessons learned from two respiratory emergencies". Annual Congress of the European Respiratory Society, Barcelona, Spain, 21 September 2010.
 154. "Situazione globale della TBC e grandi sfide", at the Convegno "Le Malattie Infettive del Migrante e del Viaggiatore - II Edizione", organized by the University of Ferrara, Italy. Ferrara, 5 November 2010 (via videoconference).
 155. "Review of WHO STAG recommendations on Xpert", at the FIND and Partners Symposium on Recent Advances in Diagnostics for TB". International Congress Center, Berlin, Germany, 12 November 2010.
 156. Panelist. "Dal globale al locale - che succede dottore? - Le frontiere della medicina: malattie del viaggiatore, influenza, tubercolosi, AIDS...". Organized by Fondazione Biblioteca Biomedica

- Biellese 3Bi, ASL Biella. Centro Congressi Città degli Studi, Biella, Italy, 28 January 2011.
157. "Tematiche globali sulle malattie infettive". 1° Congresso Scientifico Fondazione Biblioteca Biomedica Biellese 3Bi, in collaborazione con ASL Biella, "Dal globale al locale: grandi pandemie e malattie infettive emergenti", organized by Fondazione Biblioteca Biomedica Biellese 3Bi, ASL Biella. Centro Congressi Città degli Studi, Biella, Italy, 29 January 2011.
 158. Chair and moderator, 1° Congresso Scientifico Fondazione Biblioteca Biomedica Biellese 3Bi, in collaborazione con ASL Biella, "Dal globale al locale: grandi pandemie e malattie infettive emergenti", organized by Fondazione Biblioteca Biomedica Biellese 3Bi, ASL Biella. Centro Congressi Città degli Studi, Biella, Italy, 29 January 2011.
 159. "Global burden of TB and progress towards 2015 targets", at the 15th Annual Conference of IUATLD - North American Region, Vancouver, Canada, 24-2-2011 (via video).
 160. "Eliminating TB by 2050: a possible reach?", at the meeting "The need for a global research agenda to target elimination", organized by WHO and Stop TB Partnership, Bellagio, Italy, 15-3-2011.
 161. Panelist, at "Open dialogue with national Red Cross and Red Crescent Societies and partners on tuberculosis", organized by the International Federation of the Red Cross and Red Crescent Societies, IFRC, Genève, Suisse, 22 March 2011.
 162. "Tuberculosis - the disease, progress in addressing it and remaining obstacles", at The Geneva Roundtable on Tuberculosis, organized by IFPMA, Centre de Conférences Varembe, Genève, Suisse, 24 March 2011.
 163. "From science to policy and impact", at the 18th CDC Public Health Grand Round, devoted to TB/HIV, organized by CDC, Atlanta, Ga, USA, 24 March 2011 (via video - 17,246 external viewers).
 164. Keynote speech, at The TB Symposium "Challenge and urgency to scale-up tuberculosis care in Central Asia", organized by MSF, Uzbekistan, 3 June 2011 (video recorded).
 165. "Introduction to the WHO Policy Package to combat Antimicrobial Resistance", at the World Health Day High-level Panel, 7 April 2011, WHO Executive Board Room, Geneva, Switzerland.
 166. "Global tuberculosis control – Plans and challenges for TB elimination", at the WHO Centre for Health Development, Kobe, Japan, 31 May 2011.
 167. "MDR-TB in the world – Situation analysis and control efforts", at the 86th Annual Congress of the Japanese Society for Tuberculosis, Tokyo, Japan, 2 June 2011.
 168. "Global tuberculosis targets", at the Gordon Research Conference "Tuberculosis drug development", Il Ciocco, Barga (Lucca), Italy, 2 July 2011 (opening lecture).
 169. "The global burden of tuberculosis: where are we now towards the global targets?", at the International Review Meeting on "New 2020 Plan for TB Elimination", organized by the Korea Center for Disease Control and Prevention, Osong, Republic of Korea, 25 August 2011.

170. “Introduction” to panel discussion on “Antimicrobial resistance”, at PAHO/AMRO Regional Committee Session, Washington, D.C.,USA, 28 September 2011.
171. “Global perspective on TB control in the 21st century”, at the 3rd International Congress on Infectious and Tropical Diseases – 6th GCC Conference on Infection Control. Organised by the Ministry of Health of Oman in collaboration with Sultan Qaboos University and Executive Board of GCC. Muscat, Oman, 7 December 2011.
172. “TB antibiotic resistance: a global threat”, at the 3rd International Congress on Infectious and Tropical Diseases – 6th GCC Conference on Infection Control. Organised by the Ministry of Health of Oman in collaboration with Sultan Qaboos University and Executive Board of GCC. Muscat, Oman, 8 December 2011.
173. “Eliminating TB by 2050”, at the 3rd Global Symposium on IGRAs, organized by the U.C. San Diego School of Medicine, Waikoloa, Hawaii, USA, 15-1-2012 (via video).
174. “Next challenges for improved TB prevention, care and control”, at the Symposium “Action on social determinants of tuberculosis: are social protection interventions the way forward?”, organized by the London School of Hygiene & Tropical Medicine, WHO, UNDP, BMGF, HPA, Chatham House, London, UK, 15 February 2012.
175. Panelist at. “New thinking in policy making – Challenging the policy makers: the stakeholders response”, at the Economist Conference “Healthcare in Africa”, Cape Town, South Africa, 6 March 2012.
176. “Global perspective on TB prevention, care and control in the 21st century” and Chairmanship, at the US Congress World TB Day Congressional Briefing “Tuberculosis – Why this ancient disease remains a global health threat”, in cooperation with the House TB Elimination Caucus. Washington, DC, USA, 20-3-2012.
177. “Global perspectives on TB control strategies, including diagnosis and management of drug-resistant tuberculosis”, at the “High-level Meeting on Drug-resistant TB Management in India”, organized by the Government of India – Ministry of Health & Family Welfare, New Delhi, India, 30-8-2012.
178. “The global TB situation, progress, challenges and research needs”, at the First TDR Lunchtime Seminar, organized by the Tropical Disease Research Programme, WHO, Geneva, Switzerland, 19-9-2012.
179. “Opening of the 3rd National Symposium: Tuberculosis: a Social Disease”, organized by Stop TB Italia and “The Permanent TB Training Centre, Milan, under the aegis of Region Lombardy, the City of Milan, Hospital Niguarda, Milan, Italy, 21-9-2012.
180. “Tuberculosis: new dawn in the fight against an ancient killer”, at the “Off-the-record: improving human health in a global village”, organized by Eurovision Academy, WHO, Geneva, 5 October 2012.
181. “Control y eliminacion mundial de la tuberculosis: desafios para la salud publica”, at the “Special Event” organized by Sociedad Cubana de Hygiene y Epidemiologia, Cuba Salud 2012, La Habana, Cuba, 5-12-2012.

182. “Situazione globale e sfide per il controllo e l’eliminazione della tubercolosi”, at the MSF Conference “Il Mal Sottile è sceso dalla montagna incantata: attualità critiche della tubercolosi”, organized by MSF Italia, Accademia Medica di Roma e Università La Sapienza. Auditorium della 1a Clinica Medica, Roma, 7 March 2013 (via video-connection).
183. “Introduzione alla Giornata Mondiale della Tubercolosi”, at “Stop TB in my lifetime – Giornata Mondiale della Tubercolosi”, organizzata da Medici con l’Africa CUAMM e Stop TB Italia, Milano 14 March 2013.
184. “Basic TB epidemiology and how the TB epidemics affects children”, at the International Meeting on Childhood Tuberculosis, organized by University of Padova, Medici con l’Africa CUAMM, PtbNet. Abano Terme, Padua, 22 March 2013 (via video-connection).
185. “TB elimination: where we are and what are the needs”, Closing Lecture at the 3rd TB Vaccine Global Forum, organized by Aeras, IAVI etc. Cape Town, South Africa, 27 March 2013.
186. “TB demand forecasting”, at Session 5, Preparatory Meeting of the Global Fund 4th Replenishment 2014-16, Bruxelles, Belgium, 10 April 2013.
187. “Vision and proposed framework for a Post-2015 TB Elimination Strategy and Targets”, at the Consultation on “Eliminating the catastrophic economic burden of TB - Universal Health Coverage and Social Protection Opportunities, Sao Paulo, Brazil, 29 April 2013.
188. “The need to commit to TB elimination”, at the European Forum for TB Innovation, 2nd Meeting, ERS Annual Congress, Barcelona, Spain, 10 September 2013.
189. “La tubercolosi oggi e domani”, at the Congress “Tubercolosi polmonare: criticità, novità e prospettive”, organised by the Società Medico-Chirurgica di Ferrara, Ferrara 21-9-2013 (via videoconference).
190. “TB elimination and TB drugs: can we make it?”, Keynote Address at the CPTR 2013 Workshop, organized by the Critical Path to TB Drug Regimens. Washington, DC, USA, 1st October 2013.
191. “Dal globale al locale: grandi pandemie e malattie infettive emergenti – Tubercolosi”, at the Workshop “Health 2020: a new approach for health and well-being in Europe, organized by the Ministry of Health – Progetto Mattone Internazionale, Roma, Italy, 17-10-2013.
192. “The 2013 Global TB Report”, public launch at the House of Commons, UK Parliament, hosted by the All-Party Parliamentary Group on TB. London, UK, 23-10-2013.
193. “Aggiornamenti in epidemiologia e terapia della tubercolosi”, opening lecture at the XII Congresso Nazionale Società Italiana di Malattie Infettive (SIMIT), Università di Milano,

Milan, Italy, 27-10-2013.

194. “The pathway to eliminate TB: why we need new tools”, at the lunch-break session “The economic urgency and pathway to eliminate TB”, organised by TBVI. 44th Union Conference on Lung Health, Paris, 1-11-2013.
195. “Tackling TB and finding solutions”, at the lunch-time Debate at European Parliament “Tuberculosis in Europe – Eliminating the modern threat”, organised by the European Respiratory Society, Bruxelles, Belgium, 13-11-2013.
196. “Il futuro dei programmi di controllo e la sfida dei bacilli MDR”, at the 7th Congresso Nazionale della Società Italiana di Medicina Tropicale (SIMET), Session III: “Tubercolosi: una sfida per il nord e il sud del mondo”, Torino, Italy, 29-11-2013.
197. “Speranza: una forza motivazionale nel lavoro del ricercatore” (“Hope: a motivational force in researchers’ work”), at the 3rd Convegno Scientifico della Fondazione 3Bi (Biblioteca Biomedica Biellese) “Speranza e Salute”, organised by the Foundation 3Bi in collaboration with the ASL BI, Biella, Italy, 1 March 2014.
198. “Achievements during the last 20 years and perspectives for TB elimination”, at the 23rd Symposium Tuberculose de Münchenwiler, organised by the Lungen Liga Schweiz, Münchenwiler, Switzerland, 20 March 2014.
199. “WHO’s view of research needs in Europe”, at the European Parliament Event “Fighting multidrug-resistant tuberculosis in Europe – In association with TB PANNET. Brussels, Belgium, 1 April 2014.
200. “Una nuova strategia globale per la tubercolosi: come cambiare le regole del gioco”, at the Convegno “Attualità e prospettive sulla tubercolosi: da oggi al 2035”, organised by the WHO Collaborating Center of the University of Brescia and MSF Italy, Brescia, Italy, 4 April 2014.
201. “Epidemiologia e nuove strategie di controllo della tubercolosi su scala internazionale”, Lectio Magistralis, at the Convegno “Tubercolosi: un nuovo strumento formativo per un’antica malattia”, organised by the U.o. Malattie Infettive, Azienda USL3, Pistoia, Italy, 9 April 2014 (via video connection).
202. “The post-2015 global tuberculosis strategy”, at the lunch-time side event “Winning the global fight against tuberculosis”, organised by the Ministry of Health of Brazil. World Health

Assembly 67, Geneva, 20 May 2014.

203. “Migration and TB in the post-2015 Global Tuberculosis Strategy: challenges and opportunities”, at the Informal Dialogue “Migration and TB”, organised by the International Organization for Migration (IOM), Geneva, Switzerland, 21 May 2014.
204. “Strengthening the orchestration of international efforts”, Keynote Address at “A strategic approach to global TB”, organised by the Center for Strategic & International Studies (CSIS), Washington, DC, USA, 9 June 2014.
205. “The post-2015 strategy and the principle for adaptation for pre-elimination in low-incidence countries”, at the Global Consultation “Towards Elimination of Tuberculosis in Countries with Low-Incidence of Disease”, co-organized by the European Respiratory Society and WHO, Rome, Italy, 4 July 2014.
206. “Le strategie dell’OMS per la prevenzione ed il controllo della tubercolosi” at the Convegno “Viaggi internazionali e Salute”, organized by the Società Italiana di Medicina del Turismo, Rimini, 10 October 2014 (via teleconference).
207. Update on TB global burden and challenges, including efforts to eliminate TB in low-prevalence settings”, at the Catholic HIV/AIDS Network (CHAN) meeting, Geneva, Switzerland, 24 October 2014.
208. “The global burden of tuberculosis: progress, challenges, strategy and opportunities beyond 2015” at the Global TB Summit of Members of Parliament”, Barcelona, Spain, 27 October 2014.
209. “Health and Millenium Development Goals: where do we stand now?”, at the India International Public Health Conference, India Medical Association, Thiruvananthapuram, Kerala, India, 7 November 2014.
210. “The role of research in the new End TB Strategy”, at the WHO Global Consultation on Research for TB elimination, Nobel Forum, Karolinska Institutet, Stockholm, Sweden, 24 November 2014.
211. “The End TB Strategy: role of WHO in supporting implementation of the new global strategy”, at the Regional Consultation Meeting on the Development of the “Tuberculosis Action Plan for the WHO European Region, 2016-20”, UN City, Copenhagen, Denmark, 27 November 2014.
212. “TB global scenario 2014” at the 7th National Conference of the AIDS Society of India-ASICON 2014. Kolkata, India, 13 December 2014 (via videoconference).
213. “Global TB and MDR-TB: challenges and WHO response”, at the Regional TB Symposium “New Treatments and approaches to drug-resistant tuberculosis”, organized by the Ministry of

- Health of the Republic of Armenia and Médecins sans Frontières, Yerevan, Armenia, 17 February 2015 (via video).
214. “Update on global TB epidemiology: how did we do on the 2006-2015 Global Plan to Stop TB? Where are we heading for 2016-2035?”, at the 19th Annual Conference of the International Union against Tuberculosis and Lung Diseases – North America Region, Vancouver, BC, Canada, 26 February 2015 (via videoconference).
 215. “Situazione globale dell’epidemia da TB e strategie del WHO per l’eradicazione”, at the 5th AMIT (Argomenti di Malattie Infettive e Tropicali) International Congress, Milan, Italy 13 March 2015.
 216. “Opening lecture: TB 2015 – burden, challenges and strategies for control and elimination”, at the TB Day and TB-RF 2009 Study Group Meeting, L. Spallanzani Hospital, Rome, Italy, 23 March 2015 (via videoconference).
 217. “Politiche nazionali, europee and internazionali di eradicazione della TBC”, at TB Day 2015, organized by Centro Riferimento Regionale TBC – Catanzaro and Regione Calabria, Lamezia Terme, Italy 24 March 2015 (via videoconference).
 218. “Fighting TB – burden, progress, challenges, way forward”, at “World TB Day: Geneva’s role in addressing a global health crisis”, organized by Geneva Diplomatic Club and Ely Lilly Foundation. IFRC, Geneva, 24 March 2015.
 219. “Organizzazione Mondiale della Sanità – le sfide per le salute globale nel nuovo millennio”, at Rotary Club, Biella, Italy, 13 April 2015.
 220. “Fighting TB – Burden, progress, challenges, way forward”, at the WHA Side Event organized by Ministries of Health of Italy and Mozambique and Dream Community of St Egidio, UN Palais, Geneva, 21 May 2015.
 221. “Accelerating progress towards ending global TB”, at the plenary session of the Annual Meeting of the Division of Global HIV and TB Centers for Disease Control and Prevention, Atlanta, GA, 1 June 2015 (via videoconference).
 222. "WHO's new End TB Strategy for the prevention and control of TB and MDR-TB - Adoption and adaptation to Asia and Pacific". Plenary speech at the 5th Conference of the UNION Asia Pacific Region, Sydney, Australia, 31 August 2015.
 223. “WHO's approach to engaging low-burden countries in the global response to TB” at the Symposium “Advocacy and commitment to global health”, 5th Conference of the UNION Asia Pacific Region, Sydney, Australia, 1 September 2015.
 224. “What we need to end TB” at the Asia Pacific Forum of the Global TB Caucus, a Member of Parliament forum, Sydney, Australia, 1 September 2015.

225. “Global TB control efforts (focus on Asia-Pacific) and the role of research” at the 5th Tuberculosis Control Symposium, 2015, organised by the Woolcock Institute of Medical Research and TB-CRE, Sydney, Australia, 3 September 2015.
226. “TB 2015: burden, challenges, response” at the YES (Young European Scientist) Meeting, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, 18 September 2015.
227. “2015 WHO Report: what’s new in the TB world?”, at the USAID Policy and Scientific Symposium in the occasion of the launch of WHO 2015 Global TB Report, National Press Club, Washington, DC, 28 October 2015.
228. “Role of WHO in global health in the SDG era: from TB to Ebola and more...”Keynote lecture, Global Health Night. McGill University, New Residence Hall, Montreal, Canada, 3 November 2015.
229. “End TB Strategy”, IDIGH Program Seminar Series, Research Institute, McGill University Health Center, Montreal, 4 November 2015.
230. “The new global End TB Strategy in the era of sustainable development goals: from policy to practice”. Global Health Conferences, Institut de Santé Globale, Université de Genève, 18 November 2015 (main lecture).
231. “Ending TB: Where we are now and what next?”, at the Global TB Summit of Members of Parliament, organised by Results, Cape Town, South Africa, 29 November 2015.
232. “Remarks” at the Gala Dinner hosted by Dr A. Motsoaledi, Minister of Health, in honour of Members of the Stop TB Coordinating Board and Parliamentarians of the Global TB Caucus, The Westin Hotel, Cape Town, 29 November 2015.
233. “Transitioning to the Sustainable Development Goal era”, at the First End TB Strategy Summit for national TB programmes of the high-burden countries, organized by WHO, Cape Town, South Africa, 30 November 2015.
234. “The role of research in the End TB Strategy”, at the TB Alliance Stakeholders Association Annual Meeting, Cape Town, South Africa, 1 December 2015.
235. “TB 2016: Burden, challenges, and the new WHO’s End TB Strategy”, public talk, Harvard School of Public Health, Boston, Ma, USA, 8 February 2016.
236. “Da Stop TB a End TB”, at the conference “TB e HIV: due storie parallele”, Convegno Interdisciplinare – “Towards the End”, organized by Stop TB Italia, Milan, Italy, 18-19 March 2016.
237. “In occasione del World TB Day 2016”, at an event of ToBeContinued 2016, organized as part of the Festivalungo 2016, Palazzo Lamarmora, Biella, 24 March 2016.

238. “Problems and management of MDR-TB” at the conference “Pulmonology, allergology, and clinical immunology 2016”, organized by the Lithuanian Society of Pulmonology and Allergy and the Lithuanian University of Health Sciences, Kaunas, Lithuania, 5 May 2016.
239. “Ending TB: global situation and a new strategy in the SDG era”, keynote address at the opening session of the “7th Conference of the Union European Region”, Slovak National Theatre, Bratislava, Slovakia, 22 June 2016.
240. “Keeping pace with innovations to end TB”, opening speech at the “Global TB Symposium - Know your epidemic – Driving change to end TB”, Liverpool, United Kingdom, 25 October 2016.
241. “Good Practice: Tuberculosis care through the engagement of communities”, at the The XXXI International Conference "Towards a culture of health that is welcoming and supportive at the service of people with rare and neglected pathologies" organised by the Pontificium Consilium pro Valetudinis Administris, Holy See, Vatican City, 10-12 November 2016.
242. “WHO global End TB Strategy”, at the 27th Meeting of the High-Level Working Group on Tuberculosis in the Russian Federation, Moscow, Russian Federation, 22 November 2016.
243. “End TB - The new WHO Strategy in the Sustainable Development Goal era and the contributions from the Russian Federation”, at the All-Russian Scientific Practical Conference with International Participation on Innovative Technologies in Tuberculosis Control – In memory of M.I. Perelman, Academician of the Russian Academia of Medical Science. Moscow, Russian Federation, 24 November 2016.
244. “WHO End TB Strategy and its meaning in EECA region”, at the 6th TB Symposium Eastern Europe and Central Asia “Tuberculosis in 2017: Searching for new solutions in the face of new challenges”, organised by The Ministry of Health of Belarus and MSF. Minsk, Belarus 1 March 2017 (via video-connection).
245. “WHO’s Global End TB Strategy for Prevention, Care and Control of Tuberculosis”, at the World TB Day 2017 - The National Conference “Twenty Years of the National TB Programme in Israel: Multifaceted Aspects and Challenges” organized by the Ministry of Health, Public Health Services, Department of Tuberculosis & AIDS of Israel, Kfar HaMaccabiah Conference Center, Ramat Gan, Israel , 28 March 2017.
246. “TB R&D goals of the WHO Ministerial Conference 2017 and HLM on TB at UNGA 2018”, at the TAG/ACTION Webinars in preparation for the WHO Global Ministerial Conference on Ending TB in the Sustainable Development Era: A Multisectoral Response”, via WebEx, 31-5-2017.

247. “A multisectoral approach to accelerate the TB response - Towards Moscow 2017”, at the All-Russia Scientific-Practical Conference “Tuberculosis and Comorbid Infections: Challenges and Perspectives”, Moscow, 1 June 2017 (via video).
248. “The development challenge of ending TB”, at the First MIKTA (Mexico-Indonesia-Korea-Turkey-Australia) – Geneva Public Health Seminar “Working together to End TB in the Sustainable Development Era: Global Momentum towards the 2017 WHO Global Ministerial Conference and the 2018 UN GA High-Level Meeting on TB”. Korean Mission, Geneva, 9 June 2017.
249. “Mapping the priorities for the fight against TB” at the Wilton Park Meeting “Time to end TB – a new path to defeating the world’s oldest epidemic”, organised by the UK Foreign & Commonwealth Office and the Wilton Park on behalf of the Global TB Caucus. Wilton Park, UK, 19 June 2017.
250. “Ending TB: from Moscow to UNGA and beyond” and “The vision and perspectives of the 1st Global Ministerial WHO Conference on Ending TB”, at the Seminar “The global challenge of drug-resistant tuberculosis” organised by the Embassy of the Kingdom of the Netherlands in Moscow. Moscow, Russian Federation, 21 September 2017.
251. “SDG 3: Assicurare la salute e il benessere per tutti e per tutte le età”, organised by the University of Brescia, Italy, as part of public evenings devoted to raise awareness of the SDGs. Teatro Grande, Brescia, Italy, 27 October 2017.
252. “Key data milestones on the road to end TB”, at the “Symposium on the past, present and future of TB”, organised by USAID in the occasion of the release of the WHO Global TB Report 2017. National Press Club, Washington, DC, USA, 30 October 2017.
253. “Global TB Report 2017”, at the 2nd Lancet Commission meeting. The Hague, The Netherlands, 13 November 2017.
254. “The politics of ending TB”, Closing session at the All-Russia Scientific Practical Conference of Phtisiologists with International Participation “An interdisciplinary approach to solve the problem of tuberculosis”. Sokolniki, Moscow, 15 November 2017.
255. “Tuberculosis 2018: burden, challenges, solutions and policies”, at the Launch of Dr Michael Voniatis’s book “Tuberculosis in Cyprus through the centuries”, organized by Lions Club Nicosia and Ministry of Labour Republic of Cyprus. Nicosia, Cyprus 12 February 2018.

256. “Politiche globali di controllo della tubercolosi”, at the Congress “Pneumologia Territoriale: Attualità e Prospettive”, organized by the Department of Pneumology of the Territory – ASL Lecce, Lecce, Italy, 24 February 2018 (via Videoconference).
257. “Progress and challenges towards ending TB in a politically charged era”, at the Plenary Session of the 22nd Annual Meeting of the Union-North America Region, Chicago, USA, 1 March 2018 (via Videoconference).
258. “La salute globale”, at the Rotary Club Biella, 12 March 2018.
259. “A multisectoral accountability framework”, at the “World TB Day Webinar: Politics of TB in 2018 – Multisectoral accountability”, organized by Citizen News Service (CNS), India, 20-3-2018.
260. “Situazione globale della TBC e strategie e politiche internazionali per la lotta”, at the Pneumo Trieste 2018, organized by Azienda Sanitaria Universitaria Integrata di Trieste, Italy, 16-4-2018.
261. “Il carico globale delle malattie oggi e domani”, at the Festival della Scienza Medica – Bologna Medicina, Public event organised by Alma Ata Studiorum Università di Bologna, Bologna 5-5-2018.
262. “La salute globale nel 2018”, at the Congress “Il nursing e le culture: integrazione nel sistema salute”, organised by Ordine Professioni Infermieristiche di Biella (OPT), Biella, 12-5-2018 (via Skype).
263. “Tuberculosis in the world: problems and solutions”, at the All-Russian scientific practical Conference with international participation “Current issues of TB care in the Russian Federation: consolidation of efforts in the fight against TB”. Sokolniki, Moscow, 1 June 2018.

Bibliography: Peer-reviewed and invited articles

1. Raviglione MC, Graham PE. Breast carcinoma in a man following local trauma. *NY State J Med* 1987;87:186-187.
2. Raviglione MC, Graham PE. Tissue injury and breast carcinoma (reply letter). *NY State J Med* 1987;87:521.
3. Raviglione MC. Appearance of chloroquine-resistant falciparum malaria in Swaziland (letter). *Lancet* 1987;2:44-45.
4. Raviglione MC, Garner GR, Mullen MP. *Pneumocystis carinii* in bone marrow (letter). *Ann Intern Med* 1988;109:253.
5. Raviglione MC, Battan R, Taranta A. Cardiopulmonary resuscitation in patients with the acquired immunodeficiency syndrome. A prospective study. *Arch Intern Med* 1988;148:2602-2605.
6. Raviglione MC, Dinan WA, Pablos-Mendez A, Palagiano A, Sabatini MT. Fatal toxic epidermal necrolysis during prophylaxis with pyrimethamine and sulfadoxine in a human immunodeficiency virus-infected person. *Arch Intern Med* 1988;148:2683-2685.
7. Raviglione MC, Battan R, Pablos-Mendez A, Aceves-Casillas P, Mullen MP, Taranta A. Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. *Am J Med* 1989;86:780-786.
8. Raviglione MC, Mariuz P, Sugar J, Mullen MP. Extrapulmonary *Pneumocystis* infection (letter). *Ann Intern Med* 1989;111:339.
9. Mathew A, Raviglione MC, Niranjana U, Sabatini MT, Distenfeld A. Splenectomy in patients with AIDS. *Am J Hematol* 1989;32:184-189.
10. Raviglione MC, Battan R, Taranta A. Cardiopulmonary resuscitation in patients with acquired immunodeficiency syndrome (reply letter). *Arch Intern Med* 1989;149:2380.
11. Raviglione MC, Pablos-Mendez A, Battan R. Clinical features and management of severe dermatological reactions to drugs. *Drug Safety* 1990;5(1):39-64 (review).
12. Pablos-Mendez A, Raviglione MC, Battan R. Drug-resistant tuberculosis in AIDS (letter). *Chest* 1990;97:511-512.
13. Raviglione MC, Mariuz P, Pablos-Mendez A, Battan R, Ottuso P, Taranta A. High *Staphylococcus aureus* nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. *Am J Infect Control* 1990;18(2):59-64.
14. Raviglione MC. Machiavelli and the chief resident. *Acad Med* 1990;65:361-362.

15. Raviglione MC, Tierno PM, Ottuso P, Klemes AB, Davidson M. Group G streptococcal meningitis and sepsis in a patient with AIDS: a method to biotype group G streptococcus. *Diagn Microbiol Infect Dis* 1990;13:261-264.
16. Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R. Drug-resistant tuberculosis among the homeless in New York City. *NY State J Med* 1990;90:351-355.
17. Raviglione MC, Nsah EN, Cortes H, Mariuz P, Sanjana V. Intermittent co-trimoxazole prophylaxis against *Pneumocystis carinii* pneumonia (letter). *Lancet* 1990;336:180.
18. Raviglione MC, Boyle JF, Mariuz P, Pablos-Mendez A, Cortes H, Merlo A. Ciprofloxacin-resistant methicillin-resistant *Staphylococcus aureus* in an acute-care hospital. *Antimicrob Agents Chemother* 1990;34:2050-2054.
19. Raviglione MC. Extrapulmonary pneumocystosis. The first 50 cases. *Rev Infect Dis* 1990;12:1127-1138.
20. Battan R, Raviglione MC, Palagiano A, Boyle JF, Sabatini MT, Sayad K, Ottaviano LJ. *Helicobacter pylori* infection in patients with acquired immunodeficiency syndrome. *Am J Gastroenterol* 1990; 85:1576-1579.
21. Mariuz P, Raviglione MC, Gould I, Mullen MP. Pleural *Pneumocystis carinii* infection. *Chest* 1991; 99:774-776.
22. Battan R, Mariuz P, Raviglione MC, Sabatini MT, Mullen MP, Poretsky L. *Pneumocystis carinii* infection of the thyroid in a hypothyroid patient with AIDS. Diagnosis by fine needle aspiration biopsy. *J Clin Endocrinol Metab* 1991;72:724-726.
23. Battan R, Raviglione MC, Wallace J, Cort S, Boyle JF, Taranta A. *Staphylococcus aureus* nasal carriage among homosexual men with and without HIV infection. *Am J Infect Control* 1991; 19:98-100.
24. Raviglione MC. Extrapulmonary pneumocystosis. *Infectious Diseases Newsletter* 1991;10:53-55.
25. Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment. *Bull World Health Organ* 1992: 70:515-526.
26. Luzzati R, Raviglione MC. Profilassi della polmonite da *Pneumocystis carinii* con trimetoprim-sulfametossazolo intermittente. *Minerva Med* 1992; 83:641-646.
27. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. *Tuberc Lung Dis* 1992; 73: 311-321.
28. Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in Western Europe. *Bull World Health Organ* 1993; 71: 297-306.
29. Chintu C, Luo C, Bhat G, Raviglione M, DuPont H, Zumla A. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-1. *Arch Dis Child* 1993; 68:665-668.

30. Chintu C, Bhat G, Luo C, Raviglione M, Diwan V, DuPont HL, Zumla A. Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis. *Pediatr Infect Dis J* 1993; 12:499-504.
31. Raviglione MC, Sudre P, Esteves K, Spinaci S, Kochi A, Rieder HL. Tuberculosis - Western Europe, 1974-1991. *MMWR* 1993; 42:628-631.
32. Godfrey-Faussett P, Mwinga A, Raviglione M, Hosp M, Baggaley R, Porter J, McAdam K. Tuberculosis and HIV infection (letter). *Lancet* 1993; 342:1368-1369.
33. Dolin JP, Raviglione MC, Kochi A. Estimates of future global tuberculosis morbidity and mortality. *MMWR* 1993; 42:961-964.
34. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. *Am Rev Respir Dis* 1993; 148:1541-1546.
35. Varedzis BP, Grosset J, de Kantor I, Crofton J, Laszlo A, Felten M, Raviglione MC, Kochi A. Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. *Tuberc Lung Dis* 1994; 75:1-7.
36. Raviglione MC, Narain JP, Kochi A, van Praag E, O'Brien R. In reply: on HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention (letter). *Tuberc Lung Dis* 1994; 75:81-82.
37. Luo C, Chintu C, Bhat G, Raviglione M, Diwan V, DuPont HL, Zumla A. Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thiacetazone free regimen. *Tuberc Lung Dis* 1994; 75:110-115.
38. Migliori GB, Borghesi A, Spanevello A, Eriki P, Raviglione M, Maciocco G, Morandi A, Ballardini L, Neri M. Risk of infection and estimated incidence of tuberculosis in Northern Uganda. *Eur Respir J* 1994; 7:946-953.
39. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. *Bull World Health Organ* 1994; 72:213-220.
40. Rieder HL, Zellweger J-P, Raviglione MC, Keizer ST, Migliori GB and a European Task Force. Tuberculosis control in Europe and international migration. Report of a European Task Force. *Eur Respir J* 1994; 7:1545-1553.
41. Chapuis L, Ji B, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and immunodeficient mice. *Am J Respir Crit Care Med* 1994; 150: 1355-1362.
42. Raviglione MC, Rieder HL, Styblo K, Khomenko A, Esteves K, Kochi A. Tuberculosis trends in Eastern Europe and the former USSR. *Tuberc Lung Dis* 1994; 75:400-416.

43. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. *JAMA* 1995; 273:220-226.
44. Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Barugahare L, Tembo G, McFarland D, Adatu Engwau F. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. *AIDS* 1995; 9:267-273.
45. Antonucci G, Girardi E, Raviglione MC, Ippolito G and the Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. *JAMA* 1995; 274:143-148.
46. Raviglione MC, Nunn PP, Kochi A, Snider DE Jr. Tuberculosis treatment in developing nations (letter). *JAMA* 1995; 274:125-126.
47. Migliori GB, Spanevello A, Ballardini L, Neri M, Gambarini C, Moro ML, Trnka L, Raviglione MC and the Varese Tuberculosis Study Group. Validation of the surveillance system for new cases of tuberculosis in a Province of Northern Italy. *Eur Respir J* 1995; 8:1252-1258.
48. Raviglione MC, Grzemska M, Alisherov ASH, Limarev PI. Tuberculosis control in Kyrgyzstan: an opportunity. *World Health Forum* 1996; 17:85-90.
49. Rieder HL, Watson JM, Raviglione MC, Forssbohm M, Migliori GB, Schwoebel V, Leitch AG, Zellweger J-P, and the Members of the Working Group. Surveillance of tuberculosis in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting of tuberculosis cases. *Eur Respir J* 1996; 9:1097-1104.
50. Chaulet P, Raviglione M, Bustreo F. Epidemiology, control and treatment of multidrug-resistant tuberculosis. *Drugs* 1996; 52 (Suppl.2):103-108.
51. The WHO/IUATLD Working Group on Antituberculosis Drug Resistance Surveillance. Manuscript prepared by: Bustreo F, Migliori GB, Nardini S, Raviglione MC. Antituberculosis drug resistance: is it worth measuring? *Monaldi Arch Chest Dis* 1996; 51:299-302.
52. Cohn DL, Bustreo F, Raviglione MC. Drug resistance in tuberculosis: review of the worldwide situation and WHO/IUATLD's Global Surveillance Project. *Clin Infect Dis* 1997; 24(Suppl.1):S121-S130.
53. Girardi E, Antonucci G, Ippolito G, Raviglione MC, Rapiti E, Di Perri G, Babudieri S and the Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. *Arch Intern Med* 1997; 157: 797-800.
54. Sawert H, Kongsin S, Payanandana V, Akarasewi P, Nunn PP, Raviglione MC. Costs and benefits of improving tuberculosis control. The case of Thailand. *Soc Sci Med* 1997; 44: 1805-1816.

55. Laszlo A, Rahman M, Raviglione M, Bustreo F and the WHO/IUATLD Network of Supranational Reference Laboratories. Quality assurance programme for drug susceptibility testing of *Mycobacterium tuberculosis* in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing. *Int J Tuberc Lung Dis* 1997; 1:231-238.
56. Maher D, Hausler HP, Raviglione MC, Kaleeba N, Aisu T, Fourie B, Nunn P. Tuberculosis care in community care organizations in sub-Saharan Africa: practice and potential. *Int J Tuberc Lung Dis* 1997; 1:276-283.
57. Raviglione MC, Dye C, Schmidt S, Kochi A for the WHO Global Surveillance and Monitoring Project. Assessment of worldwide tuberculosis control. *Lancet* 1997; 350:624-629.
58. Raviglione MC, Harries AD, Msiska R, Wilkinson D, Nunn P. Tuberculosis and HIV: current status in Africa. In: *AIDS in Africa, 2nd Edition*. *AIDS* 1997; 11 (Suppl.B): S115-S123.
59. Drobniewski F, Pablos-Méndez A, Raviglione MC. Epidemiology of tuberculosis in the world. In: Heifets L, Ed. *Tuberculosis. Sem Respir Crit Care Med* 1997; 18:419-429.
60. Cosivi O, Grange JM, Daborn CJ, Raviglione MC, Fujikura T, Cousins D, Robinson RA, Huchzermeyer HAFK, de Kantor I, Meslin FX. Zoonotic tuberculosis due to *Mycobacterium bovis* in developing countries. *Emerging Infectious Diseases* (Atlanta, USA) 1998; 4 (1): 59-70.
61. Schwoebel V, Perrocheau A, Veen J, Rieder HL, Raviglione MC. Improved bacteriological data are needed to give uniform reporting of tuberculosis in Europe (letter). *Br Med J* 1998; 316:1458.
62. Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. *Am J Respir Crit Care Med* 1998; 157:1436-40.
63. Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezembeek C, Kim SJ, Chaulet P, Nunn P, for the WHO/IUATLD Working Group on Anti-tuberculosis Drug Resistance Surveillance. Global surveillance for antituberculosis-drug resistance: 1994-1997. *N Engl J Med* 1998; 338:1641-9.
64. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R. Standardised tuberculosis treatment outcome monitoring in Europe. *Eur Respir J* 1998; 12:505-510.
65. Pablos-Méndez A, Raviglione MC, Nunn P. Antituberculosis-drug resistance (letter). *N Engl J Med* 1998; 339:1080.
66. Sawert H, Girardi E, Antonucci G, Raviglione MC, Viale P, Ippolito G for the Gruppo Italiano Studio Tuberculosis e AIDS (GISTA). Preventive therapy for tuberculosis in HIV-infected persons: an analysis of policy options based on tuberculin status and CD4+ cell count. *Arch Intern Med* 1998; 158:2112-2121.
67. Migliori GB, Khomenko AG, Punga VV, Ambrosetti M, Danilova I, Ribka LN, Grzemska M, Sawert H, Raviglione MC and the Ivanovo TB Project Study. Cost-effectiveness analysis of tuberculosis control policies in Ivanovo Oblast, Russian Federation. *Bull World Health Organ* 1998; 76: 475-483.

68. Netto EM, Dye C, Raviglione MC for the Global Monitoring and Surveillance Project. Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. *Int J Tuberc Lung Dis* 1999; 3:310-320.
69. Zalesky R, Abdullajev F, Khechinashvili G, Safarian M, Madaras T, Grzemska M, Englund E, Dittmann S, Raviglione M. Tuberculosis control in the Caucasus - successes and constraints in DOTS implementation. *Int J Tuberc Lung Dis* 1999; 3:394-401.
70. Maher D, Kibuga D, Raviglione M, Espinal M. An African solution? (letter). *Lancet* 1999; 353:1530.
71. Migliori GB, Ambrosetti M, Besozzi G, Farris B, Nutini S, Saini L, Casali L, Nardini S, Bugiani M, Neri M, Raviglione MC and the AIPO TB Study Group. Cost-comparison of different management policies for tuberculosis patients in Italy. *Bull World Health Organ* 1999; 77:467-476.
72. Espinal M, Dye C, Raviglione M, Kochi A. Rational "DOTS Plus" for the control of MDR TB. *Int J Tuberc Lung Dis* 1999; 3:561-563.
73. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC for the WHO Global Surveillance and Monitoring Project. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. *JAMA* 1999; 282:677-686.
74. Danilova I, Stoyunin M, Repina E, Vorobiov M, Adreevna O, Khomenko A, Puzanov V, Kapkov L, Punga V, Oswald G, Afanasiev N, Carrino C, Migliori GB, Ambrosetti M, Grzemska M, Espinal M, Raviglione M, Goldfarb A, Slutsky A. Primary multidrug-resistant tuberculosis – Ivanovo Oblast, Russia, 1999. *MMWR* 1999; 48:661-663.
75. Maher D, Gorkom JLC van, Gondrie PCFM, Raviglione M. Community contribution to tuberculosis care in high tuberculosis prevalence countries: past, present and future. *Int J Tuberc Lung Dis* 1999; 3:762-768.
76. Migliori GB, Ambrosetti M, Besozzi G, Casali L, Raviglione MC and the National AIPO "Tuberculosis Study Group". Prospective multicenter study on the evaluation of antituberculosis treatment results in Italy: comparison of the culture versus the smear based method. *Eur Respir J* 1999; 13:900-903.
77. Migliori GB, Raviglione MC, Schaberg T, Davies PDO, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L for the Working Group of ERS, WHO and the Europe Region of IUATLD. Tuberculosis management in Europe. Recommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organization (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. *Eur Respir J* 1999; 14: 978-992.
78. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug resistant tuberculosis. Treatment outcomes in 6 countries. *JAMA* 2000; 283: 2537-2545.

79. Schwoebel V, Lambregts-van Weezenbeck C, Moro ML, Drobniowski F, Hoffner S, Raviglione MC, Rieder HL. Standardisation of antituberculosis drug resistance surveillance in Europe. Recommendations of a WHO and IUATLD Working Group. *Eur Respir J* 2000; 16:364-371.
80. Maher D, Gupta R, Uplekar M, Dye C, Raviglione M. Directly observed therapy and treatment adherence (letter). *Lancet* 2000; 356:1031-1032 .
81. Girardi E, Raviglione MC, Antonucci G, Godfrey-Faussett P, Ippolito G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. *AIDS* 2000; 14 (suppl 3): S47-S56.
82. Raviglione MC. Issues facing TB control: multiple drug-resistant tuberculosis. *Symposium Supplement. Tuberculosis Control in the 21st Century. Scot Med J* 2000; 45 (supp 1): 52-55.
83. Gupta RA, Espinal ME, Raviglione MC. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. (letter). *Int J Tuberc Lung Dis* 2000; 4:1089-1092.
84. Matteelli A, Casalini C, Raviglione MC, El-Hamad I, Scolari C, Bombana E, Bugiani M, Caputo M, Scarcella C, Carosi GP. Supervised preventive therapy for latent tuberculosis infection in illegal immigrants in Italy. *Am J Respir Crit Care Med* 2000; 162:1653-5.
85. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC, for the WHO/IUATLD Working Group on Anti-tuberculosis Drug Resistance Surveillance. Global trends in resistance to anti-tuberculosis drugs. *N Engl J Med* 2001; 344:1294-1303.
86. Gupta R, Kim JY, Espinal MA, Caudron J-M, Pecoul B, Farmer PE, Raviglione MC. Responding to market failure in tuberculosis control. *Science* 2001; 293:1049-1051.
87. Maher D, Raviglione M, Lee JW. Direct observation of tuberculosis treatment (letter). *Lancet* 2001; 358:421
88. Antonucci G, Girardi F, Raviglione M, Vanacore P, Angarano G, Chirianni A, Pagano G, Suter F, Lauria FN, Ippolito G and GISTA. Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicenter study. *Eur Respir J* 2001; 18:369-375.
89. Uplekar M, Pathania V, Raviglione M. Private practitioners and public health: weak links in tuberculosis control. *Lancet* 2001; 358:912-916.
90. Espinal MA, Gupta R, Raviglione MC. The future may not be so dark (Editorial). *Int J Tuberc Lung Dis* 2001; 5:787-788.
91. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali E, Smith I, Suarez P, Antunes ML, George AG, Martin-Casabona M, Simelane P, Weyer K, Binkin N, Raviglione MC. Determinants of drug-resistant tuberculosis: analysis of 11 countries. *Int J Tuberc Lung Dis* 2001; 5: 887-893.

92. Gupta R, Raviglione MC, Espinal MA. Should tuberculosis programmes invest in second-line treatments for multidrug-resistant tuberculosis (MDR-TB)? *Int J Tuberc Lung Dis* 2001; 5: 1078-1079.
93. Raviglione MC, Gupta R, Dye CM, Espinal MA. The burden of drug-resistant tuberculosis and mechanisms for its control. In Davies PDO, Ed. "Drug-Resistant Tuberculosis: From Molecules to Macro-Economics". *Ann N Y Acad Sci* 2001; 953: 88-97.
94. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. *Lancet* 2002; 359: 775-780 .
95. Floyd K, Blanc L, Raviglione M, Lee JW. Resources required for the achievement of global tuberculosis control targets. *Science* 2002; 295: 2040-2041.
96. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. *Science* 2002; 295: 2042-2046.
97. Broekmans JF, Migliori GB, Rieder HL, Leese J, Ruutu P, Loddenkemper R, Raviglione MC. European framework for effective tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union against Tuberculosis and Lung Disease (IUATLD), and KNCV (Royal Netherlands Tuberculosis Association) Working Group. *Eur Respir J* 2002; 19:765-775.
98. Suarez PG, Floyd K, Portocarrero J, Alarcón E, Rapiti E, Ramos G, Bonilla C, Sabogal I, Aranda I, Dye C, Raviglione M, Espinal MA. Feasibility and cost-effectiveness of second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. *Lancet* 2002; 359:1980-1989.
99. Nunn P, Harries A, Godfrey-Faussett P, Gupta R; Maher D, Raviglione M. The research agenda for improving health policy, systems performance, and service delivery for tuberculosis control: a WHO perspective. *Bull World Health Organ* 2002; 80:471-476.
100. Gupta R, Espinal MA, Raviglione MC. Rebuttal : evidence and uncertainties. *Int J Tuberc Lung Dis* 2002 ; 6: 651-653.
101. Laszlo A, Rahman M, Espinal M, Raviglione M, and the WHO/IUATLD Network of Supranational Reference Laboratories. Quality Assurance programme for drug susceptibility testing of *Mycobacterium tuberculosis* in the WHO/IUATLD Supranational Laboratory Network: five rounds of proficiency testing 1994-1998. *Int J Tuberc Lung Dis* 2002; 6:748-756.
102. Gupta R, Cegielski JP, Espinal MA, Henkens M, Kim JY, Lambregts-van Weezenbeck CSB, Lee JW, Raviglione MC, Suarez PG, Varaine F. Increasing transparency in partnership for health – Introducing the Green Light Committee. *Trop Med Intern Health* 2002; 7:970-976.
103. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M, Raviglione MC. Frequency of recurrence among MDR-TB cases “successfully” treated with standardized short-course chemotherapy. *Int J Tuberc Lung Dis* 2002; 6:858-864.

104. Godfrey-Faussett P, Maher D, Mukadi YD, Nunn P, Perriens J, Raviglione M. How human immunodeficiency virus voluntary testing can contribute to tuberculosis control. *Bull World Health Organ* 2002; 80:939-945.
105. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. *Arch Intern Med* 2003; 163: 1009-1021.
106. Raviglione MC. The TB epidemic from 1992 to 2002. *Tuberculosis* 2003; 83: 4-14.
107. Quy HTW, Lan NTN, Borgdorff MW, Grosset J, Linh PD, Tung LB, van Soolingen D, Raviglione M, Co NV, Broekmans J. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? *Int J Tuberc Lung Dis* 2003; 7: 631-636.
108. Maher D, Uplekar M, Blanc L, Raviglione M. Treatment of tuberculosis. Concordance is a key step. *BMJ* 2003; 327: 822-823.
109. Veron LJ, Blanc LJ, Suchi M, Raviglione MC. DOTS expansion: will we reach the 2005 targets? *Int J Tuberc Lung Dis* 2004; 8: 139-146.
110. Gupta R, Irwin A, Raviglione MC, Kim JY. Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis. *Lancet* 2004; 363: 320-324.
111. Elzinga G, Raviglione MC, Maher D. Scale-up: meeting targets in global tuberculosis control. *Lancet* 2004; 363: 814-819.
112. Yach D, Raviglione MC. Commentary on the article "Smoking increases the risk of death from tuberculosis four-fold in adult males in India". *Evidence-based Healthcare* 2004; 8: 28-29.
113. Maher D, Blanc L, Raviglione M. WHO policies for tuberculosis control (letter). *Lancet* 2004; 363:1911.
114. Gupta R, Espinal MA, Raviglione MC. Tuberculosis as a major global health problem in the 21st century: a WHO perspective. In: Heifets L, Ed. *Tuberculosis and Other Mycobacterial Infections. Seminars in Respiratory and Critical Care Medicine* 2004; 25 (3): 245-253.
115. Girardi E, Antonucci G, Vanacore P, Palmieri F, Matteelli A, Iemoli E, Carradori S, Salassa B, Pasticci MB, Raviglione MC, Ippolito G and the GISTA-SIMIT Study Group. Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. *Eur Respir J* 2004; 24: 11-17.
116. Dye C, Raviglione M. Monitoring global health: WHO has mandate and expertise (letter). *BMJ* 2004; 330: 195.
117. The second Ad-hoc Committee on the tuberculosis epidemic (Billo N, Bloom A, Broekmans J, Dayrit M, Dumelle F, Elzinga G, England S, Espinal M, Kutwa A, Maher D, Narayanan PR, Omaswa F, Raviglione M, Robb A, Shah SK, Tapia R, Vink K, Weil D, Young D). Report of the Meeting of the second Ad-hoc Committee on the tuberculosis epidemic:

- recommendations to StopTB Partners. Montreux, Switzerland, 18-19 September 2003. *Int J Tuberc Lung Dis* 2004; 8:1279-1284.
118. Maher D, Watt C, Williams BG, Raviglione M, Dye C. Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance? *Int J Tuberc Lung Dis* 2004; 9 (2): 123-127.
 119. Harries AD, Salaniponi FM, Nunn PP, Raviglione M. Performance-related allowances within the Malawi National Tuberculosis Control Programme. *Int J Tuberc Lung Dis* 2005; 9 (2): 38-144.
 120. Figueroa-Munoz J, Palmer K, Dal Poz M, Blanc L, Bergstrom K, Raviglione M. The health workforce crisis in TB control: a report from high-burden countries. *Hum Res Health* 2005; 3 (2): 1-9.
 121. Maher D, Raviglione M. Global epidemiology of tuberculosis. In Schluger NW. Ed. *Clinics in Chest Medicine* 2005; 26 (2): 167-182. Elsevier WB Saunders Co., Philadelphia, Pa, USA.
 122. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence and deaths globally. *JAMA* 2005; 293: 2767-2775.
 123. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. *Nature Reviews/Immunology* 2005; 5:819-826.
 124. Raviglione MC, Uplekar M. WHO's new StopTB Strategy. *Lancet* 2006; 367: 952-955.
 125. Raviglione MC. The Global Plan to Stop TB, 2006-2015 (editorial). *Int J Tuberc Lung Dis* 2006; 10 (3): 238-239.
 126. Dye C, Maher D, Weil D, Espinal M, Raviglione M. Targets for global tuberculosis control. *Int J Tuberc Lung Dis* 2006; 10 (4): 460-462.
 127. Hopewell PC, Migliori GB, Raviglione MC. Tuberculosis care and control (editorial). *Bull World Health Organ* 2006; 84 (6): 428.
 128. Reid A, Scano F, Getahun H, Williams B, Dye C, Nunn P, De Cock KM, Hankins C, Miller BI, Castro KG, Raviglione M. Towards universal access to HIV prevention, treatment, care and support: the role of tuberculosis/HIV collaboration. *Lancet Infect Dis* 2006; 6:483-495.
 129. Nathanson E, Lambregts-van Weezenbeck C, Rich ML, Gupta R, Bayona J, Blöndal K, Caminero JA, Cegielski JP, Danilovits M, Espinal ME, Hollo V, Jaramillo E, Leimane V, Mitnick CD, Mukherjee JS, Nunn P, Pasechnikov A, Tupasi T, Wells C, Raviglione MC. Multidrug-resistant tuberculosis management in resource-limited settings. *Emerg Infect Dis* 2006; 12: 1389-1397.
 130. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International Standards for Tuberculosis Care. *Lancet Infect Dis* 2006; 6: 710-725.

131. Raviglione M. XDR-TB: entering the post-antibiotic era? (Editorial). *Int J Tuberc Lung Dis* 2006; 10 (11): 1185-1187
132. Migliori GB, Hopewell PC, Blasi F, Spanevello A, Raviglione MC. Improving the TB case management: the International Standards for Tuberculosis Care (Editorial). *Eur Respir J* 2006; 28: 687-690.
133. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deum A, Wells C, Nunn P, Blanc L, Raviglione M. Epidemiology of anti-tuberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. *Lancet* 2006; 368: 2142-2154.
134. Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients with previously treated tuberculosis no longer neglected. *Clin Infect Dis* 2007; 44:61-64.
135. Raviglione MC, Smith IM. XDR tuberculosis - Implications for global public health (Perspective). *N Engl J Med* 2007; 356: 656-659.
136. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus - The new XDR-TB threat. Is "science" enough to tackle the epidemic? (Editorial). *Eur Respir J* 2007; 29: 423-427.
137. Aziz MA, Vincent V, Blanc L, Raviglione M. Authors' reply on Controlling multidrug-resistant tuberculosis in India (letter). *Lancet* 2007; 369:742.
138. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, Ferrarese M, De Iaco G, Gori A, Raviglione MC and SMIRA/TBNET Study Group. Extensively drug-resistant tuberculosis, Italy and Germany (letter). *EID* 2007; 13 (5): 780-782.
139. Aziz M, Ryszewska K, Blanc L, Vincent V, Getahun H, Wright A, Nunn P, Raviglione M. Expanding culture and drug susceptibility testing capacity in tuberculosis diagnostic services: the new challenge. *Int J Tuberc Lung Dis* 2007; 11 (3): 247-250.
140. Raviglione MC. The new Stop TB Strategy and the Global Plan to Stop TB, 2006-2015 (Editorial). *Bull World Health Organ* 2007; 85 (5): 327.
141. Maher D, Dye C, Floyd K, Pantoja A, Lonroth K, Reid A, Nathanson E, Pennas T, Fruth U, Cunningham J, Ignatius H, Raviglione MC, Koek I, Espinal M. Planning to improve global health: the next decade of tuberculosis control. *Bull World Health Organ* 2007; 85 (5): 341-347.
142. Uplekar M, Raviglione MC. The "vertical-horizontal" debates: time for the pendulum to rest (in peace)? (Commentary to the Public Health Classic by H. Mahler, *Bull Intern Union Tuberc* 1966; 37: 77-82). *Bull World Health Organ* 2007; 85 (5): 413-414.
143. Brands A, Ottmani S, Lönnroth K, Blanc LJ, Rahman K, Bettcher DW, Raviglione M. Reply to "Addressing smoking cessation in tuberculosis control" (letter). *Bull World Health Organ* 2007; 85 (8): 647-648.

144. Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungousova OS, Ferrara G, Cirillo DM, Gori A, Matteelli A, Spanevello A, Codecasa LR, Raviglione MC and SMIRA/TBNET Study Group. Clinical and operational value of the extensively drug-resistant tuberculosis definition. *Eur Respir J* 2007; 30: 623-626.
145. Matteelli A, Migliori GB, Cirillo D, Centis R, Girardi E, Raviglione M. Multidrug-resistant and extensively drug-resistant *Mycobacterium tuberculosis*: epidemiology and control. *Expert Rev Anti Infect Ther* 2007; 5 (5): 857-871.
146. Martinez L, Blanc L, Nunn P, Raviglione M. Tuberculosis and air travel: WHO guidance in the era of drug-resistant TB. *Travel Med Infect Dis* 2008; 6: 177-181.
147. Boggio A, Zignol M, Jaramillo E, Nunn P, Pinet G, Raviglione M. Limitations on human rights: are they justifiable to reduce the burden of tuberculosis in the era of MDR- and XDR-TB? *Health and Human Rights - An International Journal* 2008; 10 (2): 121-126.
148. Espinal M, Raviglione MC. From threat to reality. The real face of multidrug-resistant tuberculosis (editorial): *Am J Respir Crit Care Med* 2008; 178: 216-217.
149. Raviglione M. Facing XDR-TB: a hope and a challenge (editorial). *N Eng J Med* 2008; 359:636-638.
150. Lönnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. *Semin Respir Crit Care Med* 2008; 29:481-491.
151. Lienhardt C, Espinal M, Raviglione M. Funding research and development for neglected diseases: the urgency is to grow the pie rather than redistributing the parts (letter). *PLoS Medicine* 2009; 6 (6 March 2009).
152. Blanc L, Raviglione M. La tuberculose en France est-elle d'actualité? (Editorial). *Bulletin Epidémiologique Hebdomadaire (InVS, Saint-Maurice, France)* 2009; 12-13:105-106.
153. Wright A, Zignol M, Van Deun A, Falzon D, Rüscher Gerdes S, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulahbal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M for the Global Project on Anti-Tuberculosis Drugs Resistance Surveillance. Epidemiology of anti-Tuberculosis drug resistance 2002-2007: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. *Lancet* 2009; 373:1861-1873.
154. Weil DEC, Zignol M, Raviglione MC. Informed patient consent for defaulter tracing: should we obtain it? ("Unresolved issues" - Multi-author article). *Int J Tuberc Lung Dis* 2009; 13 (5): 551-555.
155. Yesudian HM, Raviglione MC. World Tuberculosis Day 2009: Partnership for TB care (Editorial). *Indian J Med Res* 2009; 129:215-218.
156. Vitoria M, Granich R, Gilks CF, Gunneberg C, Hosseini M, Were W, Raviglione M, De Cock KM. The global fight against HIV/AIDS, tuberculosis and malaria. *Am J Clin Pathol* 2009;

131:844-848.

157. Granich R, Getahun H, Reid A, Raviglione M, De Cock K. Erring on the side of action: time for HIV programmes to implement isoniazid preventive therapy (Editorial). *Int J Tuberc Lung Dis* 2009; 13(8):925-926.
158. Lönnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. *Soc Sci Med* 2009; 68: 2240-2246.
159. Dye C, Lönnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. *Bull World Health Organ* 2009; 87: 683-691.
160. Frieden TR, Teklehaimanot A, Chideya S, Farmer P, Kim JY, Raviglione MC. A roadmap to control malaria, tuberculosis, and Human Immunodeficiency Virus/AIDS. *Arch Intern Med* 2009; 169:1650-1652.
161. Gargioni G, Raviglione M. The principles of primary health care and social justice. *J Med Person* 2009; 7:103-105.
162. Boggio A, Zignol M, Jaramillo E, Raviglione M. Letter in response to "Limitations on human rights in the context of drug-resistant tuberculosis: a reply to Boggio et al.". *Health and Human Rights - An International Journal* 2009; (October) available at <http://hhrjournal.org/blog/perspectives/limitations-tb/>
163. Glaziou P, Floyd K, Raviglione M. Global burden of tuberculosis. *Clin Chest Med* 2009; 30:621-636.
164. Paramasivan CN, Lee E, Kao K, Mareka M, Kubendiran G, Kumar TA, Keshajvee S, Satti H, Alabi G, Raviglione M, Roscigno G. Experience establishing TB laboratory capacity in a developing country setting. *Int J Tuberc Lung Dis* 2010; 14 (1): 59-64.
165. Onozaki I, Raviglione M. Stopping tuberculosis in the 21st century: goals and strategy: *Respirology* 2010; 15: 32-43.
166. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes". *Curr Opin Pulm Med* 2010; 16: 186-193.
167. Lönnroth K, Castro GK, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, Raviglione MC. Tuberculosis control and elimination 2010-50: cure, care, and social development. *Lancet* 2010; 375: 1814-1829.
168. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SL, El-Sadr WM, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SHE, Whitty CJM, Atun R, Zumla A. Scale-up of services and research priorities for TB diagnosis, management, and control of tuberculosis: a call to action. *Lancet* 2010; 375: 2179-2191.

169. Blanc L, Raviglione M. Prevention and control of tuberculosis during air travel (editorial). *Int J Travel Med Infect Dis* 2010; 8: 79-80.
170. Lange C, Ye WW, Migliori GB, Raviglione M. The European Respiratory Journal targets at tuberculosis (editorial). *Eur Respir J* 2010; 36: 714-715.
171. Fears R, Kaufmann S, ter Meulen V, Zumla A on behalf of the EASAC Working Group (*Observer in the EASAC Working Group: Raviglione M). Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. *Tuberculosis* 2010; 90: 182-187.
172. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, Weil D, Raviglione M. MDR tuberculosis - Critical steps for prevention and control. *N Engl J Med* 2010; 363: 1050-1058.
173. Atun R, Raviglione M, Marais B, Zumla A. Tuberculosis control is crucial to achieve the MDGs (Comment). *Lancet* 2010; 376: 940-941.
174. Getahun H, Raviglione M. Active case finding for tuberculosis in the community: time to act. *Lancet* 2010; 376: 1205-1206.
175. Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. *AIDS* 2010; 24 (Suppl. 5): S57-S65.
176. Falzon D, Raviglione M. Giving voice to those who die young: the fatal impact of tuberculosis and HIV in South Africa (Evaluation of article). *Future Microbiol* 2010; 5 (11): 1641-1643.
177. Lönnroth K, Raviglione MC. Here is diabetes in 'The Lancet's' Tuberculosis Series (letter). *Lancet* 2010; 376: 1987-1988.
178. Creswell J, Jaramillo E, Lönnroth K, Weil D, Raviglione M. Tuberculosis and poverty - Counterpoint. *Int J Tuberc Lung Dis* 2011; 15 (4): 431-432.
179. Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M. Modernizing surveillance of antituberculosis drug resistance: from special surveys to routine testing. *Clin Infect Dis* 2011; 52: 901-906.
180. Veen J, Migliori GB, Raviglione M, Rieder HL, Dara M, Falzon D, Kuyvenhoven JV, Schwoebel V, Zaleskis R. Harmonisation of TB control in the WHO European region: the history of the Wolfheze Workshops. *Eur Respir J* 2011; 37: 950-959.
181. Raviglione M, Krech R. Tuberculosis: still a social disease (Editorial). *Int J Tuberc Lung Dis* 2011; 15 (6): S6-S8.
182. Raviglione MC, Lange C, Migliori GB. Preventing and managing antimicrobial resistance: imperative for chest physicians. *Eur Respir J* 2011; 37: 978-981.
183. Creswell J, Raviglione M, Ottmani S, Migliori GB, Uplekar M, Blanc L, Sotgiu G, Lönnroth K. Tuberculosis and non-communicable diseases: neglected links and missed opportunities.

- Eur Respir J 2011; 37: 1269-1282.
184. Leung E, Weil DE, Raviglione M, Nakatani H on behalf of the World Health Organization World Health Day Antimicrobial Resistance Technical Working Group. The WHO policy package to combat antimicrobial resistance. *Bull World Health Organ* 2011; 89: 390-392.
 185. Glaziou P, Floyd K, Korenromp EL, Sismanidis C, Bierrenbach A, Williams B, Atun R, Raviglione MC. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. *Bull World Health Organ* 2011; 89: 573-582.
 186. Getahun H, Raviglione M. Transforming the global tuberculosis response through effective engagement of civil society organizations: the role of the World Health Organization. *Bull World Health Organ* 2011; 89:616-618.
 187. Migliori GB, Sotgiu G, Blasi F, Zumla A, Loddenkemper R, Raviglione MC, Abubakar I, Sandgren A, Manissero D. Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC) (Editorial). *Eur Respir J* 2011; 38: 493-495.
 188. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer J, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, Fitzpatrick C, Gebhard A, Getahun H, Henkens M, Holtz TH, Keravec J, Khan AJ, Kulier R, Leimane V, Lienhardt C, Lu C, Mariandyshev A, Migliori GB, Mirzayev F, Mitnick CD, Nunn P, Nwagboniwe G, Oxlade O, Palmero D, Pavlinac P, Quelapio MP, Raviglione MC, Rich ML, Royce S, Rüscher-Gerdes S, Salakaia A, Sarin R, Sculier D, Varaine F, Vitoria M, Watson JL, Wares F, Weyer K, White RA, Zignol M. WHO Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. *Eur Respir J* 2011; 38: 516-528.
 189. Lienhardt C, Espinal M, Pai M, Maher D, Raviglione MC (2011) What Research Is Needed to Stop TB? Introducing the TB Research Movement. *PLoS Med* 8(11): e1001135. doi:10.1371/journal.pmed.1001135.
 190. Zignol M, Van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. *Bull World Health Organization* 2012; 90: 111-119D.
 191. Zumla A, Blasi F, Raviglione M. Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance (Editorial). *Eur Respir J* 2012; 39: 802-804.
 192. Getahun H, Sculier D, Sismanidis C, Grzemska M, Raviglione M. Prevention, diagnosis and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal and child health services. *J Infect Dis* 2012 (suppl): S1-S12.
 193. Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, Mchugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R. Drug resistant tuberculosis – Current dilemmas, unanswered questions, challenges and priority needs. *J Infect Dis* 2012 (suppl.); S1-S13.
 194. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuns J. New drugs for the treatment of tuberculosis: needs, challenges, promise and

- prospects for the future. *J Infect Dis* 2012 (suppl.); S1-S9.
195. Raviglione M, Nunn P, Floyd K, Getahun H, Grzemska M, Weil D, Weyer K. WHO's relationship with the Stop TB Partnership (letter). *Lancet* 2012; 379: 611-612.
 196. Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A. A sustainable agenda for tuberculosis control and research (Comment). *Lancet* 2012; 379: 1077-1078.
 197. Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod L, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D. European Union Standards for Tuberculosis Care. *Eur Respir J* 2012; 39: 807-819.
 198. Lienhardt C, Glaziou P, Uplekar M, Lönnroth K, Getahun H, Raviglione M. Successes and challenges of global tuberculosis control. *Nature Reviews Microbiology* 2012; AOP, published online 14 May 2012; doi:10.1038/nrmicro2797.
 199. Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SHE, Zumla A. Scaling-up interventions to achieve global tuberculosis control: progress and new developments. *Lancet* 2012; 379: 1902-1913.
 200. Migliori GB, Dara M, De Colombani P, Kluge H, Raviglione MC. Multidrug-resistant tuberculosis in Eastern Europe: still on the increase? (Editorial). *Eur Respir J* 2012; 39: 1290-1291.
 201. Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. *Curr Opin HIV AIDS* 2012; 7:345-353.
 202. Granich R, Getahun H, Hirschall G, Raviglione MC. Hurry up and wait? Accelerating access for the Three P's for HIV-TB. *Int J Tuberc Lung Dis* 2012; 16 (4): 853-854.
 203. Uplekar M, Raviglione M. Hospital or home? Scripting a high point in the history of TB care and control. *WHO SE Asian J Public Health* 2012; 1 (2): 220-223.
 204. Korenromp E, Glaziou P, Fitzpatrick C, Floyd K, Hosseini M, Raviglione M, Atun R, Williams B. Implementing the Global Plan to Stop TB, 2011-2015 - Optimizing allocations and the Global Fund's contribution: a scenario projection study. *PLoS ONE* 2012; 7(6): e38816. doi:10.1371/journal.pone.0038816.
 205. Getahun H, Raviglione M, Varma JK, Cain K, Samandari T, Popovic T, Frieden T. CDC Ground Rounds : The TB/HIV syndemic. *MMWR* 2012; 61:484-489.
 206. Falzon D, Zignol M, Migliori GB, Nunn P, Raviglione MC. Migration: an opportunity for the improved management of tuberculosis world-wide. *It J Public Health* 2012; 9 (3): e7524-1 –

e7524-11.

207. Cegielski P, Nunn P, Kurbetova EV, Weyer K, Dalton T, Wares DF, Iademarco MF, Castro KG, Raviglione M. Challenges and controversies in defining totally drug-resistant tuberculosis. *Emerg Infect Dis* (Internet) Nov 2012; <http://dx.doi.org/10.3201/eid1811.120526>.
208. Dye C, Mertens T, Hirschall G, Mpanju-Shumbusu W, Newman RD, Raviglione MC, Savioli L, Nakatani H. WHO and the future of disease control programmes. *Lancet* 2013; 381:413-418.
209. Lönnroth K, Corbett E, Golub J, Godfrey-Faussett P, Uplekar M, Weil D, Raviglione M. Systematic screening for active TB: rationale, definitions and key considerations. *Int J Tuberc Lung Dis* 2013; 17 (3): 289-298.
210. Falzon D, Weyer K, Raviglione M. Drug-resistant tuberculosis: latest advances. *Lancet Respir Med* 2013; (1): e9.
211. Weyer K, Mirzayev F, Migliori GB, Van Gemert W, D'Ambrosio L, Zignol M, Floyd K, Centis R, Cirillo DM, Tortoli E, Gilpin C, Iragena J, Falzon D, Raviglione M. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF. *Eur Respir J Express*. First published on November 22, 2012; [http://doi: 10.1183/09031936.00157212](http://doi:10.1183/09031936.00157212); *Eur Respir J* 2013; 42: 252-271.
212. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. *Annu Rev Public Health* 2013; 34: 271-286.
213. Zumla A, Raviglione M, Hafner R, Von Reyn CF. Tuberculosis – Current Concepts. *New Engl J Med* 2013; 745-755.
214. Jaramillo E, Weyer K, Raviglione M. Linezolid for extensively drug-resistant tuberculosis (letter). *Lancet* 2013; 368: 290.
215. Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people who use and inject illicit drugs. *Bull World Health Organ* 2013; 91: 154-156.
216. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Mashan S, Adetifa I, Ford N, Cox H, Lawn SD, Marais B, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNERNEY R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A. Drug-resistant tuberculosis: time for visionary political leadership. *Lancet Infect Dis* 2013. [http://dx.doi.org/10.1016/S1473-3099\(13\)7-0030-6](http://dx.doi.org/10.1016/S1473-3099(13)7-0030-6).
217. Al-Hajoj S, Varghese B, Shoukri MM, Al-Omari R, Al-Herbwai M, AlRabiah F, Alrajhi A, Abuljadayel N, Al-Thawadi S, Zumla A, Zignol M, Raviglione MC, Memish Z. Epidemiology of anti-tuberculosis drug resistance in Saudi Arabia: findings of the first national survey. *Antimicrob Agents Chemother* 2013; 57 (5): 2161-2166.

218. Glaziou P, Falzon D, Floyd K, Raviglione M. Global epidemiology of tuberculosis. *Semin Respir Crit Care Med* 2013; 34: 3-16.
219. Raviglione MC, Ditiu L. Setting new targets in the fight against tuberculosis (Correspondance). *Nature Med* 2013; 9:263.
220. Codecasa LR, Murgia N, Ferrarese M, Delmastro , Repossi AC, Casali L, Besozzi G, Ferrara G, Raviglione MC. Isoniazid preventive treatment: predictors of adverse events and treatment completion. *Int J Tuberc Lung Dis* 2013. <http://dx.doi.org/10.5588/ijtld.12.0677>
221. Falzon D, Jaramillo E, Wares F, Zignol M, Floyd K, Raviglione M. Universal access to care for multidrug-resistant tuberculosis: an analysis of surveillance data. *Lancet Infect Dis* 2013; 13: 690-692.
222. Floyd K, Glaziou P, Raviglione M. Moving the goalposts for tuberculosis targets in Africa (letter). *Lancet* 2013; 382: 27.
223. Floyd K, Fitzpatrick C, Pantoja A, Raviglione M. Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2001-11, and requirements to meet 2015 targets. *Lancet Glob Health* 2013; 1: e105-115.
224. Getahun H, Raviglione M. Household tuberculosis interventions: how confident are we? *Lancet* 2013 On-line, August 1, 2013. [http://dx.doi.org/10.1016/S0140-6736\(13\)61568.8](http://dx.doi.org/10.1016/S0140-6736(13)61568.8). *Lancet* 2013; 382: 1157-1159.
225. Dye C, Raviglione M. Weigh all TB risks. *Nature* 2013; 502: S13.
226. Raviglione M, Uplekar M, Vincent C, Pablos-Mendez A. Rebalancing the global battle against tuberculosis. *Lancet Global Health* 2014; 2: e71-e72.
227. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. *Eur Respir J* 2014; 43: 1763-1775 (also on line: DOI: 10.1183/09031936.00193413)
228. D'Ambrosio L, Dara M, Tadolini M, Centis R, Sotgiu G, van der Werf M, Gaga M, Cirillo D, Spanevello A, Raviglione M, Blasi F, Migliori GB on behalf of the European national programme representatives. Tuberculosis elimination: theory and practice in Europe. *Eur Respir J* 2014; 43: 1410-1420.
229. Chakaya J, Raviglione M. Quality tuberculosis care: all should adopt the new International Standards for Tuberculosis Care. *Ann Am Thorac Soc* 2014; 11 (3): 397-398.
230. Roscigno G, Raviglione M. Comment on "Tuberculosis: drug discovery goes *au naturel*". *Nature* on-line, 10-4-2014. <http://www.nature.com/nature/journal/v506/n7489/full/506436a.html>
231. Herbert Rt Hon N, George A MP, Baroness Masham of Hilton, Sharma V MP, Oliver M, Oxley M, Raviglione M, Zumla A. World Tb Day 2014: finding the missing three million.

Lancet 2014; 383:1016-1018.

232. Voniatis C, Migliori GB, Voniatis M, Georgiu A, D'Ambrosio L, Centis R, Raviglione MC. Tuberculosis elimination: dream or reality? The case of Cyprus. *Eur Respir J* 2014, 44: 543-546. (Published online: 17 April 2014, as DOI: 10.1183/09031936.000.44314).
233. Lonnroth K, Glaziou P, Weil D, Floyd K, Uplekar M, Raviglione MC. Beyond UHC: Monitoring universal health coverage and social protection in the context of tuberculosis care and prevention. *PLoS Med* 2014; 11: (issue 9): 1-10; e1001693
234. Sotgiu G, Falzon D, Castiglia P, Migliori GB, Raviglione M. Tuberculosis and the strategy for the new Millennium: not simply "more of the same". *Epidem Biostat Public Health* 2014; 11(2): DOI: 10.2427/10116.
235. Farmer PE, Raviglione MC. Rapid impact of effective chemotherapy on transmission of drug-resistant tuberculosis: pity the guinea pig. *Int J Tuberc Lung Dis* 2014; 18(9):1009-1011.
236. Lönnroth K, Migliori GB, Raviglione MC. Towards tuberculosis elimination in low-incidence countries: reflections from a global consultation. *Ann Intern Med* 2014; 161:670-672.
237. Falzon D, Mirzayev F, Wares F, Garcia Baena I, Zignol M, Linh N, Weyer K, Jaramillo E, Floyd K, Raviglione M. Multi-drug resistant tuberculosis around the world: what progress has been made? *Eur Respir J* 2015; 45: 150-160. (Published online: 26 September 2014, as DOI: 10.1183/09031936.00101814).
238. Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global epidemiology of tuberculosis. *Cold Spring Harb Perspect Med* 2014: 1-17 (Online: doi: 10.1101/cshperspect.a017798)
239. Sulis G, Roggi A, Matteelli A, Raviglione MC. Tuberculosis: epidemiology and control. *Mediterranean J Hematol Infect Dis* 2014; 6 (1): e2014070, DOI: 10.4084/MJHID.2014.070.
240. Weyer K, Falzon D, Wares F, Jaramillo E, Raviglione M. Tuberculosis control: hard questions. *Lancet* 2014; 384: 1744 (letter).
241. Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione MC. Ensuring rational introduction and responsible use of new tools: outcome of an ERS multisector consultation. *Eur Respir J* 2014; 44: 1412-1417.
242. Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MRM, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Gogvadze L, del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo R, Voniatis C, Wanlin M

- and Raviglione MC. Towards tuberculosis elimination: an action framework for low-incidence countries. *Eur Respir J* 2015; 45: 928–952 (DOI: 10.1183/09031936.00214014).
243. Uplekar M, Weid D, Lönnroth K, Jaramillo E., Lienhardt C, Dias HM, Falzon D, Floyd K, Gargioni G, Getahun H, Gilpin C, Glaziou P, Grzemska M, Mirzayev F, Nakatani H, Raviglione M for WHO's Global Tuberculosis Programme. WHO's End TB Strategy. *Lancet* 2015; 385: 1799-1801 (on line 24 March 2015 – [http://dx.doi.org/10.1016/S0140-6736\(15\)60570.0](http://dx.doi.org/10.1016/S0140-6736(15)60570.0)).
 244. Dirlikov E, Raviglione M, Scano F. Global Tuberculosis control: toward the 2015 targets and beyond. *Ann Intern Med* 2015; 163: 52-58. DOI: 10.7326/M14-2210 (on line 28 April 2015).
 245. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent *Mycobacterium tuberculosis* infection. *N Engl J Med* 2015; 372: 2127-35.
 246. Falzon D, Raviglione M, Bel EH, Gratzou C, Bettcher D, Migliori GB. The role of eHealth and mHealth in tuberculosis and tobacco control: a WHO/ERS Consultation. *Eur Respir J* 2015; 46: 307-311.
 247. Getahun H, Chaisson RE, Raviglione M. Latent *Mycobacterium tuberculosis* Infection (reply letter). *N Eng J Med* 2015; 373: 1179-1180.
 248. Getahun H, Matteelli A, Abubakar I, Abdel Aziz M, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Bin-Eng Chee C, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, Grant AD, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MK, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandeveld W, van Kessel F, 't Hoog A, Varma JK, Vezhnina N, Voniatis C, Noordegraaf-Schouten MV, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent *Mycobacterium tuberculosis*: WHO guidelines for low tuberculosis burden countries. *Eur Respir J* 2015 (DOI: 10.1183/13993003.01245-2015)
 249. Uplekar M, Raviglione M. WHO's End TB Strategy: from stopping to ending the global TB epidemic. *Ind J Tuberc* 2015; 62:196-199.
 250. Matteelli A, Lönnroth K, Getahun H, Falzon D, Migliori GB, Raviglione M. Continued research is crucial to reach elimination targets (letter). *Eur Respir J* 2015; 46:1838-1839.
 251. Glaziou P, Floyd K, Weil D, Raviglione M. TB deaths rank alongside HIV deaths as top infectious killer. (Edit.). *Inter J Tuberc Lung Dis* 2016; 20(2): 143-144.
 252. Lönnroth K, Raviglione M. The WHO's new End TB Strategy in the post-2015 era of Sustainable Development Goals. *Trans R Soc Trop Med Hyg* 2016; 110: 148-150.

253. Lienhardt C, Lönnroth K, Menzies D, Balasegaram M, Chakaya J, Cobelens F, Cohn J, Denkinger CM, Evans TG, Källenius G, Kaplan G, Kumar AMV, Matthiessen L, Mgone CS, Mizrahi V, Mukadi Y, Nguyen VN, Nordström A, Sizemore CF, Spiegelman M, Squire SB, Swaminathan S, Van Helden PD, Zumla A, Weyer K, Weil D, Raviglione M. Translational research for tuberculosis elimination: priorities, challenges, and action. *PLOS Med*/DOI: 10.1371/journal.pmed.1001965, March 2, 2016.
254. Matteelli A, Lönnroth K, Mosca D, Getahun H, Centis R, D'Ambrosio L, Jaramillo E, Migliori GB, Raviglione M. Cross-border migration: migrant and native populations' health cannot be ignored by national TB programmes. *Eur Respir J* 2016; 47: 684-686.
255. Falzon D, Timimi H, Kurosinski P, Migliori GB, Van Gemert W, Denkinger C, Isaacs C, Story A, Garfein RS, do Valle Bastos LG, Yassin MA, Rusovich V, Skrahina A, Hoi LV, Broger T, Abubakar I, Hayward A, Thomas BV, Temesgen Z, Quraishi S, von Delft D, Jaramillo E, Weyer K, Raviglione M. Digital Health for the End TB Strategy: developing priority products and making them work. *Eur Respir J* 2016; 29-45 (DOI: 10.1183/13993003.00424-2016).
256. Falzon D, Raviglione M. The Internet of Things to come: digital technologies and the End TB Strategy. *BMJ Global Health* 2016;1:e000038 (DOI: 10.1136/bmjgh-2016-000038).
257. Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, Forcella S, Silk BJ, Ditiu L, El Idrissi A, Raviglione M, Cosivi O, LoBue P, Fujiwara PI. Zoonotic tuberculosis in humans beings caused by *Mycobacterium bovis* – A Call for Action. *Lancet Infect Dis* 2016; e21-25. [http://dx.doi.org/10.1016/S1473-3099\(16\)30139-6](http://dx.doi.org/10.1016/S1473-3099(16)30139-6).
258. Nathavitharana RR, Peters J, Lederer P, von Delft A, Farley JE, Pai M, Jaramillo E, Raviglione M, Nardell E. Engaging health-care workers to reduce tuberculosis transmission. *Lancet Infect Dis* 2016; 16:883-5 (Published Online June 14, 2106 [http://dx.doi.org/10.1016/S1473-3099\(16\)30166-9](http://dx.doi.org/10.1016/S1473-3099(16)30166-9)).
259. Zignol M, Dean AS, Falzon D, Van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A., Espinal M, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione M. Twenty years of global surveillance of anti-tuberculosis drug resistance. *N Eng J Med* 2016; 375(11):1081-1089.
260. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadee E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC. Population-based resistance of *Mycobacterium tuberculosis* isolates to pyrazinamide and fluoroquinolones: results from a multi-country surveillance project. *Lancet* 2016; 16:1185-1192 (Published online 15 July 2016 [http://dx.doi.org/10.1016/S1473-3099\(16\)30190-6](http://dx.doi.org/10.1016/S1473-3099(16)30190-6))
261. Pai M, Behr M, Dowdy D, Dheda K, Divangahi M, Boehme C, Ginsberg A, Swaminathan S, Spiegelman M, Getahun H, Menzies R, Raviglione M. Tuberculosis. *Nature Reviews Disease Primers* 2, 16076 (2016) (DOI:10.1038/nrdp.2016.76).

262. Raviglione MC, Korobitsyn AA. End TB – The new WHO strategy in the SDG era, and the contributions from the Russian Federation. *Tuberculosis and Lung Diseases (Moscow, Russian Federation)* 2016; 94:7-15 (in Russian language).
263. Uplekar M, Atre S, Well WA, Weil D, Lopez R, Migliori GB, Raviglione M. Mandatory TB case notification in high tuberculosis-incidence countries: policy and practice. *Eur Respir J* 2016; 48: 1571-1581.
264. Sulis G, Raviglione M. Tuberculosis 2015: burden, challenges and strategy for control and elimination. *Infectious Disease Reports* 2016; 8: 6570, 33-37.
265. Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, Gonzalez-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M. Target regimen profiles for treatment of tuberculosis: a WHO document. *Eur Respir J* 2017 (Jan): 49 (1) 1602352; DOI: 10.1183/13993003.02352-2016.
266. Doshi R, Falzon D, Bruce T, Zelalem T, Sadasivan L, Migliori GB, Raviglione M. Doshi R, Falzon D, Thomas BV, et al. Tuberculosis control, and the where and why of artificial intelligence. *ERJ Open Res* 2017; 3: 00056-2017 [<https://doi.org/10.1183/23120541.00056-2017>].
267. Raviglione MC, Mosca D. Migrant health and tuberculosis. *Int J Tuberc Lung Dis* 2017; 21 (6): 599-600.
268. Raviglione M, Poznyak V. Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action. *Eur Respir J* 2017; 50: 1700946 (<https://doi.org/10.1183/13993003.00946-2017>).
269. Raviglione M, Maher D. Ending infectious diseases in the era of the Sustainable Development Goals. *Porto Biomed J* 2017; 2(5):140-142 (<http://dx.doi.org/10.1016/j.pbj.2017.08.001>)
270. Marais BJ, Walker TM, Cirillo DM, Raviglione M, Abubakar I, van der Werf M, Boehme C, Niemann S, Castro KG, Zumla A, Sintchenko V, Crook DW. Aiming for zero tuberculosis transmission in low-burden countries. *Lancet Respir Med* 2017 (on line 12-10-2017; [http://dx.doi.org/10.1016/S2213-2600\(17\)30382-x](http://dx.doi.org/10.1016/S2213-2600(17)30382-x))
271. Luzzati R, Migliori GB, Zignol M, Cirillo MD, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Buseti M, Di Santolo M, Raviglione M, Confalonieri M. Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. *Eur Respir J* 2017; 50: 1701414 [<https://doi.org/10.1183/13993003.01414-2017>].
272. Falzon D, Migliori GB, Jaramillo E, et al. Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives. *Eur Respir J* 2017; 50: 1701632 [<https://doi.org/10.1183/13993003.01632-2017>].

273. Sismanidis C, Shete PB, Lienhardt C, Floyd K, Raviglione M. Harnessing the power of data to guide local action and end tuberculosis. *JID* 2017;216 (Suppl 7): S669-S671.
274. Raviglione M, Uplekar M, Weil D, Kasaeva T. TB makes it onto the international political agenda for health...finally. *Lancet Global Health* 2017: Published Online November 15, 2017 [http://dx.doi.org/10.1016/S2214-109X\(17\)30449-7](http://dx.doi.org/10.1016/S2214-109X(17)30449-7).
275. Dean AS, Forcella S, Olea-Popelka F, El Idrissi A, Glaziou P, Benyahia A, Mumford E, Erlacher-Vindel E, Gifford G, Lubroth J, Raviglione M, Fujiwara P. A roadmap for zoonotic tuberculosis: a One Health approach to ending tuberculosis. *Lancet Infect Dis* 2018; 18: 137-138.
276. Lienhardt C, Zumla A, Gebreselassie N, Frick M, Grey G, Kasaeva T, Raviglione M. Tuberculosis research and development: seeding the future. *Lancet Respir Med* 2018; 6: 242-244.
277. Floyd K, Glaziou P, Zumla A, Raviglione MC. The global tuberculosis epidemic and progress in care, prevention and research: an overview in year 3 of the “End TB” era. *Lancet Respir Med* 2018; 6: 299-314.
278. Pablos-Mendez A, Raviglione MC. A new world health era. *Global Health: Science and Practice*. <https://doi.org/10.9745/GHSP-D-17-002972018> (published on line 14-3-2018)
279. Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based study. *Lancet Infect Dis* 2018. Published Online March 21, 2018 [http://dx.doi.org/10.1016/S1473-3099\(18\)30073-2](http://dx.doi.org/10.1016/S1473-3099(18)30073-2)
280. Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K. The World Health Organization standards for tuberculosis care and management. *Eur Respir J* 2018; 51: 1800098 [<https://doi.org/10.1183/13993003.00098-2018>].
281. Carter DJ, Glaziou P, Lönnroth K, Siroka A, Floyd K, Weil D, Raviglione M, Houben RMGJ, Boccia D. The impact of social protection and poverty elimination on global tuberculosis incidence: a statistical modelling analysis of Sustainable Development Goal 1. *Lancet Global Health* 2018. Published Online March 23, 2018 [http://dx.doi.org/10.1016/S2214-109X\(18\)30195-5](http://dx.doi.org/10.1016/S2214-109X(18)30195-5)
282. Glaziou P, Floyd K, Raviglione MC. Trends in tuberculosis in the UK. *Thorax* 2018. First published as 10.1136/thoraxjnl-2018-211537 on 19 April 2018. Downloaded from <http://thorax.bmj.com/>.

283. Dias HM, Pai M, Raviglione M. Ending tuberculosis in India: A political challenge & an opportunity. *Ind J Med Res* 2018 (in press)
284. The Lancet Commission on TB (Commissioners: Goosby E, Jamison D, Reid M, Arinaminpathy N, Bloom A, Bloom B, Boehme C, Chaisson R, Chin D, Churchyard G, Cox H, Ditiu L, Dybul M, Farrar J, Fauci A, Fedaku E, Fujiwara P, Hallett T, Hanson C, Harrington M, Herbert N, Hopewell P, Ikeda C, Khan A, Koek I, Krishnan N, Motsoaledi A, Pai M, Raviglione M, Sharman A, Skvortsova V, Small P, Temesgen Z, Vassall A, Venkatesan N, van Weezenbeek K, Yamey G, Swaminathan S.) (Contributing Authors: Agins B, Andrews J, Brigden G, Cattamanchi A, Cazabon D, Daftary A, Dewan P, Doepel L, Eisinger R, Fan V, Furin J, Graham S, Goldhaber-Fiebert J, Gomez G, McHugh L, Mitchell E, Moon S, Prince L, Pande T, Seddon J, Shete P, Stallworthy G, Vesga Gaviria J. Building a TB-free world. *Lancet* 2018 (in press)

Bibliography: Books and chapters

1. Raviglione MC. Section on Infectious Diseases. In: Pablos-Mendez A, Petersen-Aranguren F, Breien-Alcaraz HS, Aceves-Casillas P, Panduro-Baron JG, Luna-Borgaro E, Eds. *Manual del Clínico*. 2nd edition, Editorial Universidad de Guadalajara, Guadalajara, Mexico, 1993.
2. Snider DE Jr, Raviglione M, Kochi A. Global burden of tuberculosis. In: Bloom BR, Ed. *Tuberculosis. Pathogenesis, protection, and control*. American Society for Microbiology Press, Washington, DC, 1994 (p. 3-11).
3. Ara G, Raviglione MC e Collaboratori. Il contatto di due brufoli è contagioso? Manuale informativo per i giovani del Biellese. Lions Club Biella Host; Ministero della Sanità, Istituto Superiore di Sanità, Progetto AIDS; USL 12, Biella. Biella, Italy, 1995.
4. Harries A, Maher D, with contributions from Raviglione M, Chaulet P, Nunn P, van Praag E. *TB/HIV. A clinical manual*. Global Tuberculosis Programme, World Health Organization, Geneva, 1996 (WHO/TB/96.200) (available for Africa in English, French and Portuguese; adapted for South-East Asia in English; for Latin America in Spanish; for Brazil in Portuguese; and for Arabic-speaking countries in Arabic).
5. Raviglione MC, Nunn PP, Kochi A, O'Brien R. The pandemic of HIV-associated tuberculosis. In: Mann J, Tarantola D, Eds. *AIDS in the World II. Global dimensions, social roots, and responses*. The Global AIDS Policy Coalition. Oxford University Press, New York and Oxford, 1996 (p. 87-96).
6. Kumaresan JA, Raviglione MC, Solomon J, Murray CJL. Tuberculosis. In: Murray CJL and Lopez AD, Eds. *The Global Epidemiology of Infectious Diseases*. Harvard University Press (on behalf of the World Health Organization and the World Bank), Cambridge, MA, USA (1996, never formally published).
7. Raviglione MC, Nunn PP. Epidemiology of tuberculosis. In: Zumla A, Johnson MA, Miller RF, Eds. *AIDS and Respiratory Medicine*. Chapman & Hall Medical, London, U.K., 1997 (p. 117-141).

8. Migliori GB, Raviglione MC. Population surveillance and prevention strategies for tuberculosis. In: *Tuberculosis in Childhood*. *Annales Nestlé* 1997; 55 (1), Vevey, Switzerland (p. 24-34).
9. Connolly MA, Chaulet P, Raviglione MC. Epidemiology of tuberculosis. In: Wilson R, Ed. *Tuberculosis. The European Respiratory Monograph*. European Respiratory Society, vol. 2, Monograph 4 (p. 51-67). July 1997. Sheffield, UK.
10. Raviglione MC, O'Brien RJ. Tuberculosis (Chapter 171:1004-1014). In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, Eds. *Harrison's Principles of Internal Medicine*, 14th Edition. McGraw-Hill, Inc., New York, USA, 1998.
11. Styblo K, Raviglione MC. Tuberculosis, Public Health Aspects. In: Dulbecco R, Ed. *Encyclopedia of Human Biology*, Second Edition. Volume 8:537-558. Academic Press, Inc., San Diego, CA, 1997.
12. Pablos-Méndez A, Laszlo A, Bustreo F, Binkin N, Cohn DL, Lambregts-van Weezembek C, Kim SJ, Chaulet P, Nunn P, Raviglione MC and the members of the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. *Anti-tuberculosis drug resistance in the world. Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland, 1997 (WHO/TB/97.229)*.
13. Migliori GB, Raviglione MC. Central and Eastern Europe. In: Davies PDO, Ed. *Clinical Tuberculosis*, 2nd Edition. Chapman and Hall Medical, London, UK, 1998 (p. 643-660).
14. Drobniewski F, Raviglione MC. Epidemiology of tuberculosis in adults within industrialized countries. In: Pons G, Gendrel D, Grosset J Eds. *Les Médicaments de la Tuberculose chez l'enfant. Comptes Rendus de la Neuvième Journée de Pharmacologie Clinique Pédiatrique, Hôpital Saint-Vincent de Paul, Paris, 20 novembre 1998. Collection Recherche Clinique et Décision Thérapeutique*. Springer-Verlag France, Paris 1999 (p.11-22).
15. Valway S, Watson J, Bisgard C, Scudeller L, Espinal M, Raviglione M and a WHO Consensus Committee. *Tuberculosis and air travel - Guidelines for prevention and control*. Communicable Diseases Cluster, World Health Organization, Geneva, Switzerland, 1998 (WHO/TB/98.256).
16. Maher D, Raviglione MC. The global epidemic of tuberculosis. A World Health Organization perspective. In: Schlossberg D, Ed. *Tuberculosis and Non-Tuberculosis Mycobacterial Infections*, 4th Edition. W.B. Saunders Company, Philadelphia, PA, USA 1999 (pp. 104-115).
17. Raviglione MC. Prefazione. In: Angarano G, Carbonara S, Di Pisa G, Raviglione MC, Eds. *“La tubercolosi farmacoresistente”*. Systems Comunicazioni Edizioni, Vigano di Gaggiano, Milano, Italy, 1999.
18. Raviglione MC, Migliori GB, Ambrosetti M. La tubercolosi farmacoresistente nel mondo. In: Angarano G, Carbonara S, Di Pisa G, Raviglione MC, Eds. *“La tubercolosi farmacoresistente”*. Systems Comunicazioni Edizioni, Vigano di Gaggiano, Milano, Italy, 1999.

19. Heymann DL, Kochi A, Raviglione MC. Foreword. In: Harvard Medical School and Open Society Institute, The Global Impact of Drug-Resistant Tuberculosis. Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, MA, USA, 1999.
20. World Health Organization. Global Buruli Ulcer Initiative. Buruli ulcer – *Mycobacterium ulcerans* infection. Asiedu K, Scherpbier R, Raviglione M, Eds. Geneva, Switzerland, 2000 (WHO/CDS/CPE/GBUI/2000.1).
21. O'Brien RJ, Raviglione MC. Tuberculosis in the future. Chapter 35: 867-884. In Reichman LB, Hershfield ES, Eds. Tuberculosis. A Comprehensive International Approach, 2nd Edition, Revised and Expanded. Mercel Dekker Inc. New York, USA, 2000.
22. Bleed D, Dye C, Raviglione MC. Dynamics and control of the global tuberculosis epidemic. In: Current Opinion in Pulmonary Medicine. Lippincott Williams & Wilkins, Inc. London, UK, 2000; 6: 174-179.
23. Raviglione MC. DOTS and multidrug-resistant tuberculosis, Chapter 7. In: Bastian I, Portaels F (eds.), Multidrug-resistant tuberculosis. Kluwer Academic Publishers, The Netherlands, 2000; 115-131.
24. Scientific Panel of the WHO Working Group on DOTS-PLUS for MDR-TB. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Edited by Gupta RA, Raviglione MC, Espinal ME, Arnadottir T. World Health Organization, Geneva, Switzerland, 2000 (WHO/CDS/TB/2000.279).
25. Espinal M, Simonsen L, Laszlo A, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC and the Members of the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Antituberculosis drug resistance in the world. Report n. 2. Prevalence and trends. Communicable Diseases, World Health Organization. Geneva, Switzerland, WHO/CDS/TB/2000.278.
26. Bone A, Aerts A, Grzemska M, Kimerling M, Kluge H, Levy M, Portaels F, Raviglione M, Varaine F. Tuberculosis control in prisons. A manual for programme managers. World Health Organization and International Committee of the Red Cross, Geneva, Switzerland, 2000 (WHO/CDS/TB/2000.281).
27. Raviglione MC, O'Brien RJ. Tuberculosis (Chapter 169: pages 1024-1035). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jamison JL, Eds. Harrison's Principles of Internal Medicine, 15th Edition. McGraw-Hill, Inc., New York, USA 2001.
28. Uplekar M, Pathania V, Raviglione M, with contributions from Blanc L, Nunn P, Ottmani S, Seita A and a WHO Consensus Committee. Involving private practitioners in tuberculosis control: issues, interventions, and emerging policy framework. StopTB Department, World Health Organization, Geneva, Switzerland, 2001 (WHO/CDS/TB/2001.285).
29. Global Alliance for TB Drug Development. The economics of TB drug development. Chapter 5.3: Private sector involvement in TB care: pages 91-93 (authored by Uplekar M and Raviglione M). New York, Brussels, Cape Town, October 2001.

30. Cegielski JP, Chin DP, Espinal ME, Frieden TR, Rodriguez Cruz R, Talbot EA, Weil DEC, Zaleskis R, Raviglione MC. The global tuberculosis situation: progress and problems in the 20th century, prospects for the 21st century. In "Mycobacterial infections", Infectious Disease Clinics of North America. Volume 16, number 1, March 2002. W.B. Saunders Company 2002.
31. Gupta RA, Espinal MA, Raviglione MC. Treatment of multidrug-resistant tuberculosis. Editorial related to Chapter 169: Tuberculosis. Harrison's Online – Updates Article. McGraw-Hill, 2002.
32. Strategic framework to decrease the burden of TB/HIV. Prepared by Maher D, Floyd K, Raviglione M, on behalf of the TB/HIV Working Group of the Global Partnership to StopTB. StopTB Department and Department of HIV/AIDS, World Health Organization, Geneva, Switzerland 2002 (WHO/CDS/TB/2002.296 and WHO/HIV_AIDS/2002.2).
33. Maher D, Floyd K, Sharma BV, Jaramillo E, Nkhoma W, Nyarko E, Wilkinson D, Raviglione M. Community contribution to TB care: practice and policy. Review of experience of community contribution to TB care and recommendations to National TB Programmes. StopTB Department, World Health Organization, Geneva, Switzerland 2003 (WHO/CDS/TB/2003.312).
34. Espinal MA, Raviglione MC. Global epidemiology of tuberculosis. In: Monir Madkour M, Ed. Tuberculosis. Springer-Verlag, Berlin Heidelberg, Germany, 2003 (ISBN 3-540-01441-1).
35. Aziz MA, Laszlo A, Raviglione M, Rieder H, Espinal M, Wright A. Guidelines for surveillance of drug resistance in tuberculosis. World Health Organization, Geneva, Switzerland, 2003 (WHO/TB/2003.320).
36. Maher D, Raviglione M. Why is a recording and reporting system needed, and what system is recommended? (Chapter 63). In: Toman's Tuberculosis. Case detection, treatment and monitoring. Questions and answers. 2nd edition. World Health Organization, Geneva, Switzerland, 2004 (ISBN 9241546034) (WHO/HTM/TB/2004.334).
37. Raviglione M. Can effective case detection and treatment prevent and reverse drug resistance in a community? (Chapter 70). In: Toman's Tuberculosis. Case detection, treatment and monitoring. Questions and answers. 2nd edition. World Health Organization, Geneva, Switzerland, 2004 (ISBN 9241546034) (WHO/HTM/TB/2004.334).
38. Raviglione M, Frieden T. What are examples of effective tuberculosis control programmes? (Chapter 72). In: Toman's Tuberculosis. Case detection, treatment and monitoring. Questions and answers. 2nd edition. World Health Organization, Geneva, Switzerland, 2004 (ISBN 92 4 154603 4) (WHO/HTM/TB/2004.334).
39. Corbett L, Raviglione M. Global burden of tuberculosis: past, present and future. In: Cole ST, Eisenach KD, McMurray DN, Jacobs WR Jr, Eds. Tuberculosis and the Tubercle Bacillus. ASM Press, Washington DC, USA 2005 (ISBN 1-55581-295-3).
40. Raviglione MC, O'Brien RJ. Tuberculosis (Chapter 150: pages 953-966). In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jamison JL, Eds. Harrison's Principles of Internal Medicine, 16th Edition. McGraw-Hill, Inc., New York, USA 2005.

41. Harries A, Maher D, Graham S with contributions from Raviglione M, Nunn P, Gilks C, Qazi S, Weber M, van Praag E. TB/HIV. A clinical manual. Second Edition. StopTB Department, Department of HIV/AIDS, Department of Child and Adolescent Health and Development. World Health Organization, Geneva, 2004 (WHO/HTM/TB/2004.329) (ISBN 92 4 154634 4).
42. Raviglione M. Tuberculosis and disease due to other Mycobacteria (pages 560-573). In Heymann DL, Editor. Control of Communicable Diseases Manual, 18th Edition. American Public Health Association, Washington, DC, USA, 2004 (ISBN 0-87553-034-6).
43. Working Group on TB of the UN Millennium Project Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines (Writing Committee: Broekmans J, Caines K, Paluzzi JE, Maher D, Raviglione M, Schwalbe N, Weil D). Investing in strategies to reverse the global incidence of TB. Millennium Project. Earthscan, London-Streling, VA, USA 2005 (ISBN 1-84407-223-1).
44. Aziz MA, Wright A, De Muynek A, Laszlo A, with contributions of Portaels F, Rieder H, Infuso A, van Deun A, Luna A, Rüesch-Gerdes S, Weyer K, Drobniowski F, Liefoghe R, Well C, Williams B, Lambregts K, Grzemska M, Nunn P, Espinal M, Blanc L, Raviglione M and the members of the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance surveillance in the world - Report n. 3. World Health Organization, Geneva, Switzerland 2004 (ISBN 92 4 156285 4).
45. Maher D, Raviglione M. Tuberculosis - A WHO perspective (pages 133-146). In: Schlossberg D, Ed. Tuberculosis and Non-Tuberculosis Mycobacterial Infections, 5th Edition. McGraw-Hill Companies, New York, USA, 2006.
46. Tuberculosis Coalition for Technical Assistance. Steering Committee, chaired by Hopewell P and Raviglione M. International Standards for Tuberculosis Care (ISTC) - Diagnosis, Treatment, Public Health. The Hague: Tuberculosis Coalition for Technical Assistance, 2006.
47. Raviglione M. Preface. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization. WHO/HTM/TB/2006.361. ISBN 92 4 154695 6. Geneva, Switzerland, 2006.
48. World Health Organization. Tuberculosis and air travel - Guidelines for prevention and control. Second Edition. Writing Committee: Dowdall N, Evans A, Figueroa J, Ijaz K, Maloney S, Martinez L, Ponce C, Raviglione M, Thibeault C, with the coordination by Kwon JW. Published in collaboration with International Civil Aviation Organization and International Air Transport Association. WHO/HTM/TB/2006.363. ISBN 92 4 154698 0. Geneva, Switzerland, 2006.
49. **Reichman & Hershfield's Tuberculosis - A comprehensive, international approach. Third Edition (in two parts). Edited by Mario C. Raviglione. Lung Biology in Health and Disease Series, vol. 219. ISBN 0-8493-9271-3. Informa Healthcare USA, Inc. New York, NY, USA 2006.**
50. Raviglione MC. Preface. In: Reichman & Hershfield's Tuberculosis - A comprehensive, international approach. Third Edition (in two parts). Edited by Mario C. Raviglione. Lung Biology in Health and Disease Series, vol. 219. ISBN 0-8493-9271-3. Informa Healthcare

USA, Inc. New York, NY, USA 2006: vii-ix.

51. Uplekar M, Weil DE, Raviglione MC. The new Stop Tb Strategy of WHO: reaching global targets. Chapter 50. In: Reichman & Hershfield's Tuberculosis - A comprehensive, international approach. Third Edition (in two parts). Edited by Mario C. Raviglione. Lung Biology in Health and Disease Series, vol. 219. ISBN 0-8493-9271-3. Informa Healthcare USA, Inc. New York, NY, USA 2006: 1227- 1246.
52. Raviglione M. Foreword. In "Scaling-up the UK's response to the global TB epidemic - An agenda for action". All-Party Parliamentary Group on Global Tuberculosis, London, UK, March 2007.
53. Raviglione M, Billo NE, Battcher D. Preface - Tuberculosis and tobacco: joining efforts now. In: A WHO/The Union Monograph on TB and Tobacco Control. WHO/HTM/TB/2007.390. ISBN 978 92 4 1596220. Geneva, Switzerland, 2007.
54. Cegielski JP, Chauhan LS, Chin DP, Granich R, Nelson LJ, Raviglione MC, Rodriguez Cruz R, Talbot EA, Wright AB, Zaleskis R. The global epidemiology and control of tuberculosis. Chapter 1 in Spiegelburg DD Ed.: New Topics in Tuberculosis Research. New York: Nova Science Publishers, 2007 (pag. 1-70).
55. Raviglione MC, O'Brien RJ. Tuberculosis (Chapter 158: pages 1006-1020). In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jamison JL, Loscalzo J. Eds. Harrison's Principles of Internal Medicine, 17th Edition. McGraw-Hill, Inc., New York, USA 2008.
56. Maher D, Espinal M, Raviglione M. Tuberculosis (Section 9 -Major Health Problems. 9.14). In: Oxford Textbook of Public Health. Vol III: The practice of public health: 1213-1230. Oxford University Press 2008.
57. England S, Espinal M, Raviglione M. The Global Plan to Stop TB, 2006-2015 (pages 489-505). In Davies PDO, Barnes PF, Gordon SB Eds. Clinical Tuberculosis, 4th Edition. ISBN 13 978 0340 94840 8. Hodder Arnold, London, UK, 2008.
58. **Tuberculosis - A Comprehensive Clinical Reference. Edited by Schaaf S & Zumla A. Associate Editors: Grange JM, Donald PR, Pai M, Raviglione M, Starke JR, Yew WW. ISBN 9781 4160 3988 4. Elsevier Publishers, London, UK, 2008.**
59. Maher D, Raviglione M. The history of the DOTS strategy: achievements and perspectives (Chapter 105). In: Schaaf S & Zumla A Eds. Grange JM, Donald PR, Pai M, Raviglione M, Starke JR, Yew WW Associate Eds: Tuberculosis - A Comprehensive Clinical Reference. ISBN 9781 4160 3988 4. Elsevier Publishers, London, UK, 2008.
60. Uplekar MW, Raviglione MC, Weil DE. The WHO Stop TB Strategy for the coming decade (Chapter 107). In: Schaaf S & Zumla A Eds. Grange JM, Donald PR, Pai M, Raviglione M, Starke JR, Yew WW Associate Eds: Tuberculosis - A Comprehensive Clinical Reference. ISBN 9781 4160 3988 4. Elsevier Publishers, London, UK, 2008.
61. Raviglione M. Foreword. In "Community involvement in tuberculosis care and prevention: towards partnership for health". WHO/HTM/TB/2008.397. ISBN 97892 4 1596 40 4.

Geneva, Suisse, 2008.

62. Raviglione M, Buff A. Tuberculosis and diseases due to other mycobacteria. In Heymann DL, Ed.: Control of Communicable Diseases Manual, 19th Edition. ISBN 978-0-87553-189-2. American Public Health Association, Washington, DC, USA, 2008.
63. Raviglione M. Foreword. In "Practical Approach to Lung Health - Manual on initiating PAL implementation". WHO/HTM/TB 2008.410, WHO/NMH/CHP/CPM/08.02. Geneva, Switzerland.
64. Uplekar MW, Raviglione MC. Global TB control: persisting problem, shifting solutions. In: Gatti A & Boggio A. Health and Development: Towards a Matrix Approach. ISBN 13:978-1-4039-4737-6. Palgrave Macmillan, Houndmills, UK, 2009.
65. Raviglione MC. Foreword. In Sharma SK, Editor: "Tuberculosis", Second Edition. ISBN 978-81-8448-514-1. Jaypee Brothers Medical Publishers Ltd. New Delhi, India, 2009.
66. Raviglione MC. Prefazione (pagine XV-XIX). In Paganelli M, Serlupi Crescenzi O: "L'ospite indesiderato. Storie della tubercolosi dalle origini alla super-resistenza". Il Pensiero Scientifico Editore, Roma, Marzo 2009. ISBN 978-88-490-0273-7.
67. Raviglione MC, Migliori GB. Cap. 18 - Prospettive e conclusioni (pagine 109-115). In Paganelli M, Serlupi Crescenzi O: "L'ospite indesiderato. Storie della tubercolosi dalle origini alla super-resistenza". Il Pensiero Scientifico Editore, Roma, Marzo 2009. ISBN 978-88-490-0273-7.
68. **Tuberculosis: Fourth Edition, The Essentials. Edited by Mario C. Raviglione. Lung Biology in Health and Disease Series, vol. 237. ISBN 978-142009021-5. Informa Healthcare USA, Inc. 2009.** (a review of this book was published in The Lancet 2010; 375:1771-1772).
69. Raviglione MC. Preface. In: Tuberculosis: Fourth Edition, The Essentials. Edited by Mario C. Raviglione. Lung Biology in Health and Disease Series, vol. 237. ISBN 978-142009021-5. Informa Healthcare USA, Inc. 2009: ix-x.
70. Uplekar M, Weil D, Raviglione MC. WHO's Stop TB Strategy: progress and prospects. In: Tuberculosis: Fourth Edition, The Essentials. Edited by Mario C. Raviglione. Lung Biology in Health and Disease Series, vol. 237. ISBN 978-142009021-5. Informa Healthcare USA, Inc. 2009: 300-324.
71. Raviglione MC. Globalisering og helse (Globalization and health). In: Grötan T: "Globaliseringboka" (pag. 109-112). Det Norske Samlaget Ed., Oslo, Norway, 2009. ISBN 978-82-521.7347.5
72. Lönnroth K, Jaramillo E, Williams B, Dye C, Raviglione M. Tuberculosis: the role of risk factors and social determinants. In: Blas E and Sivasankara Kurup A, Eds. Equity, social determinants and public health programmes. World Health Organization 2010: 219-241. Geneva, Switzerland.

73. Raviglione MC, O'Brien RJ. Tuberculosis (Chapter 165: pages 1340-1359). In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Eds. *Harrison's Principles of Internal Medicine*, 18th Edition. McGraw-Hill, Inc., New York, USA, 2011.
74. Raviglione MC. "Foreword" to "Blue Henry - The almost forgotten story of the blue glass sputum flask", by Ivo Haanstra. Cortex Design Publisher, Birmingham, UK, November 2010.
75. Raviglione M. Preface to TB/MDR-TB Advocacy Tool Kit, by Advocacy Partnership. DahliaDesigns, Leamington Spa, UK, March 2011.
76. Espinal M, Raviglione MC. Tuberculosis – a World Health Organization perspective (pages 182-204). In: Schlossberg D., Editor. *Tuberculosis and Non-tuberculous Mycobacterial Infections*, 6th Edition. American Society of Microbiology Press, 2011.
77. Migliori GB, Sotgiu G, Centis R, Grzemska M, Falzon D, Getahun H, Raviglione MC. Antituberculosis therapy and current global guidelines. In: Kaufmann SHE, Editor (e-Book). *Current and emerging diagnostics, therapeutics and vaccines for tuberculosis*. Future Medicine, London, UK: 42-63, 2011.
78. Raviglione M, Falzon D. TB and migration in an increasingly globalized world. In: IOM-OIM Editor, *Migration Health – Report of Activities 2010*. Special 60th Anniversary Edition. *Health of migrants in an increasingly globalized world*. International Office of Migration, Geneva, Suisse, 2011.
79. Raviglione M, Falzon D. TB control: achievements, obstacles and the role of vaccines. In: Mohd Nor N, Acosta A, Sarmiento ME Editors. *The Art & Science of tuberculosis vaccine development* 2nd. Edition. Oxford University Press 2014: 13-28.
80. Sotgiu G, Zignol M, Raviglione MC. Epidemiology of tuberculosis. In: Meyers RA, Ed. *Encyclopedia of Sustainability Science and Technology*: 11129-11148. Springer Science + Business Media 2012.
81. Gunneberg C, Getahun H, Raviglione M. Tuberculosis – The neglected killer of women in Africa. In: *African Synergy – Against AIDS and suffering*: 32-35. Editor: Kronos Régies, Paris, March 2012.
82. Falzon D, Getahun H, Raviglione MC, Migliori GB, Centis R. "Tuberculosis". In W.C. Cockerham, R. Dingwall and S.R. Quah, eds., *The Blackwell Encyclopedia of Health, Illness, Behavior and Society*. London: John Wiley & Son, Ltd, 2014.
83. **Raviglione, M. and Nunn, P. (eds), Tuberculosis: The Biomedical & Life Sciences Collection, Henry Stewart Talks Ltd, London, 2013 (online at <http://hstalks.com>)**
84. Raviglione, M. "The international approach to the control of tuberculosis", in Raviglione, M. and Nunn, P. (eds), *Tuberculosis: , The Biomedical & Life Sciences Collection*, Henry Stewart Talks Ltd, London, 2013 (online at <http://hstalks.com/?t=BL1533174-Raviglione>)
85. Falzon D, Jaramillo E, Raviglione MC, Weyer K. A short history of drug-resistant tuberculosis - Chapter 5 in "Tuberculosis – A short history". Medcalf A, Altink H, Saavedra

- M, Bhattacharya S, Eds. The University of York. Orient Blackswan, Hyderabad, 2013.
86. Migliori GB, Centis R, Zumla A, Memish ZA, Raviglione MC. Tuberculosis, Public Health Aspects. Encyclopedia of Human Biology, 3rd Edition. Volume x. Elsevier (in press).
 87. **Raviglione MC. Tuberculosis (Chapter 202: pages 1102-1122). In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Eds. Harrison's Principles of Internal Medicine, 19th Edition. McGraw-Hill, Inc., New York, USA, 2015.**
 88. Migliori GB, Raviglione M. Management of a micro-epidemic of tuberculosis in a low TB incidence setting. ERS/CME on line. Access: www.ers-education.org/cmeonline/selection.
 89. Raviglione MC, Getahun H. Tuberculosis and other mycobacterial diseases. In: Heymann DL, Ed.. Control of Communicable Diseases Manual, 20th Edition. ISBN 978-0875530185, American Public Health Association Press, Washington DC, USA, 2015 : 637-650.
 90. Raviglione MC. Preface: Tuberculosis research in the Netherlands: innovation to accelerate global tuberculosis elimination. KNCV Tuberculosis Foundation, September 2015.
 91. Raviglione M. Forward. The PARTNERS Report on MDR-TB Treatment. The Task Force for Global Health, Decatur, Georgia, USA, 2015.
 92. Sismanidis C, Glaziou P, Grzemska M, Floyd K, Raviglione M. Global epidemiology of pediatric tuberculosis. In: Starke JR, Donald PR, Eds. Handbook of child and adolescent tuberculosis – Oxford University Press, New York, USA, 2016.
 93. Sotgiu, G., Glaziou, P., Sismanidis, C., Raviglione, M., 2017. Tuberculosis Epidemiology. In: Quah, S.R. and Cockerham, W.C. (eds.) The International Encyclopedia of Public Health, 2nd edition. vol. 7, pp. 229–240. Oxford: Academic Press. Copyright © 2017 Elsevier Inc. Academic Press
 94. **Raviglione MC. Tuberculosis (Chapter 173: pages TBA). In: J. Larry Jameson, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, Dan L. Longo, Joseph Loscalzo Eds. Harrison's Principles of Internal Medicine, 20th Edition. McGraw-Hill, Inc., New York, USA, 2018 (in press)**

Bibliography: Other journals

1. Raviglione MC. Graduation Thesis "Prolactin secretion inhibitory and stimulatory tests", awarded Publication Rights, 1980.
2. Zampaglione VM, Azzoni A, Raviglione MC. Contributo clinico e terapia del feocromocitoma con prazosin. *Terapie essenziali in clinica* (Roma) 1981;5:569-575.
3. Raviglione MC, Pablos-Mendez A. *Mycobacterium xenopi* infection in AIDS. *Residents' Forum in Internal Medicine* (West Berlin, NJ) 1988;1(3):26-29.

4. Pablos-Mendez A, Raviglione MC, Sanjana V, Battan R. Disseminated cryptococcal infection treated with fluconazole in a patient with AIDS. *Residents' Forum in Internal Medicine* (West Berlin, NJ) 1990;2(3):22-24.
5. D'Amore TF, Gomez-Hermosillo L, Raviglione MC, Usai A, Lobbato VJ Jr. Splenic abscess caused by *Mycobacterium avium-intracellulare* in a patient with AIDS. *Complications in Surgery* 1991;10:7-8.
6. Raviglione MC, Currier JS. Low-dose trimethoprim-sulfamethoxazole for PCP prophylaxis. *AIDS Clinical Care* (Waltham, MA) 1991;3:21-22.
7. Battan R, Raviglione MC, D'Amore T, Pablos-Mendez A, Raggi P, Hedni R. Vancomycin prophylaxis for infections related to long term central venous catheters in AIDS patients: a pilot study. *AIDS Patient Care* (New York) 1991;5:120-124.
8. Arossa W, Caria E, Raviglione MC, Spinaci S. Il programma di controllo della tubercolosi. *CUAMM Notizie* (Padova) 1991; VI:14-19.
9. Raviglione MC, Battan R, Garner G, Cortes H, Sugar J, Taranta A. Risk of exposure to HIV-infected body fluids among medical housestaff. *AIDS Patient Care* (New York) 1992: 6:52-55.
10. Raviglione MC, Spinaci S. Tubercolosi ed infezione da HIV: la situazione nel mondo e strategie di intervento. *Giornale Italiano dell'AIDS* (Roma) 1992: 3:1-11.
11. Ara G, Rosazza A, Vercellino PC, Bottura G, Raviglione MC. Conoscenze e curiosità in tema di AIDS tra gli studenti delle scuole medie superiori. *Giornale Italiano dell'AIDS* (Roma) 1993; 4:35-43.
12. Rieder H, Raviglione M. TB revisits the industrialized world. *World Health* (Geneva) 1993; 46 (4):20-21.
13. Raviglione M. La tubercolosi associata all'infezione da HIV: aspetti epidemiologici, patogenetici e clinici. *Nova Acta Medica Virgiliana* (Mantova) 1993 (2):5-14.
14. Raviglione MC. Pandemia da tubercolosi associata ad infezione da HIV: la situazione attuale. *Giornale Italiano dell'AIDS* (Roma) 1994; 5:53-62.
15. Raviglione MC. Guidelines on management of pulmonary tuberculosis in HIV-infected patients. *TB & HIV n. 2 - Supplement of SidAlerte n. 30* (Lyon) 1994:22-25.
16. Raviglione MC. Guidelines on management of pulmonary tuberculosis in HIV-infected patients. *Thai Journal of Tuberculosis and Chest Diseases* (Bangkok) 1994; 15:5-16
- 16b. Raviglione MC. Guidelines on management of pulmonary tuberculosis in HIV-infected patients. *Proceedings of the 17th Eastern Regional Conference on Tuberculosis and Respiratory Diseases of the International Union Against Tuberculosis and Lung Disease, Eastern Region*, Ed. S. Charoenratanakul. Bangkok, Thailand, 1-4 November 1993: 59-70.

17. Raviglione MC, Esteves K, Kochi A, Rieder HL, Styblo K, Khomenko A. Trends in tuberculosis morbidity and mortality in Eastern Europe and the former USSR. *Problemy Tuberkuloze (Moscow)* 1994 (6):2-10.
18. Raviglione MC, Migliori GB. Linee guida per la sorveglianza della farmacoresistenza nella tubercolosi. Una proposta per il programma nazionale di controllo. *Rassegna di Patologia dell'Apparato Respiratorio (Genova)* 1995; 10:100-103.
19. Raviglione MC, Spinaci S. Tubercolosi: situazione globale e strategia di controllo. *La Medicina Tropicale (Roma)* 1995; 11:1-10.
20. Raviglione MC. Trends in the global rates of tuberculosis. Proceedings of the First Mid Year Conference of the International Union Against Tuberculosis and Lung Disease, North American Region, "Tuberculosis and Migration". Chicago, Illinois, USA, 1-2 March 1996: 4-11.
21. Schwoebel V, Rieder HL, Watson JM, Raviglione MC for the Working Group for uniform reporting on tuberculosis cases in Europe. *Surveillance of tuberculosis in Europe. Eurosurveillance (Saint-Maurice, Paris)* 1996; 1:5-8.
22. Hausler HP, Raviglione MC, Kaleeba N, Aisu T, Fourie B. Prise en charge de la tuberculose au niveau communautaire en Afrique Subsaharienne. *SidAlerte No. 56, September 1996 and TB & VIH. Le Journal de la Tuberculose et du SIDA, No. 7 (Lyon)* 1996: 8-15.
23. Raviglione MC, Luelmo F. Update on the global epidemiology of tuberculosis. *Current Issues in Public Health (Philadelphia, PA, USA)* 1996; 2:192-197.
24. Raviglione M. Tubercolosi nel mondo: epidemia riemergente o mai controllata? *L'Internista Ospedaliero (Genova)* 1996 (3); 1:6-13.
25. Antoine D, Schwoebel V, Veen J, Raviglione MC, Rieder HL and the National Coordinators for Tuberculosis Surveillance in 50 Countries of the WHO European Region. *Surveillance of tuberculosis in the WHO European Region, 1995-1996. Eurosurveillance (Saint-Maurice, Paris)* 1998; 3:103-107.
26. Raviglione MC, Espinal MA. Towards optimisation of surveillance of resistance to antituberculosis drugs in Europe (editorial). *Eurosurveillance (Saint-Maurice, Paris)* 2000; 5: 103-104.
27. Schwoebel V, Lambregts CSB, Moro ML, Drobniewski F, Hoffner SE, Raviglione MC, Rieder HL. European recommendations on surveillance of antituberculosis drug resistance. *Eurosurveillance (Saint-Maurice, Paris)* 2000; 5: 104-107.
28. Raviglione M. La situacion mundial de la TBC: retos para el nuevo siglo. *Revista Espanola de Sanidad Penitenciaria* 2000; 2. 145-148.
29. Raviglione MC, Kumaresan J, Billo N, Gondrie P, Broekmans J, Lee JW. DOT, DOTS and the need to act now. *Global HealthLink (Washington, USA)* 2002: issue January-February 2002: 7.

30. Zignol M, Scano F, Gargioni G, Raviglione M. Fermare la tubercolosi. Le strategie dell'Organizzazione Mondiale della Sanità dal 1947 ad oggi ed il ruolo delle organizzazioni non governative. Salute e Sviluppo. Cuamm Medici con l'Africa (Padova, Italy) 2003. Issue n.3/02: 21-28.
31. Centis R, Migliori GB, Raviglione M. La tubercolosi nel mondo: situazione nel 2002 e prospettive a breve termine. Epidemiologia e Prevenzione. Rivista dell'Associazione Italiana di Epidemiologia (Milano, Italia) 2003; 27 (2): 106-113.
32. Raviglione MC. International Standards for Tuberculosis Care. Giornale Italiano di Malattie Infettive (Pavia, Italia). Atti del 5° Congresso Nazionale della Società Italiana di Malattie Infettive e Tropicali 2006; 12: 77-79.
33. Zignol M, Migliori GB, Raviglione MC. La tubercolosi polmonare: le priorità a livello globale ed il progetto "Stop TB Italia". Multidisciplinary Respiratory Medicine (Milano, Italia) 2006; 1 (2): 39-42.
34. Raviglione MC, Zignol M, Scano F, Gargioni G, Cirillo D. Emergenza TBC. KOS - Rivista di Medicina, Cultura e Scienze Umane (Milano, Italia) 2006; anno XXIII, 253: 18-25.
35. Migliori GB, Besozzi G, Codecasa LR, Raviglione MC. International standards for tuberculosis care: finalmente il documento universale che aspettavamo. Rassegna di Patologia dell'Apparato Respiratorio (Genova) 2006; 21:179-180.
36. Matteelli A, Raviglione MC. The International Standards for Tuberculosis Care: why should we care? (Editoriale) Giornale Italiano di Medicina Tropicale (Roma) 2006; 11 (3-4): 1-2.
37. Raviglione M. Tubercolosi - Il ritorno. La Repubblica Salute (Roma). Anno 13, n. 528: 24-25. 22-3-2007.
38. Migliori GB, Besozzi G, Codecasa LR, Raviglione MC. International Standards for Tuberculosis Care: finalmente il documento universale che aspettavamo (Editoriale). Rassegna di Patologia dell'Apparato Respiratorio (Genova) 2006; 21:179-180.
39. Raviglione MC. Infectious diseases and globalization. *Dolentium Hominum* - Chiesa e Salute nel Mondo (Città del Vaticano) 2007; 64 (1): 24-30 (available also in Italian).
40. Raviglione M, Espinal M. Stop TB. Millenium Development Goals - Review 2008, April Issue: pages 43-44. Published by VRS Media, Oakley Vale, Corby, Northamptonshire, UK. Available at www.mdg-review.com.
41. Matteelli A, El-Hamad I, Raviglione MC. Tubercolosi e immigrazione. Africa e Mediterraneo (Sasso Maggiore, Bologna) 2008; 64: 51-57.
42. Raviglione M. Challenges and efforts for stopping TB in the world with WHO. Public Health Weekly Report, KCDC (Seoul, Republic of Korea, 27-3-2009) 2009; 13:205 (in Korean).

43. Raviglione M. Vecchi farmaci, studi fermi, e la TBC torna a far paura. La Repubblica (Roma). Anno 15: 18. 24-3-2009.
44. Raviglione M. La tubercolosi: situazione globale, controllo e sfide future. Salute Internazionale.Info (published by Osservatorio Italiano di Salute Globale, May 2009). Available at <http://saluteinternazionale.info/2009/05/06/la-tubercolosi-situazione-globale-controllo-e-sfide-future/>
45. Raviglione M. L'esperto - Quei batteri resistenti in Est Europa un problema per tutti. La Repubblica - Salute (Roma). Anno 16:30. 23 Marzo 2010.
46. Raviglione M, Zignol M. Global MDR- and XDR-TB situation and trends. Centers for Global Development. Washington, DC, USA 25 March 2010. Available at <http://www.cgdev.org/content/general/detail>
47. Raviglione M. An opportunity: World Health Day devoted to combating antimicrobial resistance. Centers for Global Development. Washington, DC, USA 28 October 2010. Available at <http://www.cgdev.org/content/general/detail>
48. Jaramillo E, Nunn P, Raviglione M. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. Center for Global Health Policy. Washington, DC, USA 24 March 2011. Available at: <http://sciencespeaksblog.org>
49. Raviglione M. La TBC colpisce 9 milioni di persone. Il Biellese, Biella, 22 Marzo 2011.
50. Raviglione M. Raggiunto l'obiettivo del millennio per la lotta alla tubercolosi. Salute Internazionale. Info, published by the Osservatorio Italiano di Salute Globale, 22-10-2012. <http://saluteglobale.it/2012/10/22/oms-raggiunto-lobiettivo-del-millennio-per-la-lotta-alla-tubercolosi/>
51. Raviglione MC. The WHO supports India's fight against MDR-TB (letter). The Wall Street Journal, 20-2-2013. Available at: <http://online.wsj.com/article/SB10001424127887323549204578315911020609112.html>
52. Raviglione M, Sotgiu G. Emergenza tubercolosi nei Paesi dell'ex Unione Sovietica. Salute Internazionale.Info, published by the Osservatorio Italiano di Salute Globale, 15-7-2013. <http://www.saluteinternazionale.info/2013/07/emergenza-tubercolosi-nei-paesi-dell'ex-unione-sovietica/>
53. Raviglione M, Sotgiu G. Emergenza tubercolosi nei paesi ex URSS. Salute e Sviluppo. Rivista Quadrimestrale di Cooperazione e Politica Sanitaria Internazionale. Medici con l'Africa CUAMM. Giugno 2013 – n. 67: 15-16.
54. Raviglione M. Tuberculosis: one of the greatest killers! UN Special, n.731. September 2013: 22-23.
55. Castro J, Raviglione M. The child and tuberculosis in the 21st century: curable yet remains prevalent. Global Health Diplomacy. Fall 2013: 18-19.

56. Dirlikov E, van Weezenbeck C, Raviglione M, Scano F. Global tuberculosis control: then and now. *J Tuberc Lung Health* 2013; 2 (3): 143-149 (published in Chinese language by the China Anti-TB Association, Beijing. Chief editor: Wang Xie Xiu).
57. Pablos-Mendez A, Raviglione M, Mustikawati DE, Mametja LD. Global leadership, collaboration aligned in the fight against tuberculosis. USAID Blog, 11 June 2014. <http://blog.usaid.gov/2014/06/global-leadership-collaboration-aligned-in-the-fight-against-tuberculosis/>
58. Raviglione M. Superbatteri, multiresistenza e nuove strategie. *La Repubblica* (Roma). Anno 20: 34. 1 July 2014.
59. Migliori GB, Raviglione M. Nuova strategia contro la TBC. *Il Sole 24 ore – Sanità* (Roma): 23. 1 July 2014.
60. Migliori GB, Raviglione M. La malattie resiste agli antibiotici tradizionali divenuti meno efficaci. *Il Tempo*: 33. 20 July 2014.
61. Raviglione M, Pablos-Mendez A. Lessons from multidrug-resistant TB on how evidence can catalyze policy change. *Huffington Post*, 23 October 2014 (<http://www.huffingtonpost.com/impact>).
62. Raviglione M. The TB response: the road taken, and the journey ahead. WHO Media Center, 22 October 2014 (<http://www.who.int/mediacentre/commentaries/tuberculosis/en>).
63. Raviglione M, Spigelman M. Just like Ebola, the TB threat is all too real. *The Drum TV*. ABC News (<http://www.abc.net.au/news/>30 October 2014).
64. Uplekar M, Raviglione M. From DOTS strategy to post-2015 global TB strategy (End TB Strategy). Newsletter from Kiyose, n.20, February 2015, Japan.
65. Hofmann K, Raviglione M. On the path to end TB: how social franchising can effectively engage private practitioners. *DevexImpact* 24 March 2015 (<http://www.devex.com/news/>).
66. Zignol M, Raviglione M. Global surveillance of resistance to anti-tuberculosis drugs. *Policies for Equitable Access to Health (PEAH)*, 4 June 2015 (<http://www.peah.it/2015/06/global-surveillance-of-resistance-to-anti-tuberculosis-drugs/>).
67. Mattelli A, Gargioni G, Zignol M, Raviglione M. Tuberculosis 2015: La situazione mondiale, le sfide et la nuova “End TB Strategy”. *Salute e Sviluppo. Rivista Quadrimestrale di Cooperazione e Politica Sanitaria Internazionale. Medici con l’Africa CUAMM*. Giugno 2015 – n. 71: 8-9.
68. Pablos-Mendez A, Raviglione M. A turning point in the battle against drug-resistant tuberculosis. *Huffington Post*, 12 May 2016 (http://www.huffingtonpost.com/ariel-pablosmendez-md-mph/a-turning-point-in-the-ba_b_9930908.html).

69. Raviglione M. Gearing up to end tuberculosis: a model for tackling antimicrobial resistance? AMR Control 2016. Published by the Global Health Dynamics Limited in official association with the World Alliance Against Antibiotic Resistance (WAAAR). May 2016. ISBN 978-0-9576072-5-5.
70. Pablos-Mendez A, Goosby E, Raviglione M. Why is multidrug-resistant TB a health security threat? Huffington Post, 13 October 2016 (http://www.huffingtonpost.com/entry/multidrug-resistant-tb-health-security-treat_us_57ff955fe4b0e8c198a6560e).
71. Raviglione M. Elevating the fight against TB: reaching those left behind to move forward faster. Huffington Post, 24 March 2017. (http://www.huffingtonpost.com/entry/reaching-left-behind-move-forward-tb_us_58d53bd3e4b02a2eaab32f5c?n5lkypng3mn9daemi)
72. Raviglione M, Zignol M, Jaramillo E, Falzon D, Weyer K. WHO's Global TB Programme and its work to respond to MDR-TB. In: Antimicrobial Resistance – A special report on MDR-TB. Focusing on core competencies of policy, research and financing. The Center for Global Health and Diplomacy, Washington, D.C, USA, May 2017: 89-97.
73. Zignol M, Raviglione M. Resistance to isoniazid, pyrazinamide and fluoroquinolones in patients with tuberculosis. Policies for Equitable Access to Health (PEAH), 6 June 2017. <http://www.peah.it/2017/06/resistance-to-isoniazid-pyrazinamide-and-fluoroquinolones-in-patients-with-tuberculosis/>
74. Weyer K, Falzon D, Jaramillo E, Zignol M, Mirzayev F, Raviglione M. Tuberculosis: what is the situation, what are the needs to roll it back. AMR Control 2017. 2017, Healthcare, 31 July 2017 (<http://resistancecontrol.info/2017/drug-resistant-tuberculosis-what-is-the-situation-what-are-the-needs-to-roll-it-back-2/>)
75. Raviglione M. High-level spotlight on tuberculosis, the top infectious killer. Huffington Post, 30 October 2017 (http://www.huffingtonpost.com/entry/high-level-spotlight-on-the-top-infectious-killer_us_59f71cd4e4b03cd20b82e44b).
76. Raviglione M, Carraro dD. TB Day – 24 March. CUAMM Website. Published 23-3-2018. Available at: <https://doctorswithafrica.org/en/our-voice/news/tb-day24-march/>

Bibliography: WHO documents, other documents, and anonymous articles

1. Anonymous. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treated with thioacetazone. WHO Wkly Epidem Rec 1992; 67:1-3.
2. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. WHO/TB/92.166, 1992.
3. Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in Western Europe: epidemiological situation in 14 countries. WHO/TB/92.170, 1992.
4. Anonymous. Secular trends of tuberculosis in Western Europe. WHO Wkly Epidem Rec 1993; 68:65-67.
5. Raviglione MC, Sudre P, Rieder HL, Spinaci S, Kochi A. Secular trends of tuberculosis in Western Europe. Meeting of the Tuberculosis Surveillance Research Unit, 10-11 October 1992. TSRU Progress Report 1992, volume 2. KNCV Ed., The Hague, The Netherlands, 1992.
6. Dolin PJ, Raviglione MC, Kochi A. A review of current epidemiological data and estimation of future tuberculosis incidence and mortality. WHO/TB/93.173.
7. Raviglione MC, Rieder HL, Styblo K, Khomenko AG, Esteves K, Kochi A. Tuberculosis trends in Eastern Europe and the former USSR. WHO/TB/94.176.
8. Anonymous. Tuberculosis. WHO Wkly Epidem Rec 1994; 69:77-80.
9. Anonymous. Tuberculosis trends in Central and Eastern Europe and countries of the former USSR. WHO Wkly Epidem Rec 1995; 70:21-24.
10. Anonymous. Tuberculosis. WHO Wkly Epidem Rec 1995; 70:73-77.
11. Hausler HP, Raviglione MC, Kaleeba N, Aisu T, Fourie B. Assessment of tuberculosis management in community care projects in sub-Saharan Africa. WHO/TB/95.195.
12. Anonymous. Tuberculosis notification update. WHO Wkly Epidem Rec 1996; 71:65-69.
13. Connolly MA, Raviglione MC. Assessment of tuberculosis management in community care projects in India. WHO/TB/96.205.
14. Anonymous. Tuberculosis. The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance. WHO Wkly Epidem Rec 1996; 71:281-285.

15. World Health Organization. Global Tuberculosis Programme (Raviglione M, Schmidt S, Nunn P, Dye C, Spinaci S, Chaulet P, Grzemska M, Hanson C, Kumaresan J, Levy M, Luelmo F, Tayler E, Kochi A) Global tuberculosis control. WHO Report 1997. Geneva, Switzerland, WHO/TB/97.225.
16. Anonymous. Tuberculosis. WHO Wkly Epidem Rec 1997; 72: 117-122.
17. WHO/IUATLD Global Working Group on Antimicrobial Drug Resistance Surveillance. Guidelines for surveillance of drug resistance in tuberculosis, 1997. Edited by Bustreo F, Pablos-Mendez A, Raviglione M, Murray J, Trébuçq A, Rieder H. Geneva, Switzerland, WHO/TB/96.216
18. EuroTB (CESES/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on the feasibility study (1996-1997). Tuberculosis cases notified in 1995. October 1997. Report prepared by: Schwoebel V, Perrocheau A, Veen J, Jean F with the kind collaboration of the members of the Advisory Committee: Antunes-Pereira M, Clancy L, Grosset J, Klein J-P, Madaras T-A, Moro ML, Raviglione M, Rieder H, Romanus V, Roszkowski K, Smith E, Watson J.
19. Pio A, Chaulet P, edited by Raviglione M, Hanson C, Scherpbier R. Standardization of district-based packages of care for the management of tuberculosis and other respiratory diseases among youth and adults. WHO/TB/97.232.
20. Pablos-Mendez A, Espinal-Fuentes M, Raviglione M and the Writing Committee of the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance. The global surveillance project and new research perspectives. Meeting of the Tuberculosis Surveillance Research Unit, 18-20 March 1998. TSRU Progress Report 1998, volume 1. KNCV Ed., The Hague, The Netherlands, 1998.
21. Maher D, van Gorkom JLC, Gondrie PCFM, Raviglione M. Community contribution to tuberculosis care in high tuberculosis prevalence countries: past, present and future. Meeting of the Tuberculosis Surveillance Research Unit, 18-20 March 1998. TSRU Progress Report 1998, volume 2. KNCV Ed., The Hague, The Netherlands, 1998.
22. World Health Organization. Global Tuberculosis Programme (Netto EM, Dye C, Schmidt S, Raviglione M). Global tuberculosis control. WHO Report 1998. Geneva, Switzerland, WHO/TB/98.237.
23. Anonymous. Antituberculosis drug resistance worldwide. WHO Wkly Epidem Rec 1998; 73:249-254.
24. Global Tuberculosis Programme. Edited by: Asiedu K, Raviglione M, Scherpbier R. Report. International Conference on Buruli Ulcer Control and Research. Yamoussoukro, Côte d'Ivoire, 6-8 July 1998. Geneva, Switzerland, WHO/TB/98.252.
25. EuroTB (CESES/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 1996. September 1998. Report prepared by: Schwoebel V, Antoine D, Veen J, Jean F with the collaboration of the members of the Advisory Committee: Clancy L, Grosset J,

- Klein J-P, Kruuner A, Madaras T-A, Moro ML, Raviglione M, Rieder H, Romanus V, Ruutu P, Sorli J.
26. Report. Adult Lung Health Initiative. Basis for the development of algorithms for assessment, classification and treatment of respiratory illness in school-age children, youths and adults in developing countries. Recommendations of the Consultation, Geneva, 4-15 May 1998. Edited by: Scherpbier R, Hanson C, Raviglione M. Geneva, Switzerland, WHO/TB/98.257.
 27. World Health Organization. Communicable Diseases (Netto EM, Dye C, Raviglione M). Global tuberculosis control. WHO Report 1999. Geneva, Switzerland, WHO/CPC/TB/99.259.
 28. Report. Coordination of DOTS-PLUS pilot projects for the management of MDR-TB. Proceedings of a Meeting. Geneva, 29 January 1999. Edited by: Espinal MA, Raviglione MC. Geneva, Switzerland, WHO/CPC/TB/99.262.
 29. Anonymous. Tuberculosis control. Progress in 1995-1997. WHO Wkly Epidem Rec 1999; 74: 217-227.
 30. EuroTB (CESES/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 1997. September 1999. Report prepared by: Schwoebel V, Antoine D, Veen J, Jean F with the collaboration of the members of the Advisory Committee: Clancy L, Grosset J, Klein J-P, Kruuner A, Lambregts K, Madaras T-A, Moro ML, Raviglione M, Rieder H, Romanus V, Ruutu P, Sorli J, Drobniowski F.
 31. Report. WHO Working Group on DOTS-PLUS for MDR-TB. Procurement of second-line anti-tuberculosis drugs for DOTS-PLUS pilot projects. Proceedings of a Meeting. Cambridge, USA, 5-6 July 1999. Edited by: Gupta R, Brenner JG, Henry CL, Kim JH, Shin S, Espinal MA, Raviglione MC. Geneva, Switzerland, WHO/CDS/TB/2000.276.
 32. World Health Organization. Communicable Diseases (Bleed D, Watt C, Dye, C, under the overall coordination of M.Raviglione). Global tuberculosis control. WHO Report 2000. Geneva, Switzerland, WHO/CDS/TB/2000.275.
 33. Scientific Panel of the WHO Working Group on DOTS-PLUS for MDR-TB. Guidelines for establishing DOTS-PLUS pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Edited by: Gupta R, Raviglione MC, Espinal MA, Arnadottir T. World Health Organization, Geneva, Switzerland, WHO/CDS/TB/2000.279.
 34. Green Light Committee of the Working Group on DOTS-PLUS for Multidrug-Resistant Tuberculosis. Instructions for applying to the Green Light Committee for Access to Second-line Anti-tuberculosis. Contributors: Gupta R, Cegielski JP, Espinal MA, Gondrie P, Henkens M, Kim JH, Lambregts-van Weezenbeek KSB, Raviglione MC, Suarez PG, Varaine F. Communicable Diseases, World Health Organization, Geneva, Switzerland, WHO/CDS/TB/2001.286.
 35. Scientific Panel of the Working Group on DOTS-Plus for MDR-TB (Arnadottir T, Binkin N, Cegielski P, Espinal M, Farmer P, Goldfarb A, Gupta R, Kim J, Kimerling M, Lambregts-van Weezenbeek K, Laszlo A, Raviglione M, Reichman L, Rieder H, Salfinger M, Suarez P).

- Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, Geneva, Switzerland, WHO/CDS/TB/2000.279.
36. World Health Organization. StopTB Department (Blanc L, Floyd K, Norval P-Y, Raviglione M). Global DOTS Expansion Plan. Progress in TB control in high-burden countries, 2001. One year after the Amsterdam Ministerial Conference. Geneva, Switzerland, WHO/CDS/STB/2001.11.
 37. EuroTB (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 1998. February 2001. Report prepared by: Antoine D, Infuso A, Schwoebel V, Bousquié H, Veen J with the collaboration of the members of the Advisory Committee: Clancy L, Drobniowski F, Hoffner S, Klein J-P, Kruuner A, Lambregts K, Moro ML, Raviglione M, Rieder H, Romanus V, Ruutu P, Sorli J, Watson J, Zaleskis R.
 38. Anonymous. Global DOTS Expansion Plan. Progress in tuberculosis control in high-burden countries, 2001. *Wkly Epidem Rec* 2001; 76:181-183.
 39. World Health Organization and StopTB Partnership (Billo N, Bloom A, Broekmans J, Dayrit M, Dumelle F, Elzinga G, England S, Espinal M, Kutwa A, Maher D, Narayanan PR, Omaswa F, Raviglione M, Robb A, Shah SK, Tapia R, Vink K, Weil D, Young D). Report of the Meeting of the second Ad-hoc Committee on the tuberculosis epidemic. Recommendations to StopTB Partners. Montreux, Switzerland, 18-19 September 2003. ISBN WHO/HTM/STB/2004.28.
 40. World Health Organization. Respiratory care in primary care services - A survey in nine countries. Edited by: Ottmani SE, Scherpbier R, Chaulet P, Pio, Van Beneden C, Raviglione M. Geneva, Switzerland. WHO/HTM/TB/2004.333.
 41. Practical Approach to Lung Health (PAL). A primary health care strategy for the integrated management of respiratory conditions in people five years of age and over. Edited by Ottmani SE, Scherpbier R, Pio A, Chaulet P, Ait Khaled N, Blanc L, Khaltayev N, Raviglione M. World Health Organization, Geneva, Switzerland. WHO/HTM/TB/2005.351 & WHO/NMH/CHP/CRA/05.3.
 42. European Academies Science Advisory Council (EASAC). Drug-resistant tuberculosis: challenges and strategies for control. EASAC Policy Report 10. March 2009: 1-41. ISBN 978 0 85403 746 9 (Observer Member of the Working Group).
 43. Preface. Priorities in operational research to improve tuberculosis care and control. WHO, Geneva, Switzerland 2011. ISBN 978 92 4 1548250.
 44. Aspen Institute Italy. Working Group of the Initiative “I protagonisti italiani all'estero”. Brain drain, brain exchange and brain circulation – Il caso italiano nel contesto globale. Prepared by: Milio S, Lattanzi R, Casadio F, Crosta N, Raviglione M, Ricci P, Scano F. Aspen Institute Italy, Roma, Marzo 2012. Available at: <https://www.aspeninstitute.it/attivita/i-protagonisti-italiani-all%E2%80%99estero>

45. Ministero degli Affari Esteri. Task Force “Scienziati Italiani nel Mondo”. Documenti finali prodotti dai Gruppi di Lavoro su : Rapporto tra ricerca e produzione; Aspetti normativi dei sistemi universitario e della ricerca; Visti e permessi di soggiorno. Focal points Scienziati Task Force: Mario Raviglione, Vito Campese, Fabiola Gianotti, Giorgio Margaritondo. Roma, Settembre 2012.
46. Doctors with Africa CUAMM. People, communities and health services: together for tuberculosis care and control in Africa. Authors: Atzori A, Besozzi G, Cirillo DM, Codecasa LR, Gargioni G, Inojosa W, Manenti F, Manfrin V, Matteelli A, Migliori GB, Putoto G, Raviglione MC, Segafredo G, Tagliaferri E. Padova, October 2012.

Bibliography: Other scientific publications

Books:

1. Raviglione MC, Boggio F. Entomofauna. In Bovo PG Ed. Conservazione e valorizzazione naturalistica del Lago di Viverone. Pro Natura Biellese and Museo Civico Città di Biella, Biella, Italia, 1981.
2. Malausa JC, Raviglione MC, Boggio F, con la collaborazione di Bovo PG e Cossutta F. Il *Carabus olympiae* Sella dell'Alta Valle Sessera. Pro Natura Biellese, Biella, Italia, and Office pour l'Information Ecoentomologique, Versailles, France, Eds. Biella, Italia, 1983 (pag. 1-114).
3. Albis O, Boggio F, Bordignon L, Bovo PG, Calleri G, Chiaberge G, Dellarole C, Falletti C, Isocrono D, Pascutto T, Perino PL, Raviglione MC, Valz Blin G. Le Alpi Biellesi. Ambienti, natura e cultura. Pro Natura Biellese, Biella. Ed. Gariazzo, Vigliano, Italia, 1999.
4. Raviglione M. e Boggio F. Le Farfalle del Biellese. Collana Ambiente. Assessorato alla Tutela Ambientale, Provincia di Biella, in collaborazione con Ente di Gestione Aree Protette Baragge-Bessa-Brich. Ed. Amministrazione Provinciale di Biella. Biella, Italia, 2001 (pag. 1-372).

Articles:

1. Raviglione M, Boggio F. Il Carabo d'Olimpia, vanto della fauna biellese. *Animali, Natura, Habitat* 1982; 5 (4):30-31.
2. Raviglione M, Boggio F. Il Carabo "estinto". Una gemma vivente delle Prealpi Biellesi. *Rivista del Club Alpino Italiano* 1983; Anno 104 (n.7-8):302-303.
3. Raviglione M. Un po' di pace per il *Carabus olympiae*. *Natura e Società* 1983; n.8:16.
4. Raviglione MC. Lepidotteri Ropaloceri del Biellese (Piemonte). *Boll Soc Entomol Ital, Genova* 1985; 117:34-38.
5. Raviglione MC, Boggio F, Raviglione M. Lepidotteri Ropaloceri dell'Alta Valle Sessera in Piemonte. *Boll Soc Entomol Ital, Genova* 1994; 125:255-258.
6. Boggio F, Raviglione MC. Fauna lepidotterologica delle baragge biellesi. *Boll Soc Entomol Ital, Genova* 1997; 129:141-144.
7. Raviglione M, Boggio F. Farfalle nelle riserve Baragge e Bessa. *Piemonte Parchi* 2001; anno XVI, n. 10 (Dicembre 2001): 7-9.
8. Raviglione M. Farfalle di torbiera nel Giura francese. *Piemonte Parchi* 2003; 132: anno XVIII, n. 10 (Dicembre 2003):2-3.
9. Raviglione MC, Boggio F. Segnalazioni Faunistiche Italiane 431: *Pharmacis claudiae*. *Boll Soc Entomol Ital, Genova* 2004; 136 (1): 78.

10. Raviglione MC, Boggio F. Segnalazioni Faunistiche Italiane : *Chelis simplonica*. Boll Soc Entomol Ital, Genova 2007; 139 (1): 59.
11. Raviglione MC, Boggio F. Aggiornamento della lista di lepidotteri diurni presenti nel territorio biellese (Lepidoptera). Riv Piem St Nat 2010; 31: 101-106.
12. Raviglione MC, Boggio F, Fiumi G. Lepidotteri notturni del territorio Biellese-Monte Rosa, Piemonte (Lepidoptera) - Primo contributo. Riv Piem St Nat 2011; 32: 135-172.
13. Raviglione M, Boggio F. Silenziosi voli notturni. Rivista Biellese (Biella). Anno 16 – Numero 2 – Aprile 2012: 31-39.
14. Raviglione M, Boggio F, Fiumi G. Segnalazioni Faunistiche Italiane: *Trychopteryx carpinata*, *Stilbia faillae*, *Xestia (Xestia) cobsaesa*, *Caradrina noctivaga*. Boll Soc Entomol Ital, Genova 2012; 144 (1): 47-48.
15. Raviglione MC, Boggio F. Contributo alla conoscenza dei Sesiidae del settore Biellese-Monte Rosa (Piemonte Nord-orientale)(Lepidoptera). Riv Piem St Nat 2013; 34: 147-157.
16. Raviglione MC, Boggio F, Butté F. Prima segnalazione di *Cydalima perspectalis* (Walker, 1859) in Piemonte (Lepidoptera Crambidae). Riv Piem St Nat 2013; 34: 150-170.
17. Negro M, Boggio F, Raviglione M. Sentinelle del cambiamento. Rivista Biellese (Biella). Anno 17 – Numero 4 – Ottobre 2013: 5-15.
18. Raviglione MC, Boggio F, Taverna R, Fiumi G. Lepidotteri notturni del territorio Biellese-Monte Rosa, Piemonte (Lepidoptera). Secondo contributo. Riv Piem St Nat 2014; 35: 139-150.
19. Comoglio G, Comoglio MG, Raviglione M. Le farfalle del Brich di Zumaglia. Rivista Biellese (Biella). Anno 21 – Numero 3 – Luglio 2017 :18-27.
20. Sindaco R, Savoldelli P, Raviglione M, Boggio F, Bonifacino M, Cabella C. Le farfalle (Insecta: Lepidoptera) di interesse comunitario in Piemonte: stato attuale delle conoscenze. Riv Piem St Nat 2018: 39: 349-431.

Articles in newspapers:

1. Boggio F, Raviglione M. Un parco naturale in Val Sessera? Il Biellese, pag. 11, 23 Gennaio 1981.
2. Raviglione M, Boggio F. J.C. Malausa, entomologo biellese, parlerà della conservazione del Carabus. Il Biellese, 8 Gennaio 1982.
3. Raviglione M, Boggio F. Biellesi, salviamo la nostra "Boja d'or". Il Biellese, pag. 11, 11 Febbraio 1983.

4. Raviglione M. Scampato alla glaciazione, fu scoperto da una bambina. Gazzetta del Popolo, anno 136, n.291, pag: 3, 11 Dicembre 1983.
5. Raviglione M, Boggio F. A proposito del Carabus. Eco di Biella, n. 40, 24 Maggio 1993.
6. Boggio F, Raviglione M. Naturalisti lanciano l'allarme "Nessun lago al Moncerchio, pena la morte del Carabo". Il Biellese, pag. 18, 27 Gennaio 1995.
7. Boggio F, Raviglione M. Siamo contro la neve artificiale. Il Biellese, 7 Marzo 1995.
8. Boggio F, Raviglione M. Farfalle africane - Sono state isolate ai giardini Zumaglini. Eco di Biella, 29 Agosto 2005.

Photographs published

1. *Erebia christi*. Pag. 19. In: Casale F, Toninelli V, Eds. La conservazione della biodiversità nelle Alpi Occidentali. Quaderni di Natura e Paesaggio del Verbano Cusio Ossola, n.5. Published by: Provincia del Verbano Cusio Ossola. Verbania, Italy, 2005.
2. *Pharmacis claudiae* & *anselminae*. Site: Lepidoptera and some other life forms (2008): http://ftp.funet.fi/index/Tree_of_life/insecta/lepidoptera/exoporia/hepialoidea/hepialidae/pharmacis/index.html
3. *Rothschildia erycina*. Site: Lepidoptera and some other life forms (2008): http://ftp.funet.fi/index/Tree_of_life/insecta/lepidoptera/ditrysia/bombycoidea/saturniidae/saturniinae/rothschildia/index.html
4. *Pharmacis claudiae* & *anselminae*. Site: Moths and butterflies of Europe and North Africa (2008): <http://www.leps.it/>
5. Tavole II, III, IV e retrocopertina. In : Hellmann F, Parenzan P – I macrolepidotteri del Piemonte. Monografie XLVI, 2010. Regione Piemonte e Museo Regionale di Scienze Naturali, Torino.
6. *Erebia christi*. Pag. 136. In: Regione Piemonte - Museo Regionale di Scienze Naturali, Torino. I Parchi Naturali del Piemonte - Laboratori di Futuro. Hapax Editore, Torino, Febbraio 2010.
7. *Crypsedra gemmea*, *Lycia alpina*, *Polymixis xanthomistha*. Sito: Moths and butterflies of Europe and North Africa (2011): <http://www.leps.it/>
8. *Carabus olympiae*. Pag. 52. In: Istituto Superiore per la Protezione e la Ricerca Ambientale & Ministero dell'Ambiente, del Territorio e della Tutela del Mare – Manuali per il monitoraggio di specie e habitat di interesse comunitario (Direttiva 92/43/CEE) in Italia. Specie Animali. ISPRA Serie Manuali e linee guida. 141/2016. Disponibile in: <http://www.isprambiente.gov.it/it/pubblicazioni/manuali-e-linee-guida/manuali-per-il-monitoraggio-di-specie-e-habitat-di-interesse-comunitario-direttiva-92-43-cee-in-italia-specie-animali>
9. *Holoarctia cervini*. Site: Moths and butterflies of Europe and North Africa (2017): <http://www.leps.it/>

Abstracts:

1. Raviglione MC, Battan R, Taranta A. Cardiopulmonary resuscitation in patients with AIDS. Proceedings of the IV International Conference on AIDS. Abstract n. 7522. June 12-16, 1988; Stockholm, Sweden (poster presentation).
2. Mathew A, Raviglione MC, Niranjian U, Sabatini MT, Distenfeld A. Splenectomy in HIV infection. Proceedings of the XXII Congress of the International Society of Hematology. Abstract n. P-TU-5-18. August 28 -September 1, 1988; Milan, Italy (poster presentation).
3. Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R, Garcia-Pamias K, Bottinger E. Drug-resistant tuberculosis among the homeless in New York City. Proceedings of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract n. 1291. October 23-26, 1988, Los Angeles, CA (poster presentation).
4. Mariuz P, Raviglione MC, Pablos-Mendez A, Battan R, Ottuso P, Scimeca S, Taranta A. *Staphylococcus aureus* nasal carriage in patients with AIDS or ARC. Abstract n. M.B.P. 72. June 4-9, 1989, Montreal, Canada (poster presentation).
5. Raviglione MC, Battan R, Pablos-Mendez A, Aceves-Casillas P, Mullen MP, Taranta A. Hickman catheter infections in AIDS. Proceedings of the V International Conference on AIDS. Abstract n. M.B.P. 89. June 4-9, 1989, Montreal, Canada (poster presentation).
6. Sanjana V, Davidson M, Mullen MP, Boyle D, Raviglione M, Cortes H. Intravenous and oral fluconazole (FCZ) for the treatment of acute cryptococcal meningitis. Proceedings of the V International Conference on AIDS. Abstract n. W.B.P. 5. June 4-9, 1989, Montreal, Canada (poster presentation).
7. Pablos-Mendez A, Raviglione MC, Battan R. Drug-resistant tuberculosis in AIDS and ARC. Proceedings of the V International Conference on AIDS. Abstract n. Th.B.P. 41. June 4-9, 1989, Montreal, Canada (poster presentation).
8. Battan R, Palagiano A, Raviglione MC, Sabatini MT, Boyle J, Sayad K, Ottaviano L. *Helicobacter pylori* infection in patients with AIDS or ARC. Proceedings of the VI International Conference on AIDS. Abstract n. Th.B. 370. June 20-24, 1990, San Francisco, CA (poster presentation).
9. Sanjana V, Cortes H, Davidson M, Mullen M, Boyle D, Raviglione M. Intravenous and oral fluconazole in the treatment of acute cryptococcal meningitis. Proceedings of the VI International Conference on AIDS. Abstract n. Th.B. 459. June 20-24, 1990, San Francisco, CA (poster presentation).
10. Battan R, Raviglione MC, Wallace J, Cort S, Boyle J, Taranta A. *Staphylococcus aureus* nasal carriage in gay men with and without HIV infection: influence of sexual behavior. Proceedings of the VI International Conference on AIDS. Abstract n. Th.B. 530. June 20-24, 1990, San Francisco, CA (poster presentation).
11. Battan R, Raviglione MC, D'Amore T, Pablos-Mendez A, Raggi P, Hedni R. Vancomycin prophylaxis for long term central venous catheter infections in AIDS patients. Proceedings of the VI International Conference on AIDS. Abstract n. Th.B. 531. June 20-24, 1990, San Francisco, CA (poster presentation).

12. Battan R, Raviglione MC, Cortes H, Sugar J, Garner G, Taranta A. Risk of exposure to HIV-infected body fluids among medical housestaff (MHS). Proceedings of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract n. 957. October 21-24, 1990, Atlanta, GA (oral presentation).
13. Hulme P, Raviglione M, Currier J, Hanff P. Quantitation of *Pneumocystis carinii* cysts, trophozoites, and matrix in induced sputum using fluorescent monoclonal antibodies. Proceedings of the 91st General Meeting of the American Society for Microbiology. Abstract n. C-41. May 5-9, 1991, Dallas, TX (poster presentation).
14. Raviglione MC, Hanff P, Hulme P, Currier JS. Clinical predictors of early deterioration in *Pneumocystis carinii* pneumonia (PCP). Proceedings of the VII International Conference on AIDS. Abstract n.2202. June 16-21, 1991, Florence, Italy (poster presentation).
15. Aisu T, Raviglione MC, Narain JP, Eriki P, Adoi O, Naamara W, ten Dam HG, Kochi A. Monitoring HIV-associated tuberculosis in Uganda: seroprevalence and clinical features. Proceedings of the VIII International Conference on AIDS. Abstract n.PoC 4023. July 19-24, 1992, Amsterdam, the Netherlands (poster discussion).
16. Aisu T, Van Praag E, Raviglione MC, Eriki P, Narain JP, Adatu F, Tembo G. Feasibility of preventive chemotherapy for HIV-associated tuberculosis in Uganda: preliminary results. Proceedings of the VIII International Conference on AIDS. Abstract n.PoB 3356. July 19-24, 1992, Amsterdam, the Netherlands (poster presentation).
17. Chintu C, Bhat GJ, Luo C, Kabika M, Raviglione MC, O'Brien RJ. Fatal skin reactions in children treated for tuberculosis in Zambia. Proceedings of the VIII International Conference on AIDS. Abstract n.PoB 3859. July 19-24, 1992, Amsterdam, the Netherlands (poster presentation).
18. Ara G, Raviglione MC, Rosazza A, Vercellino PC, Bottura G. Adolescents and AIDS: what they know and what they would like to know. Proceedings of the VIII International Conference on AIDS. Abstract n.PoD 5106. July 19-24, 1992, Amsterdam, the Netherlands (poster presentation).
19. Aisu T, Raviglione MC, Van Praag E, Eriki P, Narain JP, Adatu F, Tembo G, O'Brien R. Feasibility of isoniazid preventive chemotherapy for HIV-associated tuberculosis in Uganda: preliminary results. Proceedings of the 1992 World Congress on Tuberculosis. Abstract n. 36A. November 16-19, 1992, Bethesda, MD, USA (poster presentation).
20. Aisu T, Raviglione MC, Narain JP, Eriki P, Naamara W, Adatu F, ten Dam HG, Kochi A. Monitoring HIV-associated tuberculosis in Uganda. Proceedings of the 1992 World Congress on Tuberculosis. Abstract n. 43D. November 16-19, 1992, Bethesda, MD, USA (poster presentation).
21. Chintu C, Bhat GJ, Luo C, Kabika M, Raviglione MC, O'Brien RJ. HIV seroprevalence and fatal skin reactions in children treated for tuberculosis in Lusaka, Zambia. Proceedings of the 1992 World Congress on Tuberculosis. Abstract n. 44A. November 16-19, 1992, Bethesda, MD, USA (poster presentation).

22. Aisu T, Van Praag E, Raviglione MC, Eriki P, Narain JP, Adatu F, Naamara W, Tembo G. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: preliminary results of a feasibility study. Proceedings of the International Congress on Drug Therapy in HIV Infection. Abstracts n. O-12.5. November 9-12, 1992, Glasgow, Scotland (oral presentation).
23. Ara G, Raviglione MC, Rosazza A, Vercellino PC, Bottura G. Conoscenze e curiosità in tema di AIDS tra gli studenti delle scuole medie superiori. Proceedings of the VI Convegno Nazionale AIDS e Sindromi Correlate: 136. November 22-24, 1992, Venezia, Italy (poster presentation).
24. Aisu T, Tembo G, Van Praag E, Eriki P, Narain JP, Adatu F, Naamara W, Raviglione MC. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: preliminary results of a feasibility study. Proceedings of the VII International Conference on AIDS in Africa. Abstracts n. WO 013 and W.RT.001. December 8-11, 1992, Yaounde', Cameroon (oral and round table presentations).
25. Safran C, Rind DM, Davis RB, Ives DV, Sands DZ, Currier JS, Raviglione M, Cotton D, Makadon H. Implementing practice guidelines within a knowledge-based medical record. Proceedings of the 1993 Spring Congress of the American Medical Informatics Association: 118. St. Louis, Missouri, USA, 9-12 May 1993.
26. Aisu T, Raviglione MC, van Praag E, Eriki P, Narain JP, Tembo G, Adatu F, Naamara W. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: a feasibility study. Proceedings of the IX International Conference on AIDS. Abstract n. WS-B09-3. Berlin, Germany, 7-11 June, 1993 (oral presentation).
27. Luo C, Chintu C, Bhat G, Raviglione M, Dupont H, Zumla A. Tuberculosis and HIV-1 infection in Zambian children: seroprevalence and evaluation of a thioacetazone-free regimen. Proceedings of the IX International Conference on AIDS. Abstract n. PO-B07-1134. Berlin, Germany, 7-11 June, 1993 (poster presentation).
28. Girardi E, Antonucci G, Ippolito G and Gruppo Italiano di Studio Tubercolosi ed AIDS (GISTA). High incidence of tuberculosis in tuberculin positive and in anergic HIV-infected persons: a cohort study. Proceedings of the IX International Conference on AIDS. Abstract n. PO-B07-1153. Berlin, Germany, 7-11 June, 1993 (poster presentation).
29. Ara G, Vercellino PC, Rosazza A, Ferraris F, Bottura G, Raviglione MC. AIDS and adolescents: differences in knowledge, risk behaviours, and curiosities between workers and students. Proceedings of the IX International Conference on AIDS. Abstract n. PO-D02-3470. Berlin, Germany, 7-11 June, 1993 (poster presentation).
30. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, Roscigno G, Grosset J. Effectiveness of rifampin, rifabutin and rifapentine for preventive therapy of tuberculosis in mice. Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract n. 289. New Orleans, LA, USA, 17-20 October 1993 (poster presentation).
31. Raviglione MC. Guidelines on management of pulmonary tuberculosis in HIV-infected patients. Proceedings of the 17th Eastern Regional Conference on Tuberculosis and

- Respiratory Diseases of the Union against Tuberculosis and Lung Disease (IUATLD). Abstract S-2(2). Bangkok, Thailand, 1-4 November 1993 (oral presentation).
32. Ippolito G, Antonucci G, Girardi E, e GISTA. Elevata incidenza di tubercolosi in soggetti con infezione da HIV PPD+ o anergici. Proceedings of the VII Convegno Nazionale A.I.D.S. e Sindromi Correlate: 57. Bari, Italy, 12-14 November 1993 (oral presentation).
 33. Ara G, Vercellino PC, Rosazza A, Ferraris F, Raviglione MC. AIDS e adolescenti: stesse conoscenze, differenti comportamenti a rischio tra studenti e lavoratori. Proceedings of the VII Convegno Nazionale A.I.D.S. e Sindromi Correlate. Abstract G 139: 309. Bari, Italy, 12-14 November 1993 (poster presentation).
 34. Dolin PJ, Raviglione MC, Kochi A. Estimation of global tuberculosis incidence and mortality during the years 1990-2000. Abstracts of the ALA/ATS International Conference. Boston, MA, USA, 21-25 May 1994. *Am J Respir Crit Care Med* 1994; 149 (Suppl., N. 4, part 2):A526 (oral presentation).
 35. Raviglione MC, Rieder HL, Styblo K, Khomenko A, Esteves K, Kochi A. Trends of tuberculosis in Eastern Europe and the former USSR. Proceedings of the 28th World Conference of IUATLD/UICTMR/Global Congress on Lung Health. Abstract n. 41. Mainz, Germany, 14-17 June 1994. *Tuber Lung Dis* 1994; 75 (suppl. 1):24 (poster and oral presentation).
 36. Migliori GB, Eriki P, Mugerwa R, Aisu T, Adatu F, Neri M, Raviglione M. Prediction of expected tuberculosis cases in Uganda. Proceedings of the 28th World Conference of IUATLD/UICTMR/Global Congress on Lung Health. Abstract n. 275. Mainz, Germany, 14-17 June 1994. *Tuber Lung Dis* 1994; 75 (suppl. 1):76 (poster and oral presentation).
 37. Chapuis L, Ji B, Truffot C, O'Brien R, Raviglione M, Grosset JH. Preventive therapy of tuberculosis with rifapentine in immunocompetent and immunodeficient mice. Proceedings of the 28th World Conference of IUATLD/UICTMR/Global Congress on Lung Health. Abstract n. 275. Mainz, Germany, 14-17 June 1994. *Tuber Lung Dis* 1994; 75 (suppl. 1):12 (poster and oral presentation).
 38. Antonucci G, Girardi E, Ippolito G, and GISTA. Predictive factors for tuberculosis in HIV-infected persons: a cohort study. Proceedings of the X International Conference on AIDS. Abstract n. PBO694. Yokohama, Japan, 7-12 August 1994 (poster presentation).
 39. Migliori GB, Spanevello A, Ballardini L, Satta A, Moro ML, Trnka L, Grandi M, Neri M, Raviglione MC. Evaluation of a tuberculosis surveillance system and implications for national surveillance. Abstracts of the ALA/ATS International Conference. Seattle, WA, USA, 20-24 May 1995. *Am J Respir Crit Care Med* 1995; 151 (4, part 2):A144 (poster presentation).
 40. Migliori GB, Besozzi G, Spanevello A, Codecasa LR, Sarassi A, Murer B, Neri M, Mantellini PV, Raviglione MC. Yield and cost of tuberculosis case finding in immigrants. Abstracts of the ALA/ATS International Conference. Seattle, WA, USA, 20-24 May 1995. *Am J Respir Crit Care Med* 1995; 151 (4, part 2):A512 (poster presentation).
 41. Zalesky R, Abdullayev F, Safarian M, Gogebashvili N, Grzemska M, Theunissen J, Raviglione M. Tuberculosis control in the Caucasus: a priority for WHO. Proceedings of the Conference

- on Global Lung Health and the 1995 Annual Meeting of the IUATLD/UICTMR. Abstract n. 058-PA12. Paris, France 9-12 September 1995. *Tuber Lung Dis* 1995; 76 (suppl. 2):110 (poster presentation).
42. Migliori GB, Spanevello A, Ballardini L, Neri M, Moro ML, Trnka L, Raviglione MC, and the Varese TB Study Group. Incidence rate of tuberculosis in the native and immigrant population in Italy. The Varese Study. Proceedings of the Conference on Global Lung Health and the 1995 Annual Meeting of the IUATLD/UICTMR. Abstract n. 175-PA12. Paris, France 9-12 September 1995. *Tuber Lung Dis* 1995; 76 (suppl. 2):125 (poster presentation).
 43. Ara G, Dodaro L, Rosazza A, Vercellino PC, Raviglione MC. Il contatto di due brufoli è contagioso? Un manuale informativo per i giovani. Atti della V Conferenza Nazionale di Sanita' Pubblica. Torino, Italy, 12-13 October 1995. *Journal of Preventive Medicine and Hygiene*, 1996; 36:85-86 (poster presentation).
 44. Ara G, Dodaro L, Rosazza A, Vercellino PC, Crestani G, Piunti F, Raviglione MC. Prevenzione AIDS: è possibile un incontro tra le culture laica e cattolica? L'esempio di un manuale. Proceedings of the Conference "AIDS and Related Diseases. X Anniversary of the Italian National Association Against AIDS". Abstract n.219. Rome, Italy, 30 November - 4 December 1995 (poster presentation).
 45. Cohn DL, Bustreo F, Raviglione MC. Drug resistance in tuberculosis: review of the worldwide situation and WHO's global surveillance project. Abstracts of the American Thoracic Society 1996 International Conference. New Orleans, LA, USA, 10-15 May 1996. *Am J Respir Crit Care Med* 1996; 153 (Suppl. N. 4, Part 2):A492 (poster presentation).
 46. Hausler HP, Raviglione MC, Kaleeba N, Aisu T, Fourie B, Nunn P. Tuberculosis management in AIDS community care projects in sub-Saharan Africa. Proceedings of the XI International Conference on AIDS. Abstract n. Th.B.404. Vancouver, Canada, 7-12 July, 1996 (oral presentation).
 47. Raviglione MC. What is the current situation of TB/HIV?. Proceedings of the Conference on Global Lung Health and the 1996 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD). Paris, France 2-5 October 1996. *Tuber Lung Dis* 1996; 77 (suppl. 2):13-14 (poster presentation).
 48. Levy MH, Schmidt S, Bustreo F, Raviglione M. Status of global tuberculosis surveillance - 1995. Proceedings of the Conference on Global Lung Health and the 1996 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD). Paris, France 2-5 October 1996. *Tuber Lung Dis* 1996; 77 (suppl. 2):45 (poster presentation).
 49. Raviglione MC, Hausler HP, Kaleeba N, Aisu T, Fourie B, Maher D, Nunn P. Managing tuberculosis (TB) in HIV/AIDS community care projects: a model. Proceedings of the Conference on Global Lung Health and the 1996 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD). Paris, France 2-5 October 1996. *Tuber Lung Dis* 1996; 77 (suppl. 2):94-95 (poster presentation).
 50. Sawert H, Girardi E, Antonucci G, Raviglione MC, Migliori GB, Ippolito G. Terapia preventiva della tubercolosi in persone con infezione da HIV: valutazione di differenti opzioni basate sulla risposta alla tubercolina e la conta dei linfociti CD4+. Proceedings of the X

- Convegno Nazionale AIDS e Sindromi Correlate. Abstract n. P 59. Milano, Italy, 21-23 November 1996 (poster presentation).
51. Raviglione MC, Valway SE, Levy M. Tuberculosis as a travel-related disease. Proceedings of the Fifth International Conference on Travel Medicine. Abstract n. 20. Geneva, Switzerland, 24-27 March 1997 (oral presentation).
 52. Migliori GB, Ambrosetti M, Raviglione MC, Farris B, Nutini S, Saini L, Casali L, Besozzi G, and AIPO TB Study Group. Cohort analysis of TB treatment results: testing a method for industrialized countries. Abstracts of the American Thoracic Society 1997 International Conference. San Francisco, CA, USA, 16-21 May 1997. *Am J Respir Crit Care Med* 1997; 155 (Suppl. N. 4, Part 2):A222 (poster presentation).
 53. Pablos-Mendez A, Raviglione M. Global surveillance of drug-resistant tuberculosis. Proceedings of the Conference "Antibiotic Resistance, the threat to international health", organized by The Wellcome Trust. Broadway, Worcestershire, UK, 18-21 May 1997: 19 (oral presentation)
 54. Pablos-Méndez A, Raviglione M. Global surveillance of drug-resistant tuberculosis. Proceedings of the 20th International Congress of Chemotherapy. Abstract n. 5034. June 29 - July 3, 1997, Sidney, Australia (oral presentation).
 55. Migliori GB, Khomenko AG, Punga VV, Ambrosetti M, Danilova I, Ribka LN, Grzemska M, Sawert H, Raviglione MC and the Ivanovo Project TB Study Group. Cost-effectiveness analysis of different policies of tuberculosis control in Ivanoco Oblast, Russian Federation. Proceedings of the ERS Annual Congress. Abstract P1394. Berlin, Germany, 20-24 September 1997. *Eur Respir J* 1997; 10 (Suppl.25):213s. (poster presentation)
 56. Raviglione MC. State of tuberculosis in the world. Proceedings of the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD/UICTMR). Paris, France, 1-4 October 1997. *Int J Tuberc Lung Dis* 1997; 1 (suppl. 1): S3 (oral presentation).
 57. Khomenko A, Punga V, Grishina T, Golyshevskaya V, Rybka L, Korneev A, Stoyunin M, Danilova I, Guskov P, Katulina N, Raviglione M, Grzemska M, Migliori G. Results of a pilot project of TB control in the Ivanovo oblast, Russia. Proceedings of the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD/UICTMR). Abstract n. 137-PC03. Paris, France, 1-4 October 1997. *Int J Tuberc Lung Dis* 1997; 1 (suppl. 1): S71 (poster presentation).
 58. Khomenko A, Punga VV, Grishina T, Golyshevskaya V, Rybka L, Korneev A, Stoyunin M, Danilova I, Shigareva E, Katulina N, Guskov P, Raviglione M, Grzemska M, Migliori G. Results of controlled standardized treatment of new cases of pulmonary tuberculosis and relapses 12-15 months after registration. Proceedings of the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD/UICTMR). Abstract n. 458-PA03. Paris, France, 1-4 October 1997. *Int J Tuberc Lung Dis* 1997; 1 (suppl. 1): S83 (poster presentation).
 59. Sawert H, Natpratan C, Akarasewi P, Antonucci F, Girardi E, Kongsin S, Raviglione M, Ippolito G. Potential benefits of preventive therapy for tuberculosis in HIV-positive persons

- and its cost-effectiveness in a middle-income country. Proceedings of the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD/UICTMR). Abstract n. 258-PA04. Paris, France, 1-4 October 1997. *Int J Tuberc Lung Dis* 1997; 1 (suppl. 1): S163 (poster presentation).
60. Okwera A, Johnson JL, Nsubuga P, Luzz H, Whalen C, Cohn DL, Raviglione M, Mugerwa RD, Ellner JJ. Preliminary report on safety and efficacy of 2EHRZ/6H₃E₃ for the treatment of smear positive pulmonary tuberculosis (PTB) in human immunodeficiency virus (HIV) infected Ugandan adults. Proceedings of the Conference on Global Lung Health and the 1997 Annual Meeting of the International Union Against Tuberculosis and Lung Disease (IUATLD/UICTMR). Abstract n. 280-PA04. Paris, France, 1-4 October 1997. *Int J Tuberc Lung Dis* 1997; 1 (suppl. 1): S163 (poster presentation).
 61. Grosset J, Lounis N, Truffot-Pernot C, O'Brien RJ, Raviglione MC, Ji B. Once weekly rifapentine-containing combined regimens for treatment of tuberculosis in mice. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract n. B-36. Toronto, Ontario, Canada, 28 September - 1 October 1997: 33 (poster presentation).
 62. Natpratan C, Akarsewi P, Fain J, Prapanwong A, Raviglione M. Demand for isoniazid preventive therapy (IPT) for TB prevention among HIV-infected persons in Chiang Mai, Thailand. Abstracts of the 4th International Congress on AIDS in Asia and the Pacific. Abstract n. B(P)082. Manila, the Philippines, 25-29 October 1997 (poster presentation).
 63. Hanson C, Chaulet P, Raviglione M. Development of district-based packages for the management of tuberculosis and other respiratory diseases in high HIV prevalence countries. Abstracts of the Xth International Conference on AIDS and STD in Africa. Abstract n E.163:62. Abidjan, Côte d'Ivoire, 7-11 December 1997 (oral presentation).
 64. Migliori GB, Ambrosetti M, Besozzi G, Farris B, Nutini S, Saini L, Casali L, Nardini S, Neri M, Raviglione MC. Cost-effectiveness analysis of different policies for management of tuberculosis patients in Italy. Abstracts of the ERS Annual Congress. *European Respiratory Journal* 1998; 12 (Suppl. 28): 137s. Abstract n. 1000. Geneva, Switzerland, 19-23 September 1998 (oral presentation).
 65. Raviglione MC. Progress in the implementation of the WHO DOTS strategy. Proceedings of the Global Congress on Lung Health, 29th World Conference of International Union Against Tuberculosis and Lung Disease, IUATLD/UICTMR. Abstract S167. Bangkok, Thailand, 23-26 November 1998. *Int J Tuberc Lung Dis* 1998; 2 (suppl. 2): S167 (oral presentation).
 66. Dye C, Netto EM, Raviglione MC. Progress in global tuberculosis control 1995-6, with emphasis on 22 high-incidence countries. Proceedings of the Global Congress on Lung Health, 29th World Conference of International Union Against Tuberculosis and Lung Disease, IUATLD/UICTMR. Abstract 32-PC. Bangkok, Thailand, 23-26 November 1998. *Int J Tuberc Lung Dis* 1998; 2 (suppl. 2): S200 (poster discussion).
 67. Netto EM, Dye C, Raviglione MC. Comparative incidence of TB among non-nationals in industrialised countries and the Gulf States. Proceedings of the Global Congress on Lung Health, 29th World Conference of International Union Against Tuberculosis and Lung

- Disease, IUATLD/UICTMR. Abstract 34-PC. Bangkok, Thailand, 23-26 November 1998. *Int J Tuberc Lung Dis* 1998; 2 (suppl. 2): S200 (poster presentation).
68. Espinal MA, Kim SJ, Hong YP, Baez J, Perez EN, Suarez PG, Portocarrero J, Khomenko AG, Migliori GB, Raviglione MC. Treatment outcome of multidrug resistant (MDR) tuberculosis (TB) cases under programme conditions. Proceedings of the Global Congress on Lung Health, 29th World Conference of International Union Against Tuberculosis and Lung Disease, IUATLD/UICTMR. Abstract 428-PC. Bangkok, Thailand, 23-26 November 1998. *Int J Tuberc Lung Dis* 1998; 2 (suppl. 2): S371 (poster discussion).
 69. Akarasewi P, Prapanwong A, Natpratan C, Raviglione MC. Risk of active TB in HIV infected persons following 9 months INH preventive therapy. Proceedings of the 30th World Conference of the International Union Against Tuberculosis and Lung Disease, IUATLD. Abstract 671-PS. Madrid, Spain, 15-18 September 1999. *Int J Tuberc Lung Dis* 1999; 3 (suppl. 1): S23 (poster presentation).
 69. Raviglione M. The worldwide tuberculosis situation and its impact on the USA. Proceedings of the 27th Annual Meeting of the Infectious Disease Society of America. Abstract W26: 40. Philadelphia, PA, USA, 18-21 November 1999 (oral presentation). An expanded summary is also published in the Syllabus of the "Tuberculosis Workshop", November 18 1999, presented by the Francis J. Curry National Tuberculosis Center and the Infectious Disease Society of America.
 70. Raviglione M. Global epidemiology of tuberculosis. Proceedings of the International Colloquium "Tuberculosis, the real millenium bug. Addressing the threat in developing and industrialised countries". Institute of Tropical Medicine, Antwerp, Belgium, 14-17 December 1999 (keynote address).
 71. Raviglione M. Tuberculosis in Eastern Europe. Final Programme and Abstract Book of the 1st Congress of the IUATLD Europe Region in association with the 51st Congress of the Hungarian Respiratory Society. Abstract 1:76. Budapest, Hungary, 12-15 April 2000 (plenary lecture).
 72. Van Beneden C, Scherpbier R, Brimkulov NN, Raviglione MC. Case management of respiratory symptomatics at primary health care level in Kyrgyzstan. Final Programme and Abstract Book of the 1st Congress of the IUATLD Europe Region in association with the 51st Congress of the Hungarian Respiratory Society. Abstract Pdisc-234:100. Budapest, Hungary, 12-15 April 2000 (poster discussion).
 73. Scherpbier R, van Beneden C, Brimkulov NN, Raviglione MC. Diagnosis of respiratory symptomatics at primary health care level in Kyrgyzstan. Final Programme and Abstract Book of the 1st Congress of the IUATLD Europe Region in association with the 51st Congress of the Hungarian Respiratory Society. Abstract Pdisc-123:136. Budapest, Hungary, 12-15 April 2000 (poster discussion).
 74. Migliori GB, Danilova ID, Stoyunin MB, Punga VV, Ambrosetti M, Grzemska M, Espinal M, Raviglione MC. Chance of relapse among successfully treated MDR-TB cases. Final Programme and Abstract Book of the 1st Congress of the IUATLD Europe Region in association with the 51st Congress of the Hungarian Respiratory Society. Abstract OP-

- 33:155. Budapest, Hungary, 12-15 April 2000 (oral presentation).
75. Floyd K., Nganda B., Okello D., Moalosi G., Maher D., Ya Diul M., Raviglione M., Sinanovic E. Providing tuberculosis treatment in sub-Saharan Africa in the face of the HIV/AIDS epidemic: an economic evaluation of 5 pilot projects emphasising increased community and primary care facility involvement in care. Abstract Book, Volume II, XIII International AIDS Conference. Abstract WePeC4428. Durban, South Africa, 9-14 July 2000 (oral presentation).
 76. Godfrey-Faussett P, Mukadi YD, Hargreaves N, Salaniponi F, Ayles H, Hausler H, Maher D, Raviglione M, Madji R. Progress with the ProTEST initiative: a combined approach to the combined epidemics of TB and HIV. Abstract Book, Volume II, XIII International AIDS Conference. Abstract ThPeB5205. Durban, South Africa, 9-14 July 2000 (poster presentation).
 77. Raviglione M. "La situation globale de la tuberculose et les défis actuels". Proceedings of the Congrès International sur les Maladies Infectieuses: 38-41. Société Algérienne de Microbiologie (SAM) et l'Association Solidarité Franco-Maghrebine. Alger, Algeria, 12-14 May 2001 (oral presentation).
 78. Aisu T, Cohn D, Mubiru F, Ssebanja P, Sawert H, Adatu F, Raviglione M. Feasibility of isoniazid preventive therapy (IPT) of tuberculosis (TB) in HIV-infected persons in Uganda. Proceedings of the 1st International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment: abstract 453: 212. Buenos Aires, Argentina, 8-11 July 2001 (poster presentation).
 79. Migliori GB, Punga VV, Danilova I, Grzemska M, Centis R, Raviglione MC. Drug resistant tuberculosis: is it enough to justify low treatment success in Russia? Proceedings of the 11th ERS Annual Congress. Abstract 1251. Berlin, Germany, 22-26 September 2001. Eur Respir J 2001; 18 (suppl. 33): 175s (poster presentation).
 80. Raviglione MC. The global epidemiology of tuberculosis. Proceedings of the 32nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Paris, France, 1-4 November 2001. Int J Tuberc Lung Dis 2001; 5 (suppl. 1): S7 (oral presentation).
 81. Scano F, Maher D, Raviglione M. Tuberculosis preventive treatment in people living with HIV/AIDS in sub-Saharan Africa: future research directions. Proceedings of the 32nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Paris, France, 1-4 November 2001. Int J Tuberc Lung Dis 2001; 5 (suppl. 1): S109 (poster presentation).
 82. Floyd K, Kumaranayake L, Watts C, Onyebujoh P, Maher D, Godfrey-Faussett P, Raviglione M. Responding to the dual HIV and TB epidemics in Sub-Saharan Africa: economic and epidemiological evaluation of pilot "ProTEST" projects. Proceedings of the 32nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Paris, France, 1-4 November 2001. Int J Tuberc Lung Dis 2001; 5 (suppl. 1): S175 (poster presentation).

83. Floyd K, Blanc L, Raviglione M. Financial resources required for DOTS implementation in the 22 high-burden countries and beyond. Proceedings of the 32nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Paris, France, 1-4 November 2001. *Int J Tuberc Lung Dis* 2001; 5 (suppl. 1): S191 (oral presentation).
84. Raviglione MC. The TB epidemic from 1992 to 2002. Proceedings of the 4th World Congress on Tuberculosis. Speaker Abstract: 2. Washington, DC, USA, 3-5 June 2002 (oral presentation).
85. Gupta R, Espinal M, Kim JY, Lambregts CSB, Jaramillo E, Raviglione M. Taming the spectre of drug resistance: a rational approach to an irrational disease. Proceedings of the 4th World Congress on Tuberculosis. Poster session A Abstract: 54. Washington, DC, USA, 3-5 June 2002 (poster presentation).
86. Cohn DL, Aisu T, Mubiru F, Adatu-Engwau F, Raviglione MC. Feasibility of preventive therapy in HIV-infected Ugandans: role of chest X-ray screening in detecting possible tuberculosis. Proceedings of the 4th World Congress on Tuberculosis. Poster Session A Abstract: 81. Washington, DC, USA, 3-5 June 2002 (poster presentation).
87. Maher D, Raviglione M, Floyd K. Tackling HIV-associated tuberculosis: a global strategic framework. Proceedings of XIV International AIDS Conference. Poster Session, Track F, Abstract WePeF6702. Vol. II: 259. Barcelona, Spain, 7-12 2002 (poster presentation).
88. Raviglione MC. Global DOTS expansion: will we reach the targets? Proceedings of the 33rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Montreal, Canada, 6-10 October 2002. *Int J Tuberc Lung Dis* 2002; 6 (suppl. 1): S8 (oral presentation).
89. Corbett EL, Watt CJ, Walker N, Maher D, Williams GB, Raviglione MC, Dye C. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Proceedings of the 33rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Montreal, Canada, 6-10 October 2002. *Int J Tuberc Lung Dis* 2002; 6 (suppl. 1): S24 (oral presentation).
90. Maher D, Floyd K, Raviglione M. A strategic framework for HIV-related TB. Proceedings of the 33rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Montreal, Canada, 6-10 October 2002. *Int J Tuberc Lung Dis* 2002; 6 (suppl. 1): S25 (oral presentation).
91. Gupta R, Espinal MA, Jaramillo E, Raviglione MC. Defining and ensuring rational DOTS-Plus. Proceedings of the 33rd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (IUATLD). Abstract. Montreal, Canada, 6-10 October 2002. *Int J Tuberc Lung Dis* 2002; 6 (suppl. 1): S28 (oral presentation).
92. Raviglione MC. Global situation and future perspectives. Proceedings of the 3rd Congress of the Europe Region of IUATLD. Abstract 273. Moscow, Russia, 22-26 June 2004: 74 (oral presentation).

93. Richeldi L, Floyd K, Migliori GB, Losi M, Marchegiano P, Pieroni G, Fabbri LM, Lalvani A, Raviglione M. The cost of managing multidrug-resistant tuberculosis in an illegal immigrant in Italy. *Proceedings of the 14th ERS Annual Congress. Eur Respir J* 2004; 24 (Suppl. 48): 703b. Abstract n.4315. Glasgow, Scotland, UK, 4-8 September 2004.
94. Raviglione M. Tuberculosis control worldwide: situation and problems". *Proceedings of the 5th International Symposium on Antimicrobial Agents and Resistance (ISAAR - 2005). Symposia and Poster Abstracts: 85.* Seoul, Korea, 27-29 April 2005 (oral presentation).
95. Martinez L, Figueroa-Munoz J, Blanc L, Raviglione M, Kwon JW. Tuberculosis and air travel. *Proceedings of the 5th European Conference on Travel Medicine. Venezia, Italy, 23-25 March 2006 (Oral presentation).*
96. Raviglione MC. The new Stop TB Strategy. Programme and Abstract Book. Geneva Forum - Towards Global Access to Health. Abstract SY17.3: 73. Geneva, Switzerland, 30 August - 1 September 2006 (oral presentation).
97. Migliori GB, Ortmann J, Girardi E, Besozzi G, Lange C, Cirillo DM, Ferrarese M, De Iaco G, Gori A, Raviglione MC. Risk of mortality of extensively drug-resistant tuberculosis (XDR-TB) in Italy and Germany. *Proceedings of the ERS Annual Congress. Abstract 142: 216s.* Stockholm, Sweden, 16 September 2007.
98. Raviglione M. What future for TB? *Proceedings of the 13th Annual Conference. International Union against Tuberculosis and Lung Disease - North American Region. Speakers Abstract. Vancouver, BC, Canada, 26-2-2009.*
99. Raviglione MC. MDR/XDR-TB: burden and control. *Proceedings of the Third Annual New England TB Symposium "Fostering scientific collaborations". Speaker Abstracts: 16.* Broad Institute, Cambridge, Ma, USA, 12 June 2009.
100. Raviglione M. Facing MDR/XDR-TB control: policies and strategies. *Abstracts of the 6th European Congress on Tropical Medicine and International Health and 1st Mediterranean Conference on Migration and Travel Health, Verona, Italy, 6-10 September 2009. European Journal of Tropical Medicine and International Health* 2009; 14 (Suppl.2): 10.
101. Raviglione MC. Stop TB - The state of treatment for XDR-, MDR- and drug-sensitive TB: thinking out of the box to treat TB and interrupt new infections on a global scale. *Meeting Abstract Book - 2010 Keystone Symposia "Overcoming the crisis of TB and AIDS. Part of the Keystone Symposia "Global Health Series". 20-25 October 2009, Arusha, Tanzania: 58.*
102. Granich R, Getahun H, Sculier D, Mussa Muhe L, Smyth C, Doupe A, Gunneberg C, Grzemska M, Daniels C, Blanc L, Crowley S, Raviglione M, Guerna T. 2010 WHO guidelines for isoniazid preventive treatment and intensified case finding for tuberculosis in people living with HIV in resource constrained settings. Abstract number MOPE 0946, XVIII International AIDS Conference, 18-23 July 2010, Vienna, Austria: 265-266.
103. Glaziou P, Bierrenbach A, Sismanidis C, Korenromp E, Floyd K, Raviglione M. Lives saved by global TB control efforts. *Proceedings of the 41st World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease (The Union). Abstract Book.*

- Int J Tuberc Lung Dis 2010; 14 (11) (Suppl. 2): S144 (Abstract PS-100218-13).
104. Falzon D, Raviglione M, Lönnroth K, Jaramillo E. Social determinants of health and tuberculosis control. Book of Abstracts. First Global Symposium on Health Systems Research. Montreux, 16-19 November 2010: 249-250 (oral presentation).
 105. Raviglione MC. Tuberculosis is a global health issue: challenges and need for new tools. Proceedings of "Immunodiagnosis of tuberculosis: new questions, new tools". Virginia Beach, VA, USA, 21-23 September 2008. BMC Proceedings 2010; 4 (Suppl. 3): 1-2.
 106. Raviglione MC. MDR-TB in the world: situation analysis and control efforts. Proceedings of the 86th Annual Congress of the Japanese Society for Tuberculosis. Tokyo, Japan, 2 June 2011. Abstract book. Kekkaku 2011; 86 (3): 226.
 107. Raviglione MC. The global burden of tuberculosis: where are we now towards the global targets? Proceedings of the International Review Meeting on "New 2020 Plan for TB Elimination", organized by the Korea Center for Disease Control and Prevention, Osong, Republic of Korea, 25 August 2011: 93.
 108. Raviglione MC. Global perspective on TB control in the 21st century. Program & Abstracts of the 3rd International Congress on Infectious and Tropical Diseases – 6th GCC Conference on Infection Control. Organised by the Ministry of Health of Oman in collaboration with Sultan Qaboos University and Executive Board of GCC. Muscat, Oman 5-8 December 2011:67.
 109. Raviglione MC. TB antibiotic resistance: a global threat. Program & Abstracts of the 3rd International Congress on Infectious and Tropical Diseases – 6th GCC Conference on Infection Control. Organised by the Ministry of Health of Oman in collaboration with Sultan Qaboos University and Executive Board of GCC. Muscat, Oman 5-8 December 2011:75.
 110. Falzon D, Cohen T, Samson K, Raviglione M. Geolocation of patients as a tool for improved tuberculosis care and information system. Abstract PC-389-01. 44th UNION World Conference on Lung Health, Paris, France, 30-10-2013.
 111. Raviglione M. Il futuro dei programmi di controllo e la sfida dei bacilli MDR. Abstract. 7th Congresso Nazionale della Società Italiana di Medicina Tropicale, Torino, Italy, 28-30 November 2013. Available at www.simet2013torino.org.
 112. Falzon D, Migliori GB, Jaramillo E, Weyer K, Raviglione MC. Digital health technology for the End TB Strategy: developing priority products and making them work. European Respiratory Society International Congress 2016, London, UK, 3-7 September 2016.
 113. Falzon D, Migliori GB, Bill W, Jaramillo E, Weyer K, Raviglione M, on behalf of the *Global Task Force on Digital Health for TB*. Digital health for the End TB Strategy: evidence of impact and priority interventions. European Respiratory Society Congress, Milan, Italy, September 2017.